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Chapter1
Introduction; 
Pharmacological management of 
severe pre-eclampsia
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ABSTRACT
(Very) High blood pressure in pre-eclamptic women poses a serious risk of acute cerebrovas-
cular complications in these women, necessitating the use of antihypertensive treatment in 
pre-eclampsia. In this review the diﬀerent antihypertensive drugs, used in the management 
of pre-eclampsia, are discussed with a focus on eﬃcacy and maternal and neonatal safety. The 
characteristics of each drug are summarized, including placental transfer, and comparisons 
between antihypertensive drugs are shown, based on recent publications. Special emphasis 
is given on newer developments including treatment with ketanserin or nicardipine. 
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INTRODUCTION
Pre-eclampsia is a multisystem disorder with an incidence in pregnancy varying between 
2% and 7% 1 and it is still the leading cause of maternal mortality during pregnancy in the 
Netherlands 2.
The disorder is characterised by the occurrence after the 20th week of gestation, of 
elevated maternal blood pressure and proteinuria. In most women, the onset is near term 
or intrapartum and the disease is usually mild with a negligible increased risk of adverse 
pregnancy outcome. However, in severe cases, pre-eclampsia can lead to serious maternal 
complications, such as HELLP-syndrome (haemolysis, elevated liver enzymes, low platelet 
counts), pulmonary edema, acute renal failure, liver failure or haemorrhage, abruptio 
placentae and eclampsia. The major cause of maternal death is cerebral haemorrhage. 
Pre-eclampsia is also associated with increased perinatal morbidity and mortality. 
Depending on the severity of the disease, intrauterine growth restriction, reduced amniotic 
ﬂuid and abnormal oxygenation can occur, leading to increased occurrence of iatrogenic 
preterm delivery, small-for-gestational-age (SGA) neonates and prenatal or perinatal death 3. 
PATHOGENESIS 
The cause(s) of pre-eclampsia still remain unknown, but most hypothesis focus on vascular 
dysfunction and maternal- foetal (paternal) immune maladaptation 3.
The presence of the placenta or the maternal response to placentation is considered to be 
a key-factor in the disorder. Cytotrophoblastic invasion of the spiral arteries is incomplete 
in pre-eclampsia, resulting in narrow and undilated myometrial segments 4, which may 
compromise uterine blood ﬂow during pregnancy. Recently, the anti-angiogenic protein 
sFlt-1 (soluble fms-like tyrosine kinase or sVEGFR-1) has been shown to be elevated in pre-
eclampsia as compared to normal pregnancies. This protein is thought to be involved in 
antagonising VEGF (vascular endothelial growth factor) and PIGF (placental growth factor), 
which may cause the endothelial dysfunction, known to be present in pre-eclampsia 4,5. 
In the future, this mechanism may become a possibility for an alternative and more causal 
strategy for pharmacological management of pre-eclampsia.
An important factor, implicated in the pathogenesis of pre-eclampsia is the close tissue 
contact between maternal and foetal cells, resulting from the trophoblast-cell invasion into 
the deciduas 3. Couple-speciﬁc immune maladaption is speculated to be involved in the 
superﬁcial placentation, causing increased apoptosis of cytotrophoblasts. This may trigger 
a systemic inﬂammatory response in the mother, resulting in endothelial activation and 
inﬂammation and thrombocyte activation. The latter can result in a lower production of the 
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vasodilator prostacyclin and increased release of the vasoconstrictors thromboxane A2 and 
serotonin.
PREVENTION 
One of the main problems of pre-eclampsia is that the clinical symptoms become manifest 
long after the compromised placentation and vascular dysfunction have developed. 
Management at the time of diagnosis is limited to controlling maternal symptoms, and 
assuring foetal well-being. Theoretically, pharmacological interventions at the time of early 
placentation and before the occurrence of extensive vascular dysfunction, would be needed 
to prevent the development of pre-eclampsia or reduce the severity of the disease. However, 
early identiﬁcation of women at risk for developing pre-eclampsia remains an unresolved 
challenge in obstetric practice, hampering the possibility of selective use of prophylactic 
drugs for high-risk women.
Acetylsalicyl acid is the drug most widely used to prevent pre-eclampsia, based on its 
positive eﬀect on the imbalance in the tromboxane-A2 to prostacyclin ratio, found in pre-
eclampsia. A review 6 of 32 trials (n=29331) with acetylsalicyl acid showed a 15% reduction 
in the occurrence of pre-eclampsia (95% CI 0.78-0.92). Dosages of acetylsalicyl acid and time 
of intake have been demonstrated to inﬂuence eﬃcacy, with daily dosages ≥ 75mg and 
intake before bed time showing the highest eﬀect. However, a recent placebo-controlled 
study in 3294 nulliparous women did not show an eﬀect on incidence of pre-eclampsia or 
gestational hypertension of 100 mg acetylsalicyl acid from 14-20 week’s gestation 7. To date, 
it still remains unclear which women are most such likely to beneﬁt from acetylsalicyl acid, at 
what dosage and at what gestational age treatment should be started
Based on the hypothesis that antioxidants may be eﬀective in decreasing oxidative stress 
and improving vascular endothelial function, 283 high risk women were supplemented in 
a placebo controlled study with vitamin C (1000 mg) and vitamin E (400 IE) from the 16th-
22th week gestation 8. The occurrence of pre-eclampsia was reduced from 17% to 8% in the 
treated group (p < 0.02), but no reduction on the occurrence of severe pre-eclampsia or 
improvement in perinatal outcome could be established. Currently, a large trial is undertaken 
in the UK, to assess the inﬂuence of vitamin C and vitamin E on pre-eclampsia. 
The inﬂuence of nutritional interventions such as zinc, magnesium or fish oil 
supplementation has been reviewed but no diﬀerences in incidence of hypertension 
during pregnancy or pre-eclampsia could be demonstrated 9. Calcium supplementation 
has been associated with a five-fold reduced risk on hypertension and pre-eclampsia, but 
only in patients with low baseline dietary calcium intake (RR 0.22; 95% CI 0.16-0.49) 10. In 
developed countries, its use is therefore not recommended. 
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Antihypertensive drugs (alfa-agonists, calcium-channel blockers, beta-adrenoceptor 
blockers or hydralazin) have been used orally in women with chronic hypertension with a 
beneﬁcial eﬀect on the occurrence of severe hypertension, but use of these drugs did not 
decrease the risk of pre-eclampsia according to a Cochrane review, referencing 40 clinical 
trials with 3797 women 11. The possibility of the occurrence of adverse eﬀects, such as reduced 
birth weight in patients treated with beta-adrenoreceptor blockers 12, should be taken into 
account in the decision to treat prophylactic ally with oral antihypertensive drugs.
Following the increased incidence of thrombophilia and hyperhomocysteinemia, 
demonstrated in women with a history of pre-eclampsia 13, administration of heparin or 
low-molecular heparin has been found to reduce the incidence of pre-eclampsia in women 
with thrombophilia 14. However, due to the potential risks of anticoagulant treatment during 
pregnancy, its use is currently only recommend in a trial-setting.
In summary, there is no eﬃcient prophylactic treatment available to prevent pre-eclampsia.
MAGNESIUM SULPHATE
The use of magnesium sulphate in pre-eclamptic patients is based on the eﬃcacy of the 
drug in preventing eclampsia in women with severe pre-eclampsia. As shown in a systematic 
review 15 and in a large randomised controlled trial (the Magpie trial 16) comparing magnesium 
sulphate with placebo in 10141 women, magnesium sulphate was associated with a 
signiﬁcantly reduced rate of eclampsia (RR 0.41; 95% CI 0.29-0.58). In mild pre-eclampsia, no 
impact on disease progression was found 17. 
Current dosage schedule consist of a bolus infusion of 4 to 6 g magnesium sulphate, 
followed by infusion of 1 g/h during 24 h. Because of its vasodilatating eﬀect, magnesium 
sulphate may lower maternal blood pressure, albeit not extensively. The drug can cause 
respiratory depression, nausea, drowsiness, confusion and ﬂushing as side-eﬀects in the 
mother. 
ANTIHYPERTENSIVE MANAGEMENT OF PRE-ECLAMPSIA
Delivery is the only cure for pre-eclampsia. In pre-eclampsia occurring in near-term or term 
patients, delivery is, therefore, recommended to minimize the risk of maternal complications. 
The use of antihypertensive drugs may be necessary to stabilise maternal blood pressure 
before delivery and to gain suﬃcient time to administer corticosteroids in patients with a 
gestational age below 34 weeks to enhance foetal-lung maturity 18.
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In severe pre-eclampsia occurring before 32 weeks of gestation, expectant management 
by postponing delivery using antihypertensive drugs in patients with a stable maternal and 
foetal condition, can be considered to improve neonatal outcome 19,20. A recent review 21 
showed that a mean pregnancy prolongation in early pre-eclampsia using antihypertensive 
treatment of 10-14 days can be established, which is considered clinically important for an 
improvement in neonatal outcome. Some obstetricians, however, prefer early delivery after 
stabilizing the maternal condition (interventionist care) to prevent the development of 
serious maternal complications. A meta-analysis on available studies on interventionist versus 
expectant care 22 stated that due to lack of randomised trials of suﬃcient size, no conclusions 
can be drawn. Recent trials show that short-term morbidity for the baby may be reduced by 
a policy of expectant care 23,24. However, improvement in perinatal outcome should never be 
achieved at the expense of maternal safety. This implies that only in tertiary care settings with 
experienced personnel, expectant management using adequate monitoring of both mother 
and foetus, should be considered in severe early-onset pre-eclamptic patients.
The challenge in using antihypertensive drugs in pre-eclampsia is to reduce blood pressure to 
assure maternal safety, while at the same time not compromising uteroplacental perfusion. 
There is a general consensus 25 to start antihypertensive treatment in a pregnant women 
with sustained values of systolic blood pressures of 170 mmHg or above and diastolic blood 
pressures of 110 mmHg or above. The aim of such treatment is to lower the risk of harmful 
eﬀects, especially stroke and other haemorrhagic complications, for the mother. Whether to 
target at a ﬁxed value of systolic and diastolic blood pressure or to aim for a reduction relative 
to the initial maternal blood pressure remains controversial. In patients with an initial high 
blood pressure, the latter may lower the risk of acute foetal distress, caused by diminished 
uteroplacental perfusion following aggressive antihypertensive treatment, but in patients 
with borderline blood pressure, a relative reduction might result in over-treatment. 
The ideal antihypertensive drug for treatment of severe hypertension in pregnancy should 
be potent, rapidly acting, controllable and without detrimental maternal or foetal side eﬀects. 
Unfortunately, only limited antihypertensive drugs are studied and even less are licensed for 
use in pre-eclamptic patients. As a result, most drugs currently used in pre-eclampsia, have 
long been surpassed by newer drugs in other medical areas. 
Administering antihypertensive drugs in pre-eclampsia is only treating the symptoms 
of the disease. As long as the foetus and placenta is present, the disease will not be cured 
and may even exacerbate during treatment. To maintain adequate blood pressure control, 
increased dosages, a switch from oral to parenteral administration or combination treatment 
are often necessary, but no consensus on choice of ﬁrst-, second- or even third-line treatment 
is available. Considering the fact that current antihypertensive drugs diﬀer greatly in their 
action, potency and side-eﬀects, it is surprising that (inter)national recommendations on 
which drug to prefer, are still lacking. In the next part, the diﬀerent drugs are discussed 
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with their respective properties (Table 1.1), which may be helpful for developing treatment 
protocols. 
Table 1.1 Antihypertensive drugs for management of pre-eclampsia
Drug Mode of action Route of 
administration
Dosage Onset of 
action
Duration 
of action
Methyldopa Alfa-2-receptor 
agonist
Oral 500-1,000 mg tid 
or qid
4-6 h 20-24 h
Nifedipine Calcium-channel 
blocking agent
Oral retard
Oral oros
Short-acting capsule
10-40 mg bid
30-90 mg qd
5-10 mg every 2-6 h
0.5-1 h
2-4 h
10-15 min
6-11 h
24 h
4-5 h
Nicardipine Calcium -channel 
blocking agent
Oral1
Intravenous (central 
line)
20 mg tid
3 mg/h bolus, 
followed by 0.5-10 
mg/h
20 min
5-10 min
1-2 h
Dihydralazin Arterial vasodilator Intravenous Bolus 5 –10 mg in 
30-60 min, followed 
by 1-10 mg/h 
10-20 min 3-8 h
Hydralazin Arterial vasodilator Oral
Intravenous
25-50 mg tid or qid
5–10 mg iv every 
20-30 minutes 
1 h
10-20 min
3-8 h
Labetalol Alpha-1 and beta 
receptor antagonist
Oral
Intravenous
50-200 mg tid
10-30 mg/h2
1-4 h
5-10 min
4-6 h
Ketanserin 5-HT2A-receptor 
antagonist
Oral
Intravenous
20-40 mg bid
5-10 mg bolus, 
followed by 2-14 
mg/h
0.5-2 h
1-3 min
13-18 h
1 limited data
2 higher dosages have been used
Methyldopa (Aldomet®)
Methyldopa is an oral drug with an excellent safety record for use in pregnant women 26-28. The 
drug exert its antihypertensive eﬀect from the action of its metabolite α- methylnorepinefrine 
on central inhibitory α-adrenoreceptors. Common dosages of methyldopa are 500-1,000 mg 
orally taken 3-4 times daily, with a maximum of 4 g/day.
In mild pre-eclampsia and in the management of chronic hypertension in pregnant women, 
methyldopa is regarded as drug of choice, but its limited eﬃcacy and delayed onset of action 
(4-6 h) preclude its use in acute, severe pre-eclampsia. Side-eﬀects include decreased heart 
rate and sedation. 
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Hydralazin (Apresolin®) or dihydralazin (Nepresol®)
Hydralazin and dihydralazin diﬀer slightly in their molecular structure, but both act in a 
similar way as vasodilatating agents on arterial smooth muscle, causing a reduction in total 
peripheral vascular resistance and reﬂex tachycardia. The antihypertensive eﬀects occur 10-20 
min after intravenous administration, following metabolism in the vessel wall. The duration 
of action is 3-8 h 29. The drugs are very eﬀective in lowering maternal blood pressure, but 
maternal side-eﬀects (headache, nausea, epigastric pain and ﬂuid retention) are common 
and mimic symptoms of deteriorating pre-eclampsia. Careful monitoring of central venous 
pressure and adequate volume expansion is necessary in patients receiving (di)hydralazin, to 
prevent an excessive hypotensive eﬀect, causing foetal distress 30. 
Dosage schedules vary greatly, with repeated bolus administrations of hydralazin preferred 
in the US to prevent hypotensive overshoots 31,32. In the Netherlands, dihydralazin is commonly 
used as a continuous intravenous infusion starting with 1 mg/h after a bolus infusion in 30-60 
min of 5-10 mg, to a maximum of 10 mg/h. The availability of intravenous dihydralazine has 
been severly limited in the past years. Intravenous hydralazin is still generically available in 
the US and some European countries.
Intravenous (di)hydralazin has been regarded as the drug of choice in pre-eclamptic patients 
for many years 25. Recently, however, a meta-analysis 33 of 21 available randomised clinical trials 
for the treatment of severe hypertension (including 1,085 women) showed that hydralazin 
was associated with poorer maternal and perinatal outcomes than other antihypertensive 
drugs, particularly nifedipine and labetalol. Hydralazin was associated with a trend toward 
more persistent severe hypertension compared to nifedipine or isradipine [29% (0%-32%) 
vs 19% (0%-40%)], RR 1.41 (0.95-2.1) and with the use of additional antihypertensive drugs 
[13% (0%-32%) for hydralazin vs 5% (0-24%) for nifedipine, RR 2.13 (1.2-3.9)]. Seemingly 
contradictory, hydralazin was also found to be associated with more maternal hypotension 
than other antihypertensive drugs (labetalol, nifedipine, isradipine, ketanserin or uradipil) 
[0% (0%-67%) vs 0% (0%-17%), RR 3.29 (1.5-7.23)]. Other maternal complications occurred 
more often with hydralazin than with other antihypertensive drugs; caesarean section [67% 
(8%-100%) vs 59% (5%-100%)]; placental abruption [18% (3%-20%) vs 0% (0%-2%)] and 
maternal oliguria [17% (4%-41%) vs 0% (0%-9%)]. Hydralazin was associated with more 
adverse eﬀects on foetal heart rate than other antihypertensive drugs [11% (0%-56%) vs 0% 
(0%-50%)]. Hydralazin was also associated with more low APGAR scores at 1 min [67% (38%- 
83%) vs. 15% (14%- 67%)] but not at 5 min, and a trend towards an increase in stillbirth [0% 
(0%- 31%) vs 0% (0%- 22%), risk diﬀerence 0.02 (-0.01 to 0.05)]. 
However, the number of events ranged widely within trials, numbers of participants in most 
trials were small and a large heterogeneity between trials was present (e.g. mixed populations 
of either pre-existing hypertension or gestational hypertension with or without proteinuria 
were enrolled). Importantly, dosages of hydralazin and schedules of administration varied 
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widely between trials. Probably the main conclusion that can be drawn, is that (di)hydralazin 
is a drug that should be used only in experienced hands in a well-designed dosage schedule, 
and in a setting in which careful monitoring of maternal and foetal conditions is available. 
Labetalol (Trandate®)
Labetalol is a selective alpha-blocking and non-selective beta-blocking agent, lowering high 
blood pressure while, at the same time, exerting a heart-rate-reducing eﬀect because of the 
drug’s beta-blocking eﬀect. The drug is used in dosages of 10 to 30 mg/h intravenously or 
50 to 200 mg orally three times daily. After intravenous administration, the antihypertensive 
eﬀect occurs immediately with a duration of action of 4-6 h, whereas, after oral administration 
the eﬀect is delayed for 1-4 h. The drug is tolerated fairly well, with ﬂushing, nausea and 
vomiting as main side eﬀects. Due to the beta-blocking eﬀect, its use is contra-indicated in 
patients with congestive heart failure, asthma or bradycardia 29.
Oral labetalol has been used extensively in mild to moderate hypertension in pregnancy 
and pre-eclampsia 28,34. The drug has shown to be more eﬀective than methyldopa in 
decreasing blood pressure 35.
In severe pre-eclampsia, high intravenous dosages of labetalol (up to 2,400 mg/day) are 
sometimes necessary to obtain adequate maternal blood pressure in pre-eclamptic patients. 
However, these high maternal dosages of labetalol have been associated with the occurrence 
of severe neonatal bradycardia, hypotension and hypoglycaemia 36-38. These neonatal side-
eﬀects are the major limitation for its use in severe pre-eclampsia.
Ketanserin (Ketensin®)
A drug with a diﬀerent action is ketanserin. Ketanserin is a selective 5-HT2A receptor-
blocking agent with minor alpha-1-receptor-blocking properties. Its use in pre-eclampsia 
is based upon the assumption that serotonin is involved in the vasoconstrictive processes, 
leading to hypertension in pre-eclampsia. 5-HT1 receptors are located mainly in the vascular 
endothelium, whereas 5-HT2 receptors are localised in platelets and vascular smooth 
muscle cells. In pre-eclampsia, characterised by endothelial dysfunction and concomitant 
loss of 5-HT1 endothelial receptors, free serotonin will stimulate mainly 5-HT2 receptors in 
platelets causing platelet aggregation and serotonin release, and 5-HT2 receptors in vascular 
smooth muscle, causing vasoconstriction. The observation that levels of platelet-derived 
free serotonin are found to be signiﬁcantly higher in pre-eclamptic patients than in normal 
pregnancies 39 supports this theory. 
Ketanserin acts as an antagonist on the 5-HT2A receptor, counteracting the serotonin-
depending vasoconstriction and platelet aggregation. The latter may be clinically 
advantageous, especially in pregnancies complicated with HELLP-syndrome 40. 
The pharmacokinetic characteristics of the drug are not ideal for drug treatment in pre-
eclampsia because of its long elimination half-life of 10-18.5 h, which precludes accurate 
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titration and may lead to accumulation. Ketanserin is oxidized in the liver via mixed-function 
oxidases to inactive 6-hydroxy ketanserin or reduced to ketanserinol. The latter metabolite is 
considered inactive but may be re-oxidized to form ketanserin again 41.
Side eﬀects of ketanserin are mainly dizziness, dryness of the mouth, nasal congestion 
and tiredness. A potentially serious adverse eﬀect of ketanserin is prolongation of the QTc 
interval 42 and treatment should be accompanied by ECG control. 
The drug is licensed for use in pre-eclampsia but its availability is limited to some European 
countries and South Africa. In the Netherlands the drug is a ﬁrst choice drug in settings 
in which invasive monitoring of mother and foetus is not feasible, based upon its ease in 
handling.
Conﬂicting data exist on the eﬃcacy of ketanserin. Bolte et al 43 compared intravenous 
ketanserin (5 mg bolus, followed by a continuous infusion of 4 mg/h to a maximum of 
10 mg/h) with intravenous dihydralazin (no bolus, continuous infusion of 1 mg/h to a 
maximum of 10 mg/h) in 31 patients with severe early-onset pre-eclampsia and found 
both drugs to achieve adequate blood pressure control. Ketanserin acted more rapidly, but 
showed, at the same time, a more gradual decline in blood pressure without the occurrence of 
reﬂex tachycardia. In another trial, with 44 early-onset pre-eclamptic patients using a similar 
dosage schedule, Bolte et al 44 also showed that ketanserin resulted in a better blood pressure 
control and less maternal side eﬀects than dihydralazin. However, the dosage-schedule of 
dihydralazin did not comprise a bolus infusion as starting dosage, which makes comparisons 
of time to target blood pressure hazardous. Also, signiﬁcantly more patients treated with 
ketanserin needed antihypertensive co-medication to maintain adequate blood pressure 
control. A Cochrane review 45 on three available studies of ketanserin versus dihydralazin 
found that use of ketanserin was associated with persistent high blood pressure as compared 
to dihydralazin (28/74 vs 4/70, RR 6.74 [2.49-18.28]).
These data make the role of ketanserin in the treatment of pre-eclampsia ambiguous.
Calcium-channel blocking agents
Calcium-channel blocking agents inhibit the inﬂux of calcium via voltage dependent, slow 
L-type calcium channels, causing peripheral vasodilatation. The safety of the use of calcium- 
channel blocking agents of the dihydropyridine type in pregnant women has long been 
debated. In animal studies 46,47, the use of nifedipine and nicardipine has been associated 
with foetal acidemic responses, caused by a decrease of uteroplacental perfusion. However, 
in women with pregnancy-induced hypertension, nifedipine was not associated with a 
negative eﬀect on uteroplacental blood ﬂow 48, and the same conclusion was drawn after 
reviewing the extensive experience with nifedipine as a tocolytical drug in recent years 49. 
Probably, the adverse foetal eﬀects found in animals are linked to the substantially elevated 
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dosages as compared to dosages used as tocolytical or antihypertensive drug in pregnant 
women.
The successful use of nifedipine in pre-eclampsia has been described in several studies 50, 51 
and, as cited above, a recent review showed a favourable outcome of nifedipine as compared 
to parenteral hydralazin 33. Current dosage schedules of nifedipine are 20-90 mg orally daily as 
a sustained release formulation. In treating hypertension in non-pregnant patients, the short-
acting nifedipine has been associated with excess cardiovascular morbidity and mortality 
and its use has been replaced by sustained release formulations, both in non-pregnant and 
pregnant patients 52. However, these formulations are less eﬀective and less controllable in 
acute situations, and nifedipine, therefore, may not be ﬁrst choice treatment in severe pre-
eclampsia 53. 
Another concern in using nifedipine in pre-eclampsia has been the supposed risk of 
neuromuscular blockade during concomitant use of magnesium sulphate, as reported in 
case reports 54,55. However, a recent study analysing 162 patients and 215 controls, showed 
that patients who received nifedipine and magnesium sulphate contemporaneously had 
no excess of neuromuscular weakness and no neuromuscular blockade (53%) vs control 
subjects who received antihypertensive drugs only (53.1%) or vs control subjects who receive 
no antihypertensive medication at all (44.8%) 56. 
The advantages of the use of nifedipine are its ease of administration and its low costs. Side 
eﬀects of nifedipine are limited and are mainly ﬂushing, nausea and vomiting. The tocolytical 
eﬀects of nifedipine might be disadvantageous in pre-eclamptic patients, delaying induction 
of labor or increasing the risk of postpartum haemorrhage 57. Calcium-channel blocking 
agents have been associated with the occurrence of pulmonary oedema, possibly caused 
or enhanced by the cardiovascular action of the dihydropyridine derivates 58. However, 
irrespective of antihypertensive treatment, pulmonary oedema is known to occur as a 
complication in pre-eclampsia, usually after iatrogenic ﬂuid overload in combination with 
the administration of steroids for foetal lung maturation 29.
 
The lack of an immediate acting and well-controllable formulation of nifedipine and its cardio-
depressant side-eﬀects, stimulated the search for alternative calcium-channel blocking 
agents. The use of isradipin in pre-eclampsia has been found eﬀective in small studies 59, but 
an intravenous formulation is not available in most countries. 
Nicardipine (Cardene®) is a calcium-channel blocking agent, with some potential 
advantages over nifedipine in pre-eclampsia 60. It acts more selectively on the vessels and 
causes less negative inotropic eﬀects and reﬂex tachycardia. Another advantage is that the 
drug is available both for oral and intravenous administration, but intravenous administration 
should be performed through a central line because of the risk on phlebitis. The drug has a 
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short half-life of 2-5 min which increases after prolonged infusion to 1-2 h 61. It is metabolised 
extensively in the liver to inactive metabolites.
Studies on its use in pre-eclamptic patients are limited. Carbonne 62 was the ﬁrst to describe 
its use, intravenously, in 20 pre-eclamptic patients with a gestational age between 27 and 
40 weeks with failure on oral antihypertensive treatment. Nicardipine was administered in 
a dosage of 2 to 6 mg/h, depending on body weight. Eﬃcacy was evaluated by the time 
required to decrease diastolic BP below 90 mmHg. Target BP was reached in all patients 
within 70 – 120 min and treatment was sustained for 5 days (2-15 days). Doppler velocimetry 
remained stable and neonatal outcome showed no deleterious eﬀects of the treatment. 
Maternal headache and increase in heart rate were the most common side eﬀects. 
The same group 63 compared oral nicardipine (3 dd 20 mg) to oral metoprolol (1 dd 200 
mg slow-release) in 100 pregnant patients with moderate to mild hypertension (consisting of 
a mixed population of chronic hypertension, gestational hypertension and pre-eclampsia), 
starting after the 20th week of pregnancy. Nicardipine was more eﬀective than metoprolol 
in reducing both systolic and diastolic BP. Treatment failure tended to be less frequent (n = 
7 vs n = 15, p < 0.06) and at a later gestational age in the nicardipine group as compared to 
the metoprolol group (35 ± 2.6 weeks vs 31.4 ± 4.4 weeks). The umbilical artery resistance 
was lower as well as the incidence of caesarean delivery for foetal distress in the nicardipine 
group. No signiﬁcant diﬀerence in neonatal outcome was detected. 
To assess the eﬃcacy in hypertensive emergencies in pregnancies, Elatrous et al 64 
compared the eﬀect of a 1 h infusion of labetalol with nicardipine in 60 patients with severe 
hypertension. Both drugs achieved target BP (20% lowering of BP) in the same proportion 
and at the same length of time. 
Aya et al 65, using a loading dose of nicardipine of 1 mcg/kg/min in 20 pre-eclamptic 
patients (GA 29 - 36 weeks) obtained target BP (15% reduction in MAP) in all patients within 
15-20 min. Treatment was followed by continuous infusion of a reduced dosage during one 
day to maintain MAP at 20-30% below the initial value. Foetal tolerance, assessed by foetal 
heart rate, was good, but severe tachycardia was noted in two patients.
Long-term treatment (31 - 250 days) with intravenous nicardipine (20 - 80 mg/day) in ten 
pregnant women with severe hypertension (both pre-eclampsia as pre-existing chronic 
hypertension) was shown to be eﬃcacious and without maternal or foetal/neonatal adverse 
eﬀects 66. In conclusion, nicardipine seems to be a promising drug in the treatment of pre-
eclampsia, but more data are needed on eﬃcacy and safety aspects.
Other antihypertensive drugs
For treatment of an acute hypertensive emergency, hydralazin is most widely used. If 
hydralazin is, in rare cases, not eﬀective, or, if the delayed onset of action of 10-20 min poses a 
risk to the mother, sodium nitroprusside can be used in acute situations in a dosage of 0.2-0.8 
mg/min intravenously. Sodium nitroprusside is very potent and acts almost immediately by 
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direct dilatation of arterioles and veins. Its short duration of action (3-5 min) allows accurate 
titration of the blood pressure 29. Due to the possible risk of accumulation of cyanide in foetus 
and mother, prolonged use is not recommended 26.
Several other classes of drugs are used to treat hypertension in non-pregnant patients, 
but are (relatively) contra-indicated during pregnancy. The use of angiotensin-converting 
enzyme inhibitors during pregnancy has been associated with foetal and neonatal renal 
failure, oligohydramnios, intrauterine growth retardation and increased foetal mortality 26. 
The use of diuretics is contra-indicated in pre-eclampsia because plasma volume is already 
decreased and further volume depletion could aﬀect the foetus adversely 29,67. The beta-
blocking agents metoprolol and atenolol are used orally as add-on treatment in severe pre-
eclampsia. However, long-term use of beta-blocking agents has been associated with an 
increase in small-for-gestational-age infants, especially with atenolol 68. Neonatal bradycardia, 
hypoglycemia and respiratory depression have also been reported as side eﬀects, probably 
due to the beta-blocking eﬀects.
Foetal and neonatal eﬀects of maternal antihypertensive drug treatment
Maternal drug use may exert unwanted eﬀects on the foetus by a direct pharmacological 
action of the drug after passing the placenta or by an indirect action, caused by compromising 
the uteroplacental perfusion. The latter can occur with all antihypertensive drugs through an 
overshoot of lowering of maternal blood pressure, resulting in foetal distress due to marginal 
placental function. Especially, the use of drugs which cause vasodilatation but which do not 
aﬀect placental vascular resistance, such as (di)hydralazin, can cause a reduction in placental 
ﬂow, leading to foetal distress. Indeed, a recent review 33 showed that hydralazin was 
associated with more adverse eﬀects on foetal heart rate than other antihypertensive drugs. 
Drugs, which are eﬀective at the level of the placental vasculature, such as calcium-channel 
blocking agents, should, theoretically, be able to maintain adequate placental perfusion. 
Direct pharmacological eﬀects are related to the amount of drug passing the placenta and 
the period of foetal exposure. Many drugs cross the placenta by simple diﬀusion, depending 
on the physicochemical characteristics of the drug and placental factors such as surface area 
and thickness of the membrane. An active transport mechanism across the placenta is also 
known to occur, mainly for endogenous substances such as amino acids and methyldopa. 
Recently, P-glycoprotein has been found to form a functional barrier between maternal and 
foetal blood circulation in the placenta, and use of P-glycoprotein inhibiting compounds may 
increase exposure of the foetus to P-glycoprotein substrates, such as digoxin 69.
As the use of antihypertensive drugs for management of pre-eclampsia is limited to the 
late second and third trimester, teratogenic eﬀects are not relevant. However, in expectant 
management of pre-eclampsia, drugs are used in high dosages, often in combination 
treatment, for a prolonged period of time and information regarding placental transfer and 
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possible adverse eﬀects on foetus and neonate are often unknown. This is even more relevant 
as many neonates born from mothers with severe early-onset pre-eclampsia are premature 
and are probably more susceptible to adverse drugs eﬀects.
For most drugs mentioned in this review, information is available either from animal studies 
or from human data regarding placental transfer (Table 1.2). Almost all antihypertensive 
drugs used in pre-eclampsia, pass the placenta freely, but information regarding ketanserin 
and nicardipine are lacking. 
Neonatal morbidity or mortality is usually reported in studies describing the use of 
antihypertensive drugs in severe pre-eclampsia but are hard to interpret due to the fact 
that inherent to the severity of the maternal illness, most children are born prematurely and 
growth-retarded, with a corresponding high morbidity and mortality in the ﬁrst postnatal 
months. To date, only high maternal doses of labetalol have been associated in case reports 
with direct neonatal side eﬀects (bradycardia, hypoglycaemia) 36,37.
Long-term follow up of neonates to assess possible eﬀect of maternal antihypertensive drug 
use on growth and development is scarce. A six-year follow-up after maternal prophylactic 
oral use of ketanserin did no show any negative eﬀect on mental development 70. A follow-
up study after use of dihydralazin for temporising management did not reveal any negative 
eﬀect on morbidity and development of the infants in childhood 71. For the other currently 
used antihypertensive drugs, no follow up studies are available.
Table 1.2  Transplacental transmission and foetal and neonatal effects of antihypertensive drugs 
used in pre-eclampsia.
Drug Transplacental transmission Foetal and neonatal effects
(Di)Hydralazin High (equal to mother) 72 Foetal distress due to acute drop 
maternal blood pressure33. No 
known adverse neonatal effects71.
Methyldopa High (equal to mother) 73 No foetal and pediatric adverse 
effects known26-28
Labetalol Intermediate (40-80% of maternal 
levels) 26
Possible foetal intrauterine 
growth retardation. Beta blockade 
effects at birth (hypoglycemia, 
hypotension, bradycardia)36,37 
Ketanserin Unknown No short or long term adverse 
effects in neonates reported70
Nifedipine High (equal to mother) 74, 75 In animal foetal acidemic 
responses, not conﬁrmed in 
humans48,49
Nicardipine Unknown In animal foetal acidemic 
responses, not conﬁrmed in 
humans65,66 
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AIMS AND SCOPE OF THE THESIS
Antihypertensive treatment is still the mainstay in the pharmacological approach of pre-
eclampsia, to prevent maternal complications like cerebrovascular haemorrhage and organ 
damage. Well-known drugs such as oral methyldopa for mild pre-eclampsia and parenteral 
(di)hydralazin for severe pre-eclampsia are commonly used, but because of ambiguous 
reports on the safety of (di)hydralazin and its decreasing commercial availability, other 
potent, well studied, antihypertensive drugs are warranted. 
This thesis focuses on eﬃcacy and safety aspects of two newer antihypertensive drugs in 
pre-eclampsia: the serotonin antagonist ketanserin and the calcium-channel blocking agent 
nicardipine.
To determine the eﬃcacy of ketanserin in the population of severe early-onset pre-eclamptic 
patients, admitted to the Obstetric Intensive Care ward at the Erasmus MC, we performed 
a retrospective analysis of patients treated with ketanserin (Chapter 2). Following our 
observation that a substantial proportion of our patients did not show an adequate 
antihypertensive response to ketanserin, we aimed to study pharmacological aspects in 
those patients. 
To enable us to determine plasma levels of ketanserin, we developed a bioanalytical 
method (Chapter 3). We subsequently considered both pharmacokinetic aspects (Chapter 
4), as well as pharmacodynamic aspects (Chapter 5) of ketanserin in our eﬀort to explain for 
the lack of antihypertensive eﬃcacy of ketanserin.
To obtain more information regarding the safety of maternal use of ketanserin, we 
studied placental transfer, transfer into breast milk and disposition in the neonate after 
maternal treatment with ketanserin (Chapter 6). Knowing that 5-HT is one of the earliest 
neurotransmitters produced during foetal brain development, the possible inﬂuence on 
foetal 5-HT-receptor functionality after exposure to the 5-HT-receptor antagonist ketanserin 
was analysed in Chapter 7. 
We studied the calcium-channel blocking agent nicardipine, as an innovative alternative 
treatment modality in early-onset pre-eclamptic patients, after treatment failure of either 
intravenous ketanserin or dihydralazin (Chapter 8). We made an estimate of possible risks 
for the foetus by determining placental transfer and disposition of nicardipine into human 
milk (Chapter 9).
The interpretations of our results with recommendations for the respective roles of 
ketanserin and nicardipine in the treatment of pre-clampsia are discussed in the ﬁnal chapter 
(Chapter 10).
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ABSTRACT
The objective of the study was to analyze the eﬃcacy of intravenous ketanserin in controlling 
blood pressure of severe early-onset pre-eclamptic patients. Pre-eclamptic patients (n = 47) 
with a gestational age (GA) between 21 and 32 weeks were treated with intravenous ketanserin 
in a maximum dosage of 14 mg/h, to obtain an intra-arterial diastolic blood pressure of 90 
mmHg or below. The number of patients reaching and maintaining target blood pressure was 
retrospectively assessed. Patient characteristics associated with an adequate or inadequate 
response to ketanserin treatment were identiﬁed.
With a maximum intravenous dosage of ketanserin, target blood pressure was not achieved 
in 15 (32%) patients. A high systolic blood pressure at the start of treatment was signiﬁcantly 
(p = 0.02) associated with failure of ketanserin treatment. The median period of ketanserin 
treatment in the responding group was 3 days (range 1-10 days). In 26 (55%) of initially 
successfully treated patients, additional antihypertensive drugs had to be added to maintain 
adequate blood pressure control. 
In conclusion, intravenous ketanserin lacks antihypertensive eﬃcacy in a substantial 
proportion of severe pre-eclamptic patients, despite high dosages. In patients who initially 
respond well to ketanserin treatment, additional antihypertensive treatment is often 
necessary to maintain adequate blood pressure control. 
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INTRODUCTION 
The mainstay of treatment of pre-eclampsia is to lower the elevated blood pressure in order 
to prevent maternal complications like cerebrovascular hemorrhage and organ damage. In 
early-onset pre-eclampsia, adequate antihypertensive treatment can also yield suﬃcient 
time to administer antenatal steroids in order to improve neonatal outcome. In recent years, 
temporizing management with antihypertensive drugs is increasingly applied in patients 
with early-onset pre-eclampsia as long as both maternal and foetal condition permits 1-3. 
The use of the serotonin (5-HT)- antagonist ketanserin for antihypertensive treatment of 
pre-eclampsia has increased in the past years. The drug acts by blocking the vasoconstrictive 
response upon binding of 5-HT to 5-HT2A receptors in vascular tissue 
4. Because of its inhibitory 
eﬀect on platelet aggregation, ketanserin is thought to have an additional beneﬁcial eﬀect in 
patients with HELLP-syndrome (haemolysis, elevated liver enzymes, low platelet-count) 5.
There are conﬂicting data on the eﬃcacy of ketanserin in pre-eclampsia. Bolte et al 6 showed 
that ketanserin resulted in a better blood pressure control and less maternal side eﬀects than 
dihydralazin. However, the dosage of dihydralazin was low and the patients treated with 
ketanserin needed antihypertensive co-medication to maintain adequate blood pressure 
control. Rossouw et al 7 compared short-term antihypertensive treatment with ketanserin 
and dihydralazin in a group of 80 patients with severe hypertension in the third trimester 
of pregnancy and found a better antihypertensive response with dihydralazin. However, 
ketanserin has the advantage of causing a more gradual decline in blood pressure than 
dihydralazin 6, which may reduce the risk of foetal distress. Ketanserin is one of the few drugs 
in the Netherlands licensed for pre-eclampsia in patients with a diastolic blood pressure of 
110 mmHg or higher and has become the drug of choice to stabilize pre-eclamptic patients. 
In 1999 we started using ketanserin as a ﬁrst line treatment in our hospital for severe early-
onset pre-eclampsia with the aim to control blood pressure and prolong pregnancy, as long 
as maternal and foetal condition allow. Because of the conﬂicting data on the eﬃcacy of 
ketanserin and the need for clinical evaluation of the use of ketanserin in a population of 
severe early-onset pre-eclamptic patients, we performed a retrospectively analysis of the use 
of ketanserin, in terms of its eﬃcacy in controlling blood pressure.
MATERIAL AND METHODS
Patients who were admitted to the antenatal High Care ward in the period 1999-2002 with 
severe early-onset pre-eclampsia (GA between 20 and 32 weeks on admission) were included 
in this evaluation. Severe pre-eclampsia was deﬁned as the occurrence after 20 weeks of 
gestation of a diastolic blood pressure ≥ 110 mm Hg (Korotkoﬀ V) and proteinuria ≥ 0.3 g/24h 
or the occurrence of a repetitive diastolic blood pressure > 90 mmHg in combination with 
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the HELLP-syndrome. HELLP-syndrome was deﬁned as the simultaneous occurrence of ALAT 
and/or ASAT > 31 U/l (2 SD above the mean in our hospital), platelet count below 100 x 109 
platelets/L and haptoglobin below 0.28 g/l (normal value 0.28-2.01 g/l). 
Each woman received a radial arterial line for intra-arterial blood pressure measurement 
and a central venous line for central venous pressure (CVP) measurement.
Antihypertensive treatment was continued as long as foetal and/or maternal condition did 
not warrant delivery, as judged by the attending obstetrician. Foetal condition was assessed 
using cardiotocography (CTG) after a gestational age of 26 weeks or more. 
Drug Treatment
Drug treatment was targeted at achieving an intra-arterial diastolic blood pressure of 90 
mmHg or below (with a lowest limit of acceptance of 75 mmHg).
After a bolus injection of 5 mg, the infusion rate of ketanserin (Ketensin®, Pharmacia, 
Woerden, the Netherlands) was initiated at 4 mg/h and increased, according to the blood 
pressure, with 2 mg/h every 20 minutes to a maximum of 14 mg/h. Each increment was 
preceded by an intravenous loading bolus injection of 5 mg ketanserin. Patients, who were 
already taking oral antihypertensive drugs on admission (methyldopa and/or nifedipine) 
continued these medications at their established dosage regime. 
The goal was to reach the desired intra-arterial diastolic blood pressure using the titration 
schedule with ketanserin to a maximum of 14 mg/h. If the desired blood pressure could 
not be obtained using the maximum dosage of ketanserin, oral antihypertensive drugs 
(methyldopa tot a maximum of 4 g daily or nifedipine to a maximum of 90 mg daily) and 
subsequently parenteral dihydralazin (starting with 1 mg/h to a maximum of 12 mg/h) or 
nicardipine (starting with 1 mg/h to a maximum of 10 mg/h) were started.
CVP was maintained at 5-6 mmHg, using pasteurized plasma-solution. All patients received 
antenatal steroids after 26 weeks of gestation. 
Data Analysis
The eﬃcacy of ketanserin treatment was assessed by analyzing the proportion of patients 
that reached the target blood pressure with ketanserin (responding group) and the group 
of patients that did not reach target blood pressure (non-responding group), despite the 
maximum dosage of ketanserin. The responding and non-responding groups were compared 
with respect to diﬀerences in initial patient characteristics (diastolic and systolic blood pressure 
and gestational age at the start of treatment), using the Mann-Whitney-U test. Additionally, 
both groups were compared with respect to the use of oral antihypertensive drugs at start of 
treatment and diagnosis of HELLP-syndrome at start of treatment, using the Chi-square test. 
Statistical analysis was performed using SPSS (version 10.1, SPSS Inc, Chicago, USA).
Safety of ketanserin treatment was determined as the absence of hypotensive periods during 
treatment (deﬁned as an intra-arterial diastolic BP < 70 mmHg) as well as the assessment of 
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maternal adverse eﬀects, as reported in the patient charts. Foetal and neonatal outcome was 
assessed in terms of intra-uterine foetal death (IUFD), neonatal death, number of severely 
growth restricted neonates at birth, pH-value umbilical artery, number of neonates with an 
APGAR score <7 at 5’ and number of neonates admitted to ICU.
RESULTS
Forty-seven patients between 1999-2002 were admitted with severe early-onset pre-
eclampsia to the high care obstetric ward and treated with intravenous ketanserin. Clinical 
characteristics of these 47 patients before start of treatment are presented in Table 2.1.
In 32 patients (68%) the target blood pressure was initially achieved, using ketanserin 
(responding group). In 15 patients (32%) the target blood pressure could not be achieved 
with ketanserin at the maximum dosage (non-responding group). In this latter group, 
three patients were subsequently delivered because of foetal distress, whereas in the other 
12 patients adequate blood pressure control was achieved by adding (n=6) or increasing 
(n=6) the dosage of oral antihypertensive drugs (methyldopa, nifedipine) and subsequently 
adding intravenous dihydralazin (n=9, maximum dosage needed 12 mg/h) or nicardipine 
(n=2, maximum dosage needed 7 mg/h). 
Table 2.1 Clinical characteristics of pre-eclamptic patients at the start of ketanserin treatment (n=47)
Median (range) or number (%)
Maternal age (years) 31 (20-41)
Systolic blood pressure (mm Hg) 172 (140-240)
Diastolic blood pressure (mm Hg) 105 (91-125)
Proteinuria (g/24h) 2,62 (0,31-17,5)
HELLP syndrome (n) 23 (49%)
Gestational age (weeks) 28 (21-32)
Nulliparous (n) 37 (78%)
Twin pregnancy (n) 2 (4%)
Pre-existent hypertension (n)
Oral co-medication before start of ketanserin:
- Methyldopa
- Methyldopa and nifedipine
- Methyldopa and labetalol
- Nifedipine
- None
7 (15%)
22 (47%)
3 (6%)
1 (2%)
2 (4%)
19 (41%)
1  cause of death: respiratory distress associated with very preterm birth (n=2), cerebral bleeding (n=1) and 
cerebral lesions (n=1).
2  cause of death: severe bronchopulmonary dysplasia
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No relationship between failure of ketanserin therapy and median diastolic blood pressure 
at start of treatment [non-responding group 108 mmHg versus responding group 105 mmHg 
(p=0.35)] or gestational age at start of treatment [non-responding group 27 5/7 weeks versus 
responding group 28 6/7 weeks (p=0.6)] was demonstrated. A signiﬁcantly (p=0.02) higher 
initial systolic blood pressure was found in the non-responding group (median 185 mmHg, 
range 145-240), as compared to that in the responding group (median 170 mmHg, range 140-
190). In the group of non-responders seven (47%) patients did not use oral antihypertensive 
drugs before start of treatment as compared to 12 patients (37.5%) in the responding group 
(not signiﬁcantly, p>0.1). 
In 26 (55%) of the initially responding patients, additional antihypertensive drugs had 
to be started (n=9) or increased (n=17) during admission to maintain adequate blood 
pressure control. In seven patients, after encountering no safety problems with ketanserin, 
we decided to allow a maximum intravenous dosage of 0.2 mg/kg/h ketanserin (with an 
absolute maximum of 20 mg/h) and use bolus injections of 10 mg before each increment. 
In three of these patients, the higher dosage temporarily resulted in an adequate diastolic 
blood pressure, but in all patients additional antihypertensive treatment was necessary. 
Intravenous magnesium sulphate was administered to ten pre-eclamptic patients, to prevent 
eclampsia.
Overall, pregnancy was prolonged for a median of 6.5 days (range 0-40 days) after admission, 
using antihypertensive medication. The overall median period of ketanserin treatment in the 
responding group was 3 days (range 1-10 days). Foetal distress was most frequently (66%) 
the reason to deliver the patient. About 88% of the patients were delivered by caesarean 
section. 
Twenty-three (49%) women were diagnosed with the HELLP-syndrome on admission. This 
high percentage can be attributed to the tertiary referral function of our Obstetric ward. 
Overall, in 11 (48%) of these women, the HELLP-syndrome resolved during treatment. In three 
women HELLP-syndrome developed during treatment. No signiﬁcant diﬀerences were found 
in number of responders to ketanserin treatment between patients with HELLP-syndrome 
(18 of 23 patients, 78%) or without HELLP-syndrome (14 of 24 patients, 58%) at admission. 
Maternal safety
Ketanserin was generally well tolerated. Some patients complained of fatigue, sedation 
and nasal stuﬃness. Hypotensive periods were not observed during ketanserin treatment. 
Ketanserin has been associated with a risk of QT- prolongation and cardiac arrest 8. In none 
of our patients, cardiac problems were apparent. However, obtaining an ECG was at that time 
not part of our standard procedures, so no reliable conclusions regarding QT-prolongation 
can be drawn.
Foetal and neonatal outcome are shown in Table 2.2. Although this study was primarily 
focused on maternal eﬃcacy and most neonates were born from mothers who had been 
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using combinations of antihypertensive treatment before delivery, our data on perinatal 
mortality (24%) were comparable with historical data on perinatal mortality (20.5%, n=254) 
from our hospital of pre-eclamptic patients treated with dihydralazin 1.
DISCUSSION
Pre-eclampsia is treated with antihypertensive drugs to prevent maternal complications of 
high blood pressure and to yield suﬃcient time before delivery to administer steroids to the 
mother to improve the condition of the newborn. However, the intricate balance between 
lowering maternal blood pressure while not compromising foetal circulation, complicates 
administration of antihypertensive drugs to pre-eclamptic patients. 
The current choice of antihypertensive drugs is limited. Ketanserin is one of the few 
drugs, licensed for treatment of pre-eclampsia in the Netherlands. This study describes 
our experiences with intravenous ketanserin in stabilizing blood pressure and maintaining 
adequate blood pressure control in patients with severe early-onset pre-eclampsia. 
Our data show that one third of our patients did not respond to treatment with high doses 
of ketanserin with an adequate reduction of the blood pressure. This supports the suggestion 
in the literature that pre-eclamptic women treated with ketanserin are more likely to have 
persistent hypertension than those treated with other intravenous antihypertensive drugs, 
such as hydralazin 9. 
The non-responding group warrants further analysis. An extended period of inadequate 
blood pressure control, caused by using a drug with no or insuﬃcient eﬀect may become 
critical for the patient with severe pre-eclampsia. We found that the diastolic blood pressure 
at the start of treatment did not show a signiﬁcant relationship with failure of treatment, 
whereas the height of systolic blood pressure was a prognostic factor in determining the 
Table 2.2  Foetal and neonatal outcome 
Median (range) or number (%)
Gestational age at delivery (weeks) 29 6/7 (24 5/7-34 4/7)
Number of fetuses (n) 49
Perinatal mortality (n)
- Fetal death (n)
- Neonatal death (n) (< 6 weeks)
- Infant death (n) (6 weeks- 1 year)
12 (24%)
8 (16%)
41
12
Birth weight (gram) 1030 (520-2340)
Growth percentile 
- Below 10% percentile (n)
- Below 2.3% percentile (n)
18 (43%)
3 (7%)
pH-value umbilical artery 7, 24 (6,96-7,38)
Apgar <7 at 5 min. (n) 9 (22%)
Admission to neonatal intensive care (n) 37 (90%)
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eﬃcacy of ketanserin treatment. The fact that in the responding group a (non-signiﬁcantly) 
higher number of patients used oral antihypertensive drugs before start of treatment, might 
also have contributed.
Pharmacokinetic problems such as a subtherapeutic dosage or an ineﬀective concentration 
at the receptor site 10, may also cause an insuﬃcient response. However, the fact that higher 
dosages of ketanserin did not elicit better responses, makes a dosage problem less likely. 
Another possibility is that the disease itself may account for diﬀerent reactions of pre-
eclamptic patients to treatment. The origin of pre-eclampsia is still largely unknown and the 
assumption that all pre-eclamptic patients can be considered as one group with a uniform 
disease may not be correct 11. 
Over 50% percent of the patients in the responding group needed co-medication besides 
ketanserin during the treatment period to maintain adequate blood pressure control, 
which emphasizes the potency problem with ketanserin. However, since pre-eclampsia 
is a progressive disease, increasing antihypertensive treatment is usually warranted 
during admission. According to our protocol, second-line therapy after insuﬃcient blood 
pressure control with ketanserin consisted of addition of oral antihypertensive medication 
and subsequently addition of parenteral dihydralazin or nicardipine. This protocol led to 
adequate blood pressure control in all patients and delivery in the majority of patients could 
be postponed.
Ketanserin is known to pass the placenta extensively 12 and pharmacological eﬀects on 
foetus and neonate can therefore not be excluded. Analysis of CTG in our hospital of 23 pre-
eclamptic patients during ketanserin treatment, compared to 40 dihydrazin treated patients 
(Lagro M et al, unpublished data) showed indeed that maternal ketanserin treatment 
decreases foetal heart rate, as compared to dihydralazin treated patients. The foetal and 
neonatal mortality data in this evaluation were comparable with historical data from our 
hospital, but valid conclusions regarding safety of ketanserin for the neonate cannot been 
drawn from this study, since most mothers had used a combination of antihypertensive 
drugs before delivery. However, other studies 13,14 have conﬁrmed the lack of adverse eﬀects 
in the neonate after maternal ketanserin use.
A retrospective observational and non-comparative study on the eﬃcacy of a drug, as 
reported in this paper, has its limitations. Some of the patients, included in the analysis, 
already used co-medication on admission. Treatment was not blinded and the decision for 
any intervention may therefore have been biased by former experiences of the obstetrician.
However, this analysis was intended to evaluate our current policy in clinical practice of 
using ketanserin as a ﬁrst-line treatment for severe, early-onset, pre-eclampsia. Despite 
the limitations of its methodology, our ﬁndings of a substantial group of non-responders 
on ketanserin are important for daily clinical care. More research is needed into alternative 
antihypertensive treatment strategies. 
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CONCLUSION
Intravenous ketanserin lacks antihypertensive eﬃcacy in a substantial part of severe, early-
onset pre-eclamptic patients, despite high dosages. A high systolic blood pressure at start 
of treatment was associated with an inadequate antihypertensive response on ketanserin. 
In patients who initially respond well to ketanserin treatment, additional antihypertensive 
treatment is often needed to maintain adequate blood pressure control. 
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ABSTRACT
A sensitive and selective high-performance liquid chromatographic assay for the quantiﬁ-
cation of ketanserin and ketanserinol in human plasma was developed and validated. The 
procedure involves extraction of ketanserin and ketanserinol from plasma using an Extrelut 
NT-1 solid-phase extraction column. The chromatograph was equipped with a Hypersil BDS 
column (100 x 4.5 mm, 3 μm particle size). Separation was performed with a mixture of acetate 
buﬀer 0.01 M, pH 4.9 : methanol : acetonitrile (52 : 40 : 8, v/v/v). Detection was performed with 
ﬂuorescence detection (λex = 332 nm and λem = 410 nm). Calibration curves were linear (r2 = 
0.999) in the range of 0 – 400 ng/ml for both ketanserin and ketanserinol. The repeatability 
coeﬃcient for ketanserin and ketanserinol was 3.1 and 3.0%, respectively. The reproducibility 
coeﬃcient for ketanserin and ketanserinol was 10.5 and 9.1%, respectively. The limit of 
quantiﬁcation for both ketanserin and ketanserinol was 2.0 ng/ml. The mean recovery yield 
for both ketanserin and ketanserinol was 60%. In an 8 h work day approximately 60 samples, 
including calibration and reference standards could be processed.
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INTRODUCTION
Ketanserin is a potent 5-HT2A receptor antagonist with minor α1-receptor blocking properties. 
The drug is metabolised in the liver by ketone reduction and oxidative N-dealkylation, and 
to a lesser extent in man by aromatic hydroxylation. The main metabolite is ketanserinol (R-
46,742; reduced ketanserin; Figure 3.1) 1,2.
Ketanserin has been used in the management of chronic hypertension. Recently, ketanserin 
has gained interest in the management of pre-eclampsia, a disease in which serotonin is 
thought to play a important part in the pathophysiology 3. Several studies have shown that 
ketanserin is useful in the control of blood pressure in women with pre-eclampsia, but in 
severe pre-eclamptic patients, ketanserin shows variable eﬃcacy 4. This may be caused by 
insuﬃcient dosage, resulting in subtherapeutic druglevels. Dosage regimens of ketanserin 
in the treatment of pre-eclampsia are not very well established 5. Exploration of the 
pharmacokinetic properties of ketanserin in pregnant and pre-eclamptic patients, using 
plasma levels, is essential to design and implement rational dosage regimens. Furthermore, 
little information is available regarding the disposition of ketanserin in neonates after maternal 
treatment with ketanserin. Measurements of plasma levels in neonates are therefore needed 
to determine this disposition. 
In the last two decades several methods have been published for the determination of 
ketanserin and/or its major metabolite ketanserinol in plasma. Some require UV detection 
and others ﬂuorometric detection (Table 3.1). We experimented with several methods in our 
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Figure 3.1 Chemical structure of ketanserin and reduced ketanserin (ketanserinol).
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laboratory, but none of the methods met our criteria on selectivity, speciﬁcity, sensitivity and 
throughput.
Also, measurement of plasma levels of ketanserin in neonates, who are usually premature or 
dysmature babies due to maternal pre-eclampsia, necessitated the search for a method that 
demanded only a small sample size. In order to overcome those limitations we developed an 
assay, quite diﬀerent from those that already have been published. In this paper, a sensitive 
and selective method is described for the assessment of ketanserin and its reduced metabolite 
ketanserinol in small samples with a high throughput. 
Table 3.1 Methods for the quantitative analysis of ketanserin and reduced ketanserin in biological 
matrices, applicable for clinical studies.
Method Analyte Matrix Volume Clean-up LLQ Reference
HPLC-UV KT P 1 ml LLE 7.9 ng/ml 6
HPLC-FD KT P 1 ml LLE 500 pg/ml 7
HPLC-UV KT P 1 ml LLE 2 ng/ml 8 
HPLC-UV KT, KTOL P 2 ml LLE 10 ng/ml 9
HPLC-FD KT, KTOL P
U
1 ml
0.2 ml
LLE 0.2 ng/ml 10
HPLC-UV KT P 1 ml LLE - 11
HPLC, High-performance liquid chromatography; UV, ultraviolet detection; FD, ﬂuoremetric detection; KT, 
ketanserin; KTOL, reduced ketanserin (ketanserinol); P, plasma; U, urine; LLE, liquid-liquid chromatography; 
LLQ, limit of quantiﬁcation.
EXPERIMENTAL
Chemicals and reagents 
Ketanserin(3-{2-[4-(4-fluorobenzyl)-1-piperidinyl]ethyl}-2,4-[1H,3H]-quinazolinedione, 
ketanserinol(3-{2-[4-(4-fluorobenzyl)hydroxymethyl-1-piperidinyl]ethyl}-2,4-[1H,3H]-
quinazoline dione) and R-46,594 (used as internal standard, 3-{2-[4-(4-chlorobenzyl)-1-
piperidinyl]ethyl}-2,4-[1H,3H]-quinazoline dione) were obtained from Janssen-Cilag (Beerse, 
Belgium). All organic solvents were of HPLC grade. Isoamyl alcohol, other reagents and 
chemicals were of analytical grade. Ammonia solution 25 % Suprapur, methanol, glacial 
acetic acid, sodium acetate and n-heptane were purchased from Merck (Amsterdam, The 
Netherlands). Acetonitrile was obtained from J.T. Baker (Deventer, The Netherlands).
Equipment
The chromatographic system consisted of a TSP P4000 HPLC pump, a TSP AS3000 automatic 
sampler (Thermo Separation Products Inc., San Jose, CA, USA), a Hypersil BDS C18 100 
x 4.5 mm reversed-phase column packed with 3 μm particles (Chrompack, Middelburg, 
The Netherlands). Detection was performed with a Shimadzu RF-10A spectroﬂuorometric 
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detector (Shimadzu, Kyoto, Japan). The standard software for TSP equipment, TSP software 
PC1000 version 3.5.1, was used to record and integrate detector responses. The mobile phase 
consisted of 0.01 M acetate buﬀer, pH 4.9 : methanol : acetonitrile (42:40:8, v/v/v). The ﬂow 
rate was set at 0.9 ml/min. Excitation and emission wavelengths were set at 332 nm and 410 
nm, respectively.
Sample preparation and assay
A volume of 200 μL plasma was transferred to a 10-mL tube. Subsequently, 100 μL of methanol 
containing 53 ng of R46594 (internal standard) and 500 μl of 2.5 % ammonia solution was 
added. The aliquot was passed over a solid-phase extraction column (Extrelut NT-1, Merck 
KGaA, Darmstadt, Germany). The column was eluted with 7 mL n-heptane/isoamylalcohol 
95/5. The eluent was evaporated to dryness under a gentle nitrogen stream at 60 °C. The 
residue was reconstituted in 100 μl of mobile phase. From this, 50 μl were injected into the 
HPLC system.
Plasma samples were stored at -20 °C before analysis. The inﬂuence of freezing and thawing 
on the levels of ketanserin in plasma was tested in triplicates. The levels of ketanserin were 
determined after one cycle of freezing at -20 °C and thawing, three cycles of freezing and 
thawing and six cycles of freezing and thawing. Results were compared with levels measured 
immediately after sampling in the patients. 
Calibration graph
Standard solutions containing 0.06, 0.12, 0.3, 1.2, 3.0, 6.0 and 12.0 mg/L ketanserin and 
ketanserinol in methanol were prepared for the calibration graph and stored at 4 °C. 
Thereafter, 2.9 mL of blank plasma were spiked with 100 μL of standard solution. 
Quantiﬁcation was performed by calculating the peak-height ratios of each compound to 
the internal standard.
Recovery
The extraction yield of ketanserin and ketanserinol from plasma was calculated by comparing 
the detector response (peak height) of a spiked plasma sample with a detector response of a 
reference standard prepared in methanol, with the same concentration as the spiked plasma 
sample. The recovery was determined at seven diﬀerent concentration levels and calculated 
as the ratio of peak height of plasma sample and peak height of reference solution, expressed 
as percentage. The spiked plasma samples and the reference standard solution were assayed 
in six fold.
Intra-day precision and accuracy
Inter- and intra-day precision and accuracy was calculated for the calibration curves. Spiked 
plasma samples with known concentrations of 2.0, 4.0, 10.0, 40.0, 100.0, 200.0 and 400.0 
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ng/mL ketanserin and ketanserinol were assayed. The measured concentrations were used 
to calculate the intra-day precision and accuracy. The standard deviation (SD) was used to 
calculate the intra-day precision, deﬁned as:
SD
intra-day precision = ------- * 100 %  (1)
mean
The accuracy is deﬁned as:
measured concentration – known concentration
accuracy = ---------------------------------------------------------- * 100 %  (2)
known concentration
Inter-day precision
The spiked plasma samples that were used for the determination of the inter-day precision 
were assayed on four consecutive days. The measured concentrations were used to calculate 
the inter-day precision and accuracy.
Limit of quantiﬁcation
The limit of quantiﬁcation was determined by recording the noise of 30 injected blank plasma 
samples. The integrator calculated the noise. The limit of quantiﬁcation was deﬁned as 10 
times noise level.
RESULTS 
Chromatograms of a spiked plasma sample containing 100 ng/ml ketanserin and 
ketanserinol and 50 ng/ml internal standard [Figure 3.2 (A)], and a plasma sample after 
intravenous administration of ketanserin [10 mg/h; Figure 3.2 (B)] are presented. Evidently, 
no other plasma metabolites or endogenous compounds interfere with the measurement of 
ketanserin, ketanserinol and internal standard. The total run time was 10 min. The retention 
times of ketanserin, ketanserinol and internal standard are 3.0, 4.4 and 8 min, respectively. 
In a standard working day about 60 samples could be processed, including calibration and 
reference standards. Samples can be run overnight, using an automatic sampler device. 
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The calibration curves of peak height for ketanserin and ketanserinol were linear in the, 
clinical relevant, concentration range of 10 - 400 ng/ml (r2 = 0.999). The inter-day, intra-day 
precision and accuracy are listed in Table 3.2. The recovery yield of ketanserin and ketanserinol 
was 60%. The limit of quantiﬁcation was 2.0 and 1.7 ng/ml for ketanserin and ketanserinol, 
respectively.
Table 3.2 Inter-day-, intra-day precision and accuracy at three different concentration levels
Compound Concentration Intra-day Inter-day
[ng/ml] Precision 
[%]
Accuracy
[%]
Precision
[%]
Accuracy
[%]
Ketanserin 10.5 3.1 -14.1 10.5 -5.1
105.0 0.5 -6.3 3.9 -5.8
420.0 0.4 -1.8 0.4 -1.6
Ketanserinol 10.5 3.0 -9.1 9.1 -0.5
104.6 1.0 -4.5 3.2 -2.2
418.3 0.4 -1.8 0.41 -1.8
Fig 3.2 a en b 
Figure 3.2 (A)
Chromatogram of plasma sample spiked with 
100 ng/mL ketanserin and ketanserinol and 
50 ng internal standard
Figure 3.2 (B)
Chromatogram of patient plasma sample after 
continuously intravenous administration of 
ketanserin 
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The results of the freezing and thawing experiments are shown in Table 3.3, indicating that 
the process of freezing and thawing has no inﬂuence on the levels of ketanserin. 
Table 3.3 Inﬂuence of freezing and thawing of plasma samples on the level of ketanserin 
Condition Ketanserin level (ng/ml)
No storage 259 ± 21.4
One cycle of freezing and thawing 254 (98.1%) ± 3.5
Three cycles of freezing and thawing 260 (100.3%) ± 7.5
Six cycles of freezing and thawing 259 (100%) ± 3.2
DISCUSSION
In developing a sensitive and selective assay for ketanserin and ketanserinol, we have tried 
liquid-liquid extractions with several organic compounds, but this yielded very low recovery 
of ketanserin and ketanserinol from plasma. In addition, endogenous compounds were 
interfering in the assay.
The use of Extrelut NT-1 solid-phase extraction columns allows very simple and quick 
sample preparation without the need for further sample puriﬁcation. Interfering peaks 
became negligible when these solid-phase extraction columns were used. Furthermore, 
relatively high and reproducible extraction yields of ketanserin and ketanserinol from plasma 
were obtained with solid-phase extraction. 
Fluorimetric detection was chosen because of both its sensitivity and selectivity for the 
assessment of ketanserin and ketanserinol in plasma samples. We also conducted this assay 
with UV-detection. However, chromatograms obtained with UV detection gave poor peaks, 
even for the highest calibration concentrations.
The method described in this paper can be easily implemented in other laboratories. The 
combination of sensitivity, selectivity, easy sample preparation and high sample throughput 
makes this assay suitable for application in a clinical setting with small sample volumes. 
The assay presented can be used for daily routine analysis and for clinical trials, which often 
require methods with high sample throughput and good reproducibility and accuracy. 
The small sample size required (200 μl) in this assay, makes the method useful for 
determination of drug levels in neonates. 
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CONCLUSION
The HPLC method described in this paper for the assessment of ketanserin and ketanserinol 
with solid-phase extraction and ﬂuorimetric detection in plasma allows a selective and 
sensitive analysis of these compounds without interference from endogenous compounds. 
The entire procedure including sample preparation, extraction and HPLC determination can 
be easily performed in a standard routine laboratory.
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ABSTRACT
Ketanserin is an antihypertensive drug that is increasingly being used parenterally in the 
treatment of pre-eclampsia. Because of lack of eﬃcacy in a substantial part of our pre-
eclamptic patients, we determined plasma concentrations of ketanserin in 51 pre-eclamptic 
patients. Population pharmacokinetic parameters were assessed using the iterative two-stage 
Bayesian population procedure. The inﬂuence of individual pharmacokinetic parameters on 
antihypertensive response, expressed as the attainment of a diastolic blood pressure ≤ 90 
mmHg using ketanserin treatment, was analysed.
Almost all plasma concentrations of ketanserin were in or above the therapeutic range. The 
individual pharmacokinetics of ketanserin in pre-eclamptic patients showed an accurate ﬁt 
using a three-compartment model.
The pharmacokinetic parameters in our pre-eclamptic population were a metabolic 
clearance (Clm) of 37.9 ± 10.86 L/h and a volume of distribution (V1) of 0.544 ± 0.188 L/kg, 
which is comparable with data from healthy volunteers. 
Despite a considerable interindividual variation, no correlation was found between 
diﬀerences in pharmacokinetic parameters and antihypertensive response.
We conclude that therapeutic plasma levels can be obtained in pre-eclamptic patients 
with a ﬁxed dosage schedule of ketanserin. Diﬀerences in antihypertensive responses within 
a pre-eclamptic population cannot be attributed to pharmacokinetic diﬀerences.
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INTRODUCTION
Pre-eclampsia is the major cause of morbidity and mortality in pregnant women worldwide. 
The disease is characterised by a rise in blood pressure and proteinuria after the 20th week of 
gestation. Untreated, pre-eclampsia can lead to severe organ damage, including liver, kidneys 
and/or brain. Endothelial dysfunction caused by unknown factors produced by the placenta 
is thought to be the main pathophysiological factor causing the disease 1 and the only cure 
is delivery. However, in early-onset pre-eclampsia, the resulting morbidity and mortality for 
the premature neonate is high.
In recent years, intensive management of the early-onset pre-eclamptic patient, using 
parenteral antihypertensive drugs, has shown an improved outcome for the neonate 2-5.
To obtain adequate blood-pressure control in pre-eclamptic patients, the ideal 
antihypertensive drug should be potent, safe for mother and foetus and easily titrated, 
according to the blood pressure. The drug used most often is hydralazine (or its analogue 
dihydralazin), an antihypertensive drug acting directly on the vessel-wall. (Di)hydralazine has 
the advantage of an extensive experience and a good eﬃcacy. However, administration of 
the drug needs to be accompanied with adequate volume expansion and monitoring and 
the drug causes frequently maternal adverse eﬀects like reﬂex tachycardia, headache and 
nausea. In several European countries, the drug is not commercially available anymore. 
The antihypertensive drug ketanserin has been recently licensed in the Netherlands for 
treatment of pre-eclampsia. Pharmacologically, the drug acts as an antagonist of the 5-HT2A 
receptor in the blood vessel, counteracting the vasoconstrictive response on serotonin 6. The 
drug is orally and parenterally available and causes few side-eﬀects. Its positive eﬀect on 
platelet aggregation and thrombus formation is considered an advantage in patients with 
the HELLP-syndrome (haemolysis, elevated liver enzymes, low platelets) 7. 
However, the drug appears to lack eﬃcacy in severe early-onset pre-eclamptic patients. In 
a subgroup of patients, the drug shows minor antihypertensive eﬀects and in a substantial 
part of the patients additional oral antihypertensive drugs or parenteral dihydralazine is 
needed to obtain adequate blood pressure control 8,9.
Van Schie 10 suggested that an individual dosing problem might cause the lack of eﬃcacy. 
Currently, a standard dosage schedule is applied, independent of patient characteristics, 
such as body weight, amount of oedema and liver function. However, a population of pre-
eclamptic patients can diﬀer greatly with respect to these characteristics. Diﬀerences in 
these patient characteristics may result in diﬀerences in drug levels at the receptor site and 
inﬂuence eﬃcacy. 
The aim of this study was to analyse the pharmacokinetic parameters of ketanserin within a 
pre-eclamptic population and to assess whether diﬀerences in pharmacokinetic parameters 
are related to variations in antihypertensive response to this drug.
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MATERIALS AND METHODS
Study population
Pre-eclamptic patients, admitted to our antenatal ward and treated with ketanserin, were 
included in the study in the period between 1999-2001. Severe pre-eclampsia was deﬁned 
as the occurrence, after 20 weeks of gestation, of a diastolic blood pressure ≥ 110mm Hg and 
proteinuria ≥ 0.3 g/l during a 24-h urine collection, or the occurrence of repetitive diastolic 
blood pressure > 90 mmHg in combination with the HELLP-syndrome. 
The patients received ketanserin according to a standard dosing schedule. Drug treatment 
was targeted at an intra-arterial diastolic blood pressure of ≤ 90 mmHg. In case of an 
inadequate blood pressure control with ketanserin, oral antihypertensive drugs such as 
nifedipine of methyldopa or parental dihydralazin were added. Treatment was continued 
until foetal or maternal condition warranted delivery. The Medical Ethical Committee of our 
hospital approved the study and all patients gave written informed consent.
Treatment
The standard dosing schedule was as follows: all patients started treatment within an hour 
after admission, with a bolus injection of 5 mg ketanserin, followed by a continuous infusion 
of 4 mg/h. The dosage was titrated according to the blood pressure by increments of 2 mg/h 
to a maximum of 14 mg/h. Each increment was preceded by a bolus of 5 or 10 mg. 
In 2001, after encountering no safety problems, the maximum dosage was increased to a 
maximum of 20 mg/h. A venous blood sample was drawn before each bolus injection. During 
treatment periods without dosage changes, a daily blood sample was drawn. 
Analytical techniques
The plasma levels of ketanserin were assessed using a newly developed validated reversed-
phase high performance liquid chromatographic assay with ﬂuorescence detection 11. The 
limit of quantiﬁcation for ketanserin was 2.0 ng/ml. The repeatability coeﬃcient was 3.1% 
and the reproducibility coeﬃcient was 10.5 % for the concentration range 0-400 ng/ml. 
Data analysis
Population pharmacokinetic parameters were calculated using the iterative two-stage 
Bayesian population procedure of the pharmacokinetic program MwPharm (MW Pharm 
version 3.5 0, Mediware, Groningen, the Netherlands) 12. 
The model used to describe ketanserin pharmacokinetics was based on a three 
compartment pharmacokinetic model, as described by Heykants 13 for adult male subjects, 
with elimination from the central compartment. The values of this model (as shown in Table 
4.1) were used as initial values in our study.
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For each patient, characteristics (age, body weight, serum creatinine, dosage regime, plasma 
ketanserin levels) were entered into MwPharm. Subsequently, individual pharmacokinetic 
parameters were calculated by maximum a posteriori Bayesian ﬁtting 14, applying a log-
normal distribution parameter. 
The response to ketanserin treatment was considered eﬀective if a diastolic blood pressure 
of ≤ 90 mmHg was obtained using the standard ketanserin dosage schedule. If additional 
antihypertensive treatment had to be added at the maximum dosage level of ketanserin in 
order to obtain adequate blood pressure control, the treatment was considered a failure. 
Statistical analysis
The pharmacokinetics parameters were compared between the pre-eclamptic population 
and data from literature regarding volunteers and other patient groups. Responders and 
non-responders within the pre-eclamptic population were analysed with respect to the 
pharmacokinetic parameters, using the Students t-test. A p-value < 0.05 was considered 
statistically signiﬁcant.
RESULTS 
Fifty-one patients (age ranging between 21 and 41 years) were included in our study, with a 
gestational age at admission of 28 weeks (range 21-39). The median duration of ketanserin 
treatment was 4.8 days (range 0.1-38). Diastolic blood pressure at admission ranged between 
Fig 4.1 
Plasmaconcentration ketanserin (µg/l)
 time (days)
Figure 4.1 Example of plasma concentration - time data of a pre-eclamptic patient, treated with 
intravenous ketanserin. The circles represent actually measured plasma-concentrations, the straight line is 
the plasma-concentration curve based on initial population data and the dotted line is the ﬁtted curve.
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90-140 mmHg (median 100 mmHg), and corresponding systolic bloodpressure at admission 
ranged between 135-240 mmHg (median 172 mmHg).
A total of 345 blood samples were collected and a concentration range of ketanserin of 
3 to 889 ng/ml was determined. For each patient a median of 6 (range 1-25) blood samples 
was obtained. Only ﬁve plasma concentrations (1%) were below the therapeutic range for 
ketanserin of 15-140 ng/ml as deﬁned in literature 15. Two of these samples were taken after 
infusion of ketanserin was stopped. In one patient, who received ketanserin in a low dosage 
of 2 mg/h due to border-line blood pressures, three samples were below the therapeutic 
range. A total of 134 samples (39%) fell within the therapeutic range and 206 samples (60%) 
were above the therapeutic range. Plasma drug concentration-time data showed satisfactory 
ﬁts when the three-compartment model (Figure 4.1) and the Bayesian ﬁtting procedure with 
an estimated log-likelihood value of 48.498 were applied. 
The estimated population pharmacokinetic parameters of our pre-eclamptic patients 
are shown in Table 4.1. A wide variation, mainly in metabolic clearance, was found in our 
population of pre-eclamptic patients.
Table 4.1 Initial 13 and pre-eclamptic population pharmacokinetic parameters (n=51). 
Clm (l/h) V1 (l/kg) k12 (/h) k21 (/h) k13 (/h) k31 (/h)
Initial 33 ± 3.3 0.719 ± 0.192 5.79 ± 6.97 3.43 ± 2.52 0.213 ± 0.121 0.087 ± 0.08
Pre-eclamptic 37.9 ± 10.86 0.544 ± 0.188 140.85 ± 54.27 47.12 ± 11.12 0.43 ± 0.313 0.052 ± 0.012
Results are expressed as mean (± standard deviation) Clm, metabolic clearance; V1, volume of distribution 
in central compartment, normalised to body weight; k12, rate constant from the central compartment to the 
peripheral compartment; k21, rate constant from the peripheral compartment to the central compartment; 
k13, rate constant from the central compartment to the deep tissue compartment.
In 16 of the 51 patients (31%), ketanserin treatment did not result in adequate blood pressure 
control and additional antihypertensive treatment was added (non-responding group). The 
metabolic clearance and volume of distribution for each individual responding and non-
responding patient is shown in Figure 4.2A and 4.2B. Mean pharmacokinetic parameters 
of the response group versus the non-responding group are summarized in Table 4.2. No 
signiﬁcant relationship between treatment- response and clearance or volume of distribution 
could be established.
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Table 4.2 Pharmacokinetic parameters of ketanserin in the non-responding pre-eclamptic patients 
(n=16) versus the responding pre-eclamptic patients (n=35). Results are expressed as mean  
(± standard deviation)
Clm (l/h) V1 (l/kg) k12 (/h) k21 (/h) k13 (/h) k31 (/h)
Non-responders 35 ± 5.8 0.58 ± 0.167  138 ± 17.5 47 ± 3.3 0.51 ± 0.439 0.052 ± 0.0024
Responders 40 ± 8.3 0.55 ± 0.097 146 ± 35 47 ± 3.6 0.50 ± 0.374 0.052 ± 0.0036Fig 4.2.a 
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Figure 4.2A Metabolic clearance (Clm) of responding and non-responding patients
Figure 4.2B Volume of distribution (V1) of responding and non-responding patients
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DISCUSSION
The serotonine antagonist ketanserin is an antihypertensive drug, which is increasingly being 
used in pre-eclamptic patients. Pharmacokinetic data of ketanserin have been studied well in 
other populations 15-17 but data in pregnant women as well as data in pregnant pre-eclamptic 
patients are lacking, while these populations are known to diﬀer greatly in comparison to 
healthy volunteers with respect to parameters as presence of oedema, hepatic function, renal 
function and albumin level. Depending on the severity of the disease, individual diﬀerences 
within a pre-eclamptic population can be substantial 18. The currently used ﬁxed dosage 
schedule of ketanserin is based on limited studies and might not be appropriate for all pre-
eclamptic patients. Indeed, data show that ketanserin appears to lack eﬃcacy in a substantial 
part of pre-eclamptic patients 8,9. We hypothesized that these diﬀerences in eﬃcacy of 
ketanserin treatment were caused by pharmacokinetic diﬀerences.
We found therapeutic and supratherapeutic plasma levels of ketanserin in 99% of our 
samples, indicating that the current dosage-schedule results in pharmacological plasma 
concentrations in almost all of the patients.
To analyse the individual plasma concentrations versus administered dosages, we used 
a three compartment pharmacokinetic model. A pronounced distribution of ketanserin 
to tissues takes place after administration, even more extensive than binding to plasma 
proteins (extra cellular fraction bound = 94%, 19). Ketanserin has been shown to metabolise 
by keton reduction and oxidative N-dealkylation to its main metabolite ketanserinol 20. Mean 
sequential half-lives of ketanserin were described as 0.129, 1.98 and 14.3 h 13.
The metabolite ketanserinol is excreted mainly in urine. Its aﬃnity for 5-HT2A receptor is 
approximately 1000-fold lower than the parent drug, but a reduction-oxidation equilibrium 
seems to exist between ketanserin and ketanserinol 20. The ketanserinol pool has been 
considered an adjacent metabolite compartment in the multicompartment character 
of disposition of ketanserin and it is thought to be reversibly connected with the central 
ketanserin compartment. Our data for ketanserin in individual pre-eclamptic patients showed 
a good ﬁt with the three-compartment model, described in literature 13.
The pharmacokinetic parameters, found in the study, are comparable with the data found 
in literature in healthy non-pregnant volunteers 19,21. The metabolic clearance of 37.9 L/h ± 
10.86 is slightly higher than the clearance from the initial population model and data from 
other authors on healthy non-pregnant volunteers (Clm: 24.6 L/h ± 3.72 
19 and 26.7 L/h ± 4.8 21. 
Metabolic clearance of ketanserin is primarily dependent on hepatic ﬂow, enzymatic activity 
and fraction of unbound drug 17. A pre-eclamptic population is characterised by a usually 
low but very variable level of plasma-albumin. This might result in a substantial increase 
in the fraction of unbound drug, leading to a higher metabolic clearance, which is seen in 
our patients. This hypothesis needs to be conﬁrmed by determination of unbound versus 
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protein-bound drug. Unfortunately, the detection limit of our current chromatographic assay 
did not allow for accurate measurements of the unbound drug-concentration.
The values for the intercompartmental rate constants k21 and k12 diﬀered widely from the 
initial population pharmacokinetic values. Ideally, these intercompartmental rate constants 
are best ﬁtted based on samples taken during the distribution period. For ketanserin, the 
distribution phase takes place within minutes, whereas most blood samples in our study were 
taken after 20 min of more after the dosage change. This will have inﬂuenced the reliability of 
assessment of k21 and k12 in our study.
We could not detect a relationship between antihypertensive response and individual 
variations in Clm or V1. The main part of the plasma concentrations measured was in or 
above the therapeutic range of 15-140 ng/ml. These ﬁndings suggest that the diﬀerences 
in antihypertensive response might not be attributed to pharmacokinetic diﬀerences within 
a population but might be more related to pharmacodynamic aspects, like 5-HT2A receptor 
activity within a pre-eclamptic population or to diﬀerences in the severity of the disease pre-
eclampsia itself. 
Our own limited experience in increasing the dosage of ketanserin to a maximum of 20 mg/h 
did not elicit better responses in the main part of these patients. However, the very rare but 
potentially dangerous QT prolongation, associated with use of ketanserin, might be correlated 
with high dosages of ketanserin 22 and therefore increasing the dosage of ketanserin cannot 
be done indiscriminately. Furthermore, maternal ketanserin use has shown to result in a high 
transplacental transmission of ketanserin 23 and although no negative eﬀects on the neonate 
has been observed so far, pharmacological eﬀects in the neonate cannot be excluded. 
CONCLUSION
Therapeutic concentrations of ketanserin were obtained in all patients after a ﬁxed dosage 
schedule of ketanserin. Pharmacokinetic parameters of the pre-eclamptic population were 
comparable to healthy volunteers. Individual variations in Clm and V1 could not explain the 
lack of antihypertensive response in one-third of the patients. 
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ABSTRACT
The functional reactivity of 5-hydroxytryptamine (serotonin; 5-HT) receptors in foetal 
umbilical cord arteries (UCA) and maternal subcutaneous fat resistance arteries (SFA) was 
investigated in normotensive and pre-eclamptic pregnancy. Segments of UCA and SFA 
were mounted in tissue baths and concentration-response curves to 5-HT and sumatriptan 
(5-HT1B/1D receptor agonist) were constructed in the absence or presence of ketanserin (5-HT2A 
receptor antagonist) or GR125743 (5-HT1B/1D receptor antagonist). Both 5-HT and sumatriptan 
contracted all UCA segments studied. The responses to 5-HT and the potency of ketanserin 
in UCA were not diﬀerent between the study groups, indicating a similar proﬁle of the 5-HT2A 
receptor. In contrast, the potencies of sumatriptan and GR125743 were signiﬁcantly higher 
in normotensive full-term pregnancies than in normotensive pre-term pregnancies in UCA. 
The response to sumatriptan in UCA arteries was not signiﬁcantly diﬀerent between pre-
eclamptic and normotensive pregnancies. However, the potency of both sumatriptan and 
GR125743 were positively correlated to the gestational age in the normotensive group, 
while this relationship was absent in the pre-eclamptic group. In SFA, responses to 5-HT 
and sumatriptan were not diﬀerent between the pre-eclamptics patients and normotensive 
controls.
In conclusion, in both UCA and SFA, 5-HT1B/1D and 5-HT2A receptors mediate vasoconstriction. 
The sensitivity of 5-HT1B/1D receptors increases in the last trimester in the UCA in normal 
pregnancies, which seems to be expedited in pre-eclamptic patients. Hence, further studies 
on 5-HT1B/ID receptors may give new insights into the foetal development and pathophysio-
logy of pre-eclampsia. 
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INTRODUCTION
Pre-eclampsia aﬀects about 5% of all pregnancies and is a major cause of morbidity and 
mortality to both mother and foetus 1. The etiology of pre-eclampsia is still largely unknown, 
although it has been linked to abnormalities in trophoblast invasion into the placental 
bed 2. The syndrome is clinically characterized by maternal hypertension and proteinuria, 
and diagnosed after 20 weeks of gestation. The usual physiologic adaptations in response 
to increased ﬂuid volume that are observed in normal pregnancies are attenuated in pre-
eclampsia, resulting in increased vascular resistance 3. This higher vascular resistance of the 
maternal vasculature in pre-eclampsia may be attributed to increased plasma concentrations 
of contractile agents 4-7, but could alternatively be attributed to an increased sensitivity of the 
arteries to vasoconstrictor agents like angiotensin II 8-9, 5-hydroxytryptamine (5-HT; serotonin)7 
and noradrenaline 10, combined with a decreased response to vasodilating peptides such 
as calcitonin gene-related peptide 11 and acetylcholine 12. Vascular hyperreactivity in pre-
eclamptic women has been demonstrated by, for example, an increased vasoconstrictive 
response to the cold pressor test, which is mediated by α-adrenergic receptors 13. Obviously, 
increased plasma levels of a vasoconstrictor, in combination with an increased sensitivity of 
the respective receptors, may synergistically lead to increased vascular resistance and hence 
hypertension.
It is well established that in pregnancy the umbilicoplacental circulation lacks autonomic 
innervations 14 and thus, the regulation of vascular reactivity is mainly dependent on local 
autocrine and circulating vasoactive substances in the blood. 5-HT potently constricts 
human umbilical blood vessels 15 and causes platelet aggregation, which leads to further 
release of 5-HT; both these properties may synergistically impede normal placental blood 
ﬂow in conditions like pre-eclampsia 7. 5-HT receptors have been classiﬁed into 7 main 
groups (5-HT1 - 5-HT7 receptors) with several established subtypes in the ﬁrst two groups 
16. 
Studies in umbilical cord reveal that the contractile response to 5-HT involves 5-HT1B and 5-
HT2 receptors 
17. 5-HT7 receptors are also believed to mediate relaxation in human arteries 
18, 
but information regarding their role in the regulation of hemodynamics in umbilicoplacental 
vessels is lacking. Maternal circulatory concentrations of 5-HT are signiﬁcantly increased in 
women with pre-eclampsia 5-7. High levels of circulating factors like 5-HT in pre-eclampsia 
may induce endothelial dysfunction in the resistance arteries of the mother 19, where 5-HT 
acts as a potent vasoconstrictor 20, which may further contribute to the increased vascular 
resistance observed in pre-eclampsia. In addition, the increased plasma levels of 5-HT may 
also aﬀect 5-HT receptors in umbilicoplacental and maternal resistance vessels. On this basis, 
the present study was undertaken to study the diﬀerences in the functional reactivity of 5-HT 
receptors between normotensive pregnant and pre-eclamptic women.
We studied umbilical cord arteries (UCA) as a representative of foetal blood vessels and 
subcutaneous fat arteries (SFA), representing maternal resistance arteries.
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METHODS
Umbilical cord and subcutaneous abdominal fat (in case of caesarean section) were obtained 
after informed consent from pregnant women admitted to the Obstetrics Department of 
Erasmus MC, St. Franciscus Gasthuis or Ikazia Ziekenhuis (all Rotterdam, The Netherlands). Pre-
eclamptic patients (diastolic blood pressure > 90 mmHg and protein/creatinine ratio (PCR) 
> 30 mg protein/mmol creatinine), as well as normotensive females of diﬀerent gestational 
ages were included in the study. Patients were classiﬁed as pre-term at a gestational age 
< 37 weeks; all patients with higher gestational age were classiﬁed as full-term. The pre-
eclamptic patients were treated with diﬀerent antihypertensive drugs like alpha-methyldopa, 
dihydralazine, ketanserin, labetalol and nicardipine. Women suﬀering from diabetes and 
normotensive women with intra-uterine growth retardation (IUGR, birth weight is < 10th 
percentile weight for his/her age in weeks corrected for gestational age, parity and foetal 
sex 21) and in the pre-eclamptic group patients suﬀering from pre-existing hypertension were 
not included in the study. The Ethics Committee of the Erasmus MC approved this study.
Segments of umbilical cord and maternal subcutaneous fat tissues were collected in cold 
Krebs bicarbonate solution (composition in mM: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, 
KH2PO4 1.2, NaHCO3 25 and glucose 11.1; pH 7.4), transported to laboratory and stored in 
carbogenated (95% O2 and 5% CO2) Krebs bicarbonate solution at 4˚C. UCA were isolated 
from the umbilical cord after removing the Wharton’s jelly and subcutaneous arteries were 
isolated after removing adhering subcutaneous fat. Functional experiments were performed 
on the same or the subsequent day. In pilot experiments, we did not observe any diﬀerences 
in responses of UCA to KCl, 5-HT or sumatriptan between experiments that were performed 
on the same day or the next day. 
UCA segments of 3-4 mm length (internal diameter: 1.5-2.0 mm) were suspended with the 
help of stainless-steel hooks in 15-ml organ baths. These segments were set at a pretension 
of 25 mN as determined to be the optimal tension in pilot experiments (data not shown). 
Segments showing bulging or macroscopic undulations were not used in experiments. SFA 
segments were cut into rings of 1-2 mm length with an internal diameter of 150-500 μm. 
Artery segments were suspended in Mulvany myographs on two parallel titanium wires. 
Subsequently, the distance between the wires was normalized to 0.9×l100 (l100 is the distance 
between the pins when the transmural pressure equalizes 100 mm Hg) to achieve optimal 
conditions for active force development. For both UCA and SFA, the vessel segments were 
continuously bubbled with 95% O2 and 5% CO2 and the temperature was maintained at 37˚C. 
After an initial equilibration period of 45 min, two successive challenges with KCl (30 mM) 
were performed to verify the reproducibility of the response. Subsequently, KCl (100 mM) was 
added to determine the reference contractile response of the artery segments to compensate 
for small diﬀerences in the muscle mass of the artery segments. In both UCA and SFA, 
endothelial function was evaluated by observing the relaxant response to substance P (100 
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nM) after precontraction with U46619 (9,11-dideoxy-11α, 9α-epoxy, methanoprostaglandin 
F2α 10-300 nM). Cumulative concentration response curves to 5-HT were constructed in a 
parallel setup in the presence of vehicle (saline) or after 30-min incubation with the 5-HT2A 
receptor antagonist, ketanserin (10 nM, 100 nM or 1 μM). Similarly, concentration response 
curves to sumatriptan were constructed in a parallel setup in the presence of vehicle or three 
increasing concentrations (10 nM, 100 nM or 1 μM) of the 5-HT1B/1D receptor antagonist, 
GR125743 (N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-2’-methyl-4’-(5-methyl-1,2,4-
oxadiazol-3-yl).[1,1-biphenyl]-4-carboxamide hydrochloride) 22.
 In UCA, we also investigated the relaxant response to 5-HT mediated by putative 5-HT7 
receptors. For discerning 5-HT7 responses in UCA, artery segments were incubated with 
both ketanserin and GR125743 (100 nM, each), the segment was precontracted with KCl 
(30 mM) and then 5-HT was added in a cumulative manner. Due to the limited number of 
vessel segments that could be isolated from the small samples of subcutaneous fat that 
were obtained during caesarean sections, experiments were performed using only one 
concentration (100 nM, each) of ketanserin and GR125743 and no experiments on the role of 
5-HT7 receptors were performed. In both UCA and SFA, only single concentration responses 
curve was constructed in each artery segment.
Chemicals
5-HT, U46619, substance P (Sigma Chemicals Co., Steinheim, Germany), KCl (Merck, 
Darmstad, Germany), ketanserin tartrate (Janssen, Beerse, Belgium), sumatriptan succinate 
(GlaxoSmithKline, Stevenage, U.K.) and (N-[4-methoxy-3-(4-methyl-1-piperazinyl) phenyl]-
2’-methyl-4’-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1-biphenyl]-4-carboxamidehydrochloride) 
(GR125743) (Pﬁzer Limited, Sandwich, Kent, U.K.) were all dissolved in distilled water and 
stored in aliquots at –80 ˚C. 
Statistical analysis
The contractile response to 100 mM KCl, expressed in milli-Newton (mN), was used to compare 
the contractile force developed by arteries from diﬀerent experiment groups. All contractile 
responses to the agonists are expressed as percentage of the contraction induced by 100 
mM KCl. All values are expressed as mean ± S.E.M. and n represents the number of segments, 
each segment obtained from a diﬀerent patient. Since it was not always possible to study 
all compounds in segments obtained from one patient, the number of segments for each 
experimental condition may diﬀer from the total number of patients in a group. Concentration 
response curves were analyzed using nonlinear regression analysis using GraphPad Prism 3.01 
(GraphPad Software Inc., San Diego, CA, U.S.A.). The eﬃcacy of the agonists was expressed as 
Emax (maximal response) and their potency as pEC50 (-logEC50, where EC50 is the concentration 
of the agonist required to produce half the maximal response). Since 5-HT activates diﬀerent 
5-HT receptor subtypes, the blocking potency of ketanserin (apparent pKb) was estimated by 
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calculating concentration-ratios between the EC50 of agonist in the presence and absence 
of antagonist and plotting a Schild-plot, assuming a slope of unity. The antagonism of the 
response to sumatriptan by GR125743 only reached signiﬁcance at concentrations of 
100 nM or higher. Therefore, only two concentration points of antagonist were available, which 
prohibits the calculation of a Schild slope and pA2 (concentration of the antagonist required 
to shift the concentration responses curve of agonist by two fold to right hand side). For that 
reason, the antagonist potency of GR125743 was also expressed as apparent pKb, assuming a 
slope of unity. In case of UCA, the pKb was calculated at 100 nM to allow a uniform comparison 
with data obtained with SFA, where only one concentration of the antagonists could be 
studied. The inﬂuence of the way of delivery (vaginal or caesarean section) on the response 
to KCl, 5-HT, sumatriptan or the antagonist was assessed by analysis of covariance (ANCOVA), 
using the way of delivery as a factor and gestational age as a covariant. Group means were 
compared by using unpaired Student t-test, with diﬀerences considered signiﬁcant at 
P < 0.05. Correlation analyses were carried out using Pearson’s coeﬃcient of correlation 
between gestational age or neonatal weight and responses to 5-HT, ketanserin, sumatriptan or 
GR125743.
RESULTS
The demographic details of all the subjects from whom the umbilical cord artery, 
subcutaneous fat arteries, or both were obtained, are presented in Table 5.1. The KCl (100 
mM)-induced contractions were not diﬀerent between UCA obtained from normotensive 
and pre-eclamptic women. There were no diﬀerences between the responses to KCl, 5-HT, 
sumatriptan or the antagonists in the UCA obtained from vaginal deliveries and caesarean 
sections; therefore, the results were pooled in further analysis. 
Table 5.1. Demographic details of the patients from whom the umbilical cord artery and 
subcutaneous fat arteries were obtained.
Normotensive 
pre-term 
Normotensive 
full-term 
Pre-eclamptic 
pre-term 
Pre-eclamptic 
full-term 
Number 14 48 34 12
Maternal age (y) 30.6 ± 1.5 33.0 ± 0.7 32.9 ± 1.2 31.5 ± 1.6
Gestational age at delivery (wk) 30.6 ± 1.1 39.3 ± 0.1 30.2 ± 0.7 38.8 ± 0.4
Diastolic BP (mm Hg) 69.0 ± 0.9 74.7 ± 1.4 104.2 ± 2.5 98.2 ± 1.8
Systolic BP (mm Hg) 118.5 ± 0.9 121.1 ± 1.8 167.0 ± 5.9 144.8 ± 4.9 
PCR (mg/mmol) Not determined Not determined 967 ± 293 699 ± 423
Birth weight (g) 1555 ± 193 3443 ± 73 1161 ± 99 3138 ± 131
Vaginal delivery 11 25 2 5
Caesarean section 3 23 32 7
Intra-uterine growth restriction Not included Not included 11 1
BP: Blood pressure, PCR: Protein/creatinine ratio
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Within the pre-eclamptic group, patients with or without IUGR did not diﬀer signiﬁcantly in 
the responses to KCl, 5-HT, sumatriptan or their antagonists, hence their results were pooled 
in further analyses. In none of the UCA investigated, we observed an endothelium-dependent 
relaxation to substance P. The results obtained from UCA are presented in four main groups: 
the normotensive pre-term, the normotensive full-term delivery, the pre-eclamptic pre-term 
and the pre-eclamptic full-term delivery group.
Responses to 5-HT in umbilical cord artery
5-HT induced contractions in all UCA studied. The Emax and pEC50 of 5-HT were not signiﬁcantly 
diﬀerent between the groups (Figure 5.1, Table 5.2). Ketanserin antagonized the responses to 
5-HT in a concentration-dependent manner in all groups with an average pKb of around 7.6; 
there was no diﬀerence in the potency of ketanserin between the study groups. We did not 
observe any relaxations to 5-HT, putatively mediated by 5-HT7 receptors, in precontracted 
UCA in the presence of ketanserin and GR125743 (both 100 nM, data not shown). 
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fig 5.1 
Figure 5.1. Concentration response curves to 5-HT in the absence or presence of increasing 
concentrations of the 5-HT2A receptor antagonist, ketanserin (10 nM-1 μM), in umbilical cord artery 
segments. Panel A: normotensive pre-term, panel B: normotensive full-term, panel C: pre-eclamptic pre-
term and panel D: pre-eclamptic full-term deliveries.
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Responses to sumatriptan in umbilical cord artery
Sumatriptan also induced contractions in all UCA studied (Figure 5.2, Table 5.2). In the 
pre-term normotensive group, the pEC50 of sumatriptan (5.71 ± 0.23, n=12) was signiﬁcantly 
lower than in the normotensive full-term group (6.62 ± 0.12, n=30). The Emax values between 
the groups were not signiﬁcantly diﬀerent. Within the pre-eclamptic group, there were no 
signiﬁcant diﬀerences in Emax and potency of sumatriptan between pre-term and full-term 
in UCA. In the pre-eclamptic pre-term group, the potency of sumatriptan (6.26 ± 0.19, 
n=22) tended to be higher compared to the normotensive pre-term group, although this 
diﬀerence did not reach signiﬁcance (P=0.08). GR125743 signiﬁcantly antagonized contractile 
responses to sumatriptan at concentrations ≥ 100 nM, which is in accordance with previous 
observations in human coronary artery and saphenous vein 23. Similar as observed with the 
potency of sumatriptan, the potency of GR125743 in the pre-eclamptic pre-term group (8.09 
± 0.22, n=17) tended to be higher compared to the normotensive pre-term group (P=0.06), 
while the potency of GR125743 was similar in the pre-eclamptic pre-term and pre-eclamptic fig 5.2
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Figure 5.2. Concentration response curves to sumatriptan in the absence or presence of increasing 
concentrations of the 5-HT1B/1D receptor antagonist, GR125743 (10 nM-1 μM), in umbilical cord 
artery segments. Panel A: normotensive pre-term, panel B: normotensive full-term, panel C: pre-eclamptic 
pre-term and panel D: pre-eclamptic full-term deliveries.
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full-term groups. In addition, the pKb of GR125743 was signiﬁcantly lower in normotensive 
pre-term deliveries (7.28 ± 0.37, n=7) compared to that in normotensive full-term deliveries 
(8.05 ± 0.13, n=18) in UCA, while such a diﬀerence was absent in UCA obtained from pre-
eclamptic patients.
Relationship between foetal development and functional response to 5-HT, ketanserin, sumatriptan and 
GR125743 in umbilical cord artery
The fact that sumatriptan-induced responses were diﬀerent in the UCA obtained from the 
pre-term and full-term normotensive deliveries with mean gestational ages of 31 and 39 
weeks, respectively, suggests that 5-HT1B/1D receptors are still in a development phase during 
the third trimester. To study the eﬀect of foetal development in further detail on the various 
pharmacological parameters obtained in the normotensive (both pre-term and full-term 
deliveries) and pre-eclamptic groups, we performed a correlation analysis with gestational 
age. We did not observe any signiﬁcant correlation between the gestational age and the Emax 
or pEC50 of 5-HT or the pKb of the 5-HT2A receptor antagonist, ketanserin, in either group 
(Table 5.3). In contrast, there was a signiﬁcant correlation between the gestational age and 
the potency of the 5-HT1B/1D receptor agonist, sumatriptan (r=0.456, P=0.002), as well as the 
potency of its antagonist, GR125743 (r=0.486, P=0.012), in UCA obtained from normotensive 
controls. In UCA obtained from patients suﬀering from pre-eclampsia, the potency of 
sumatriptan and its antagonist GR125743 did not correlate with gestational age. Since 
fig 5.3
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Figure 5.3. Concentration response curves to 5-HT and sumatriptan in subcutaneous fat resistance 
arteries obtained from normotensive and pre-eclamptic deliveries.
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neonatal weight has been also described a marker for foetal development 24, we also analyzed 
the correlation between neonatal weight (that strongly correlated with gestational age, 
r=0.940, P<0.001) and the responses to the agonists and antagonists. In the pre-eclamptic 
group, twelve neonates with IUGR were present; we performed our correlation analysis either 
including or excluding these patients. As with the results obtained with gestational age, there 
was no signiﬁcant correlation between the responses to 5-HT or ketanserin and neonatal 
weight in either of the groups. The potency of sumatriptan again signiﬁcantly correlated with 
neonatal weight in the normotensive group (r = 0.540, P < 0.001), but not in the pre-eclamptic 
group (r = 0.260, P = 0.137 and r = 0.233, P = 0.262), including or excluding the patients with 
IUGR, respectively). There was a signiﬁcant correlation between pKb of GR125743 (r = 0.424, 
P = 0.031) and neonatal weight in the normotensive group, but not in the pre-eclamptic 
group (r = 0.091, P = 0.651 and r = 0.188, P = 0.415, including or excluding the patients with 
IUGR, respectively). Furthermore, there was a signiﬁcant negative correlation between the 
gestational age and contractile responses to 100 mM KCl in UCA in normotensive group (r = 
0.289, P = 0.044, n = 49), but not in the pre-eclamptic group (r = 0.211, P = 0.203, n = 38).
Responses to 5-HT and sumatriptan in subcutaneous fat arteries
One SFA in the normotensive group and three in the pre-eclamptic group did not respond 
to 5-HT or sumatriptan. These patients were not included in further analysis because the 
potency of the antagonists could not be assessed in these specimens. Because of the limited 
occurrence of deliveries by caesarean sections in pre-term normotensive patients, all the SFA 
from normotensive patients were analysed as one group, irrespective of their gestational age, 
unlike for UCA. There was no signiﬁcant diﬀerence in the endothelium-dependent relaxations 
between SFA obtained from pre-eclamptic patients (46 ± 9% precontraction with U46619) 
and those obtained from normotensive women (37 ± 6%). Neither the maximal response or 
pEC50 of 5-HT, nor the potency of ketanserin was diﬀerent between the pre-eclamptic and 
normotensive group (Table 5.4). Similarly, the responses to sumatriptan were not diﬀerent 
between the two groups. In contrast, the 5-HT1B/1D receptor antagonist, GR125743, was less 
potent in arteries obtained from pre-eclamptic patients than in normotensive controls.
Relationship between foetal development and responses to 5-HT, ketanserin, sumatriptan and GR125743 
in subcutaneous fat arteries
The gestational age in the pre-eclamptic group (32.0 ± 1.2 weeks) was signiﬁcantly less than 
that of the normotensive controls (38.9 ± 0.2 weeks). There was no signiﬁcant correlation 
between gestational age or neonatal weight and responses to 5-HT or ketanserin in either 
of the groups. There was a signiﬁcant correlation between the pEC50 of sumatriptan and 
neonatal weight, but not with gestational age, in the normotensive group. This correlation 
was absent in the SFA obtained from the pre-eclamptic patients. The potency of antagonist 
also did not have any signiﬁcant correlation with neonatal weight or gestational age. The 
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correlation data should be interpreted with caution in view of the limited number of patients 
in the study group. 
Table 5.4. Pharmacological parameters derived from subcutaneous fat arteries obtained from 
normotensive pregnancies and pregnancies complicated by pre-eclampsia. 
Normotensive
(n=8-19) 
Pre-eclamptic
(n=8-16)
5-HT Sumatriptan 5-HT Sumatriptan
Emax (% 100 mM KCl) 109 ± 15 70 ± 13 115 ± 18 59 ± 15
pEC50 7.18 ± 0.12 6.15 ± 0.26 7.39 ± 0.12 5.96 ± 0.25
pKb Ketanserin (100 nM) 8.32 ± 0.36 - 8.43 ± 0.56 -
pKb GR125743 (100 nM) - 8.82 ± 0.24 - 8.01 ± 0.25*
Response to 100 mM KCl (mN) 4.72 ± 0.89 4.72 ± 0.89 6.46 ± 1.32 6.46 ± 1.32
n: number of UCA segments, each segment obtained from a different woman. *, Signiﬁcantly different 
(P<0.05) from normotensive controls.
Comparison between subcutaneous fat arteries and umbilical cord arteries responses
In SFA, we observed endothelium-dependent relaxations, whereas in UCA these responses 
were absent. The maximal response and potency of 5-HT and sumatriptan were signiﬁcantly 
lower in SFA than in UCA. In contrast, the potency of the antagonist ketanserin was higher in 
SFA than in UCA in both groups. In both UCA and SFA the maximal response to sumatriptan 
was less than the 5-HT response and in case of SFA, this diﬀerence was more pronounced. 
DISCUSSION
In the current study, we investigated vasoreactivity in foetal and maternal arteries obtained 
from pre-eclamptic and normotensive pregnancies. As pregnancies complicated by pre-
eclampsia are often associated with premature delivery, it is vital to take into account 
diﬀerences in gestational age while comparing with normotensive controls. Certain receptor 
systems are still in the developmental phase in the umbilicoplacental circulation in the third 
trimester of pregnancy. For example, in umbilical and placental veins, the reactivity of 5-HT 
and histamine tend to increase throughout this period 24. Therefore, we included a correlation 
analysis between various pharmacological parameters obtained and markers of foetal 
development (gestational age and neonatal weight).
In UCA segments, obtained both from pre-eclamptic patients and normotensive controls, 
5-HT and sumatriptan induced contractions that were sensitive to antagonism by ketanserin 
and GR125743, respectively. These results conﬁrm the role of 5-HT2A and 5-HT1B/1D receptors 
in mediating vasoconstriction in UCA. Although we did not use selective 5-HT1B or 5-HT1D 
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receptor antagonists, vasoconstriction to sumatriptan is most likely mediated via the 5-HT1B 
receptor 25. Even though 5-HT is not a selective 5-HT2A receptor agonist, we chose 5-HT as an 
agonist in this study as it encompasses the study of all 5-HT receptor subtypes and provides 
the possibility to study the 5-HT2A receptors using ketanserin. Further, the use of 5-HT allows 
comparison of our results with the other studies on 5-HT receptors in UCA 15,17,24,26. We did not 
observe any diﬀerence in the 5-HT-induced contractions in UCA between the pre-eclamptic 
and the normotensive group, which seems to be in contrast to the ﬁnding by Bertrand et al. 24. 
However, the higher Emax induced by 5-HT in UCA from pre-eclamptic patients in their study 
24 
is merely based on higher contractile responses to KCl, and disappears when the responses are 
corrected for the diﬀerences in absolute contractile force between the groups. Indeed, others 
also did not report any signiﬁcant diﬀerences in the reactivity to various vasoconstrictors, 
including 5-HT, in UCA obtained from normotensive and pre-eclamptic patients 28 and some 
studies have even reported decreased responses to 5-HT in UCA obtained from severe pre-
eclamptic patients 27. In accordance with previous reports 24, we did also not observe any 
correlation between foetal development and the potency of 5-HT or ketanserin in UCA 
obtained from normotensive and pre-eclamptic patients. In conclusion, our ﬁndings suggest 
that 5-HT2A receptors are not aﬀected in pre-eclampsia, and that these receptors are already 
fully developed early in the third trimester of pregnancy.
In the study by Lovren et al. 17, a sub-threshold concentration of a vasoconstricting agent 
was required for observing the activity of 5-HT1B/1D receptors (only three out of ten vessels 
responded to sumatriptan without prestimulation), whereas in our study sumatriptan 
produced contractile response in all UCA without prestimulation. This discrepancy might be 
explained by higher levels of endogenous vasoconstrictors such as thromboxane A2 in our 
preparations, which could then ‘unmask’ responses to sumatriptan 29,30 or could eventually 
be due to the higher pretension (25 mN) used in our study as used (20 mN) in the study by 
Lovren et al. 
In our study, the potency of sumatriptan in UCA was about 10-fold higher in the full-
term deliveries as compared to pre-term deliveries within the normotensive group, 
suggesting that 5-HT1B/1D receptors are still developing in the last trimester. This observation 
was strengthened by the signiﬁcant positive correlation between foetal development 
(expressed as either gestational age or neonatal weight) and the pEC50 of sumatriptan in the 
normotensive group, whereas this correlation was absent in pre-eclamptic group. Similarly, 
the pKb value of GR125743 only correlated with foetal development in the normotensive 
controls and not in the pre-eclamptic group. Additionally, unlike in the normotensive group, 
in the pre-eclamptic group the potency of sumatriptan does not seem to increase in full-
term pregnancies, compared to the pre-term group. Finally, the pEC50 of sumatriptan and 
the pKb of GR125743 in the normotensive pre-term control group appear to be lower than 
that in pre-eclamptic pre-term group, although this diﬀerences did not reach signiﬁcance 
(P = 0.06 - 0.08). These observations suggest that in the pre-eclamptic group the normal 
74
C
ha
pt
er
 5
development of 5-HT1B/1D receptors is compromised, and that the response to these receptors 
may already be on higher strata at an earlier gestational period. This higher sensitivity may 
be explained by a larger number of 5-HT1B/1D receptors and/or a more eﬃcient coupling of 
these receptors with the second messenger pathway in UCA of pre-eclamptic patients. The 
cause of this higher sensitivity could be increased plasma levels of 5-HT in pre-eclampsia15, 
or, alternatively, foetal factors induced by umbilicoplacental vasoconstriction, which may 
contribute to maternal hypertension. Future studies, like binding experiments of 5-HT1B/1D 
receptors in foetal and maternal blood vessels at diﬀerent gestational ages may give more 
insight into the role of these receptors in foetal development and pre-eclampsia.
A more prominent role of 5-HT1B/1D receptors in pre-eclampsia seems to gain relevance 
because contractile responses mediated by 5-HT1B/1D receptors may be augmented by other 
vasoconstrictive agents like thromboxane A2 
26-29, and indeed plasma levels of both 5-HT and 
thromboxane A2 are known to be increased in pre-eclampsia 
4. Interestingly, pre-eclampsia 
usually is manifested clinically in the third trimester, which is the same period where we 
observed an increase in the activity of 5-HT1B/1D receptors, suggesting that these receptors 
might have a pathophysiological role in pre-eclampsia. Antagonism of 5-HT receptors has 
been explored earlier as a therapeutic option for the treatment of pre-eclampsia using 
the 5-HT2A receptor antagonist ketanserin 
31,32, but in a substantial number of patients the 
antihypertensive response is insuﬃcient 33. However, the combination of ketanserin and 
aspirin, inhibiting the synthesis of thromboxane A2, is beneﬁcial in the prevention of pre-
eclampsia in women with mild to moderate hypertension 31. Since the augmentation of 
contractile responses to 5-HT by thromboxane A2 is mainly mediated by 5-HT1B/1D and not 
by 5-HT2A receptors 
34, 5-HT1B/1D receptor antagonism might have an additive therapeutic 
value in the treatment of pre-eclampsia, especially by increasing the already compromised 
umbilicoplacental blood ﬂow. 
In SFA we did not observe any diﬀerence in substance P induced-relaxations between pre-
eclamptic patients and normotensive controls, which seems to be at variance with earlier 
observations 35. However, in a recent study performed on subcutaneous and myometrial 
resistance arteries, relaxations to substance P were not diﬀerent between normotensive and 
pre-eclamptic subjects 12, which is in accordance with our observations. In UCA, we did not 
observe any relaxations to substance P, which is also in line with previous reports 36. Both 
5-HT and sumatriptan elicited contractions that were sensitive to antagonism by ketanserin 
or GR125743, respectively. Thus, our results demonstrate the presence of 5-HT2A and 5-HT1B/1D 
receptors in SFA. There were no signiﬁcant diﬀerences in the reactivity to 5-HT or sumatriptan 
between the normotensive and the pre-eclamptic group. It should be noted that although 
vascular hyperreactivity has been described in pre-eclampsia 5, increased vascular sensitivity 
is not a generalized phenomenon in this syndrome, as we pointed out above 12,27,37 and as 
observed in the present study. Contractile responses to 5-HT and sumatriptan in SFA were 
signiﬁcantly smaller than the responses observed in UCA, underscoring that humoral factors 
Functional reactivity of 5-HT receptors in human umbilical cord and maternal arteries 75
play a more dominant role in contraction of umbilical cord arteries, which are not innervated. 
As in most studies in patients, pre-eclamptic patients were treated with antihypertensive 
drugs, which might induce an underestimation of diﬀerences between the pre-eclamptic 
and the normotensive pregnant women in our study.
Admittedly, our data suggest that antagonism of 5-HT1B/1D receptors would have a more 
prominent eﬀect on the umbilicoplacental circulation than on maternal hypertension. 
However, since the umbilicoplacental blood ﬂow tends to decrease after antihypertensive 
treatment of the mother 38, resulting in foetal distress, and factors released in response to a 
reduced blood ﬂow to the foetus may also contribute to maternal hypertension, it is pivotal 
to maintain a suﬃciently high umbilicoplacental blood ﬂow. 
In conclusion, we demonstrate that 5-HT1B/1D and 5-HT2A receptors mediate contraction in 
foetal (UCA) and maternal (SFA) arteries. The functional proﬁle of 5-HT2A receptors does not 
change during the third trimester, nor is it diﬀerent between pre-eclamptic pregnancies and 
normotensive controls. In contrast, the sensitivity of 5-HT1B/1D receptors increases during the 
third trimester in UCA in normotensive pregnancies, while this development is expedited in 
pre-eclamptic patients. Further studies on the role of 5-HT1B/1D receptors may give more insight 
into the role of 5-HT in foetal development and the pathophysiology of pre-eclampsia. 
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ABSTRACT
The aim of this prospective, observational study was to assess the transplacental transmission 
and the transfer into breast milk after maternal use of ketanserin and to determine disposition 
in the neonate. In 22 pregnant women with severe pre-eclampsia, admitted to the antenatal 
ward in period 1999-2001, the ratio of drug concentrations in the umbilical cord to drug 
concentrations in maternal blood just before delivery was used as a indicator of placental 
transmission. Transfer into breast milk was determined by the ratio of the drug concentrations 
in breast milk as compared to the corresponding maternal plasma concentrations in seven 
patients. Disposition of ketanserin was assessed using neonatal plasma concentrations of 
ketanserin in eight neonates after birth. 
A median placental transmission was found in the pre-eclamptic women of 0.95 (0.612-
1.24) for ketanserin and for its metabolite, ketanserinol of 0.60 (0.5-0.77). The median breast 
milk/ plasma ratio for ketanserin was 0.4 (range, 0.2 – 1.27) and for ketanserinol 0.76 (range, 
0.42 – 1.44). Pharmacologically relevant concentrations of ketanserin were found in the 
neonate after delivery. The elimination half-life of ketanserin in the neonate varied between 
12.7 and 43.7 hours (median 19.3 hours) and of ketanserinol between 13.8 and 34.4 hours 
(median 18.7 hours). Despite the high placental transmission and disposition in the neonate, 
no apparent adverse eﬀects in the neonates could be detected
In conclusion, a high placental transmission of both ketanserin and its metabolite 
ketanserinol and an intermediate transfer into breast milk occurred after maternal treatment 
of pre-eclampsia with ketanserin. Pharmacologically active concentrations of ketanserin 
were found in the neonate for a prolonged period after delivery. 
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INTRODUCTION
The mainstay of treatment of pre-eclampsia is to lower the maternal blood pressure by 
using (parenteral) antihypertensive drugs, in order to prevent the complications of the high 
blood pressure in the mother and, in selected cases, to prolong the pregnancy. The optimal 
antihypertensive drug for treatment of pre-eclampsia should establish a fast and controlled 
decline in maternal blood pressure, while having no adverse eﬀects on mother, foetus or 
child.
Recently, the antihypertensive drug ketanserin, has been marketed in the Netherlands for 
treatment of pre-eclampsia. Ketanserin is a 5-HT2A receptor antagonist with weak alpha-1- 
agonistic properties 1. Presently, diﬀerent views exist on the eﬃcacy of ketanserin in severe pre-
eclampsia2, but the drug has the advantage of having limited adverse maternal eﬀects 3 and it 
is relatively easy to administer. However, to assess the safety of maternal use of ketanserin for 
the foetus and neonate, information regarding transplacental transfer is important. Further, 
considering the long elimination half-life of ketanserin of 14h 4, data on the transfer into 
breast milk during and after ending of ketanserin treatment, are warranted, in order to advise 
mothers with regard to lactation. In humans, no quantitative data on placental transfer of 
ketanserin and its eﬀect on the foetus are yet available, but animal studies in the pregnant 
ewe have demonstrated placental transfer of ketanserin 5. Also, no data on transfer in breast 
milk are available.
In our university hospital, patients with severe, early onset pre-eclampsia are treated 
with high doses of ketanserin for prolonged periods. To establish whether adverse eﬀects 
of ketanserin in the foetus or neonate can be demonstrated, we determined the degree of 
placental transfer of ketanserin and its metabolite, ketanserinol, as well as the degree of 
transfer into breast milk. Furthermore, the extent of exposure to ketanserin was studied in 
the neonate and the clinical outcome of the neonates was assessed.
METHODS
Patients with severe pre-eclampsia were started on ketanserin infusion upon admission to 
the antenatal ward in the period 1999 - 2001. Severe pre-eclampsia was deﬁned in our study 
as the occurrence after 20 weeks of gestation of a diastolic blood pressure ≥ 110 mmHg and 
proteinuria ≥ 0.3 g/l or a diastolic blood pressure > 90 mmHg in combination with HELLP 
(haemolysis, elevated liver-enzymes, low platelet-count) syndrome. Ketanserin infusion was 
initiated at 4 mg/h and titrated, according to the blood pressure in increments of 2 mg/h 
every 20 minutes to a maximum of 20 mg/h. Each increment was preceded by an intravenous 
loading bolus injection of 5 or 10 mg ketanserin. Treatment was targeted at an intra-arterial 
diastolic blood pressure of ≤ 90 mmHg (Korotkoﬀ sound 5, sphygmomanometer). Patients 
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who were already taking oral antihypertensive drugs on admission, such as methyldopa and/
or nifedipine, continued using these medications. 
Patients were treated with ketanserin until maternal or foetal conditions deteriorated and 
delivery was necessary. The study received permission from the Institutional Review Board of 
the Erasmus MC and all patients gave informed consent. 
To determine placental transmission of ketanserin, a maternal plasma sample was 
obtained just before delivery and an umbilical cord blood sample was drawn after delivery. 
The plasma concentrations of ketanserin and ketanserinol were assessed using a validated 
reversed-phase high performance liquid chromatographic assay with ﬂuorescence detection, 
which was developed at the hospital pharmacy 6. The limit of quantiﬁcation (LOQ) for both 
ketanserin and ketanserinol was 2.0 ng/ml. For analysis of ketanserin and ketanserinol in 
breast milk, the assay was again validated and the limit of quantiﬁcation (LOQ) was 10 ng/ml 
for both compounds.
To determine the elimination of ketanserin in the neonate, two separate plasma samples 
were collected from the neonate within 36 hours after birth to measure the half-life of 
ketanserin. The elimination half-life (t½) of ketanserin was calculated using the formula t½ = 
0.693 (t2-t1) / ln (conc1)- ln (conc2).
Data analysis
The concentration ratios of ketanserin and ketanserinol of the umbilical cord blood (F) 
versus maternal plasma (M) were used as a measure of the placental transmission (F/M). For 
determination of the breast milk/plasma ratio, the concentration ratios of ketanserin and 
ketanserinol in breast milk versus the maternal plasma concentration of a simultaneously 
drawn plasma sample of the mother, were used.
Using the Spearman’s correlation test (p < 0.05), we tested whether cumulative maternal 
dosage, duration of therapy or infusion rate before delivery, respectively, bore a signiﬁcant 
correlation with the umbilical cord concentrations of ketanserin.
RESULTS
Twenty-two patients with 23 neonates were included (including one set of twins). The clinical 
characteristics of the patients and neonates are summarised in Table 6.1. One patient received 
ketanserin orally instead of intravenously. All babies were delivered by caesarean section. 
Ketanserin and ketanserinol could be detected in each of 44 maternal (ketanserin conc. 32 - 
489 ng/ml, ketanserinol conc. 33 – 933 ng/ml) and umbilical cord plasma samples (ketanserin 
conc. 26 - 373 ng/ml, ketanserinol conc. 12 - 472 ng/ml). 
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Table 6.1. Maternal (n=22) and neonatal (n=23) clinical characteristics 
Maternal characteristics 
Maternal age (years) 31.6 [20-40]
Gestational age at admission (weeks) 28 [180-313]
Gestational age at delivery (weeks) 303 [266-341]
Nulliparity (n) 14 (64%)
Systolic blood pressure at admission (mm Hg)
Diastolic blood pressure at admission (mm Hg)
175 [140-240]
110 [95-120]
HELLP at admission (n) 18 (82%)
Indication for delivery:
- foetal ‘distress’ (n)
- maternal ‘distress’ (n)
- combination foetal/maternal ‘distress’ (n)
- spontaneous onset of labor (n)
13 (59%)
6 (27%)
2 (9%)
1 (4.5%)
Neonatal outcome 
Ph umbilical cord 7.25 [7.00-7.38]
Apgar < 7 at 5 min (n) 4 (17%)
Birthweight (g) 1250 [520-2605]
Admission
- Intensive Care Unit (n)
- Medium or transitional Care (n)
- No hospital admission (n)
21 (93%)
1 (4%)
1 (4%)
Mortality during admission (n) 3 (13%)
ICU stay (days) 6 [0-165]
Intraventricular hemorrhage grade III-IV (n) 2 (9%)
Artiﬁcial ventilation (n) 12 (53%)
Duration of ventilation (days) 4 [1-165]
Values are expressed as n (%) or mean [range]
The median transplacental transmission for ketanserin, calculated as ratio umbilical cord 
blood/maternal blood (F/M) was 0.95 (interquartiles 0.61 - 1.24, range 0.36 - 2.62). The mean 
placental transmission for ketanserinol was 0.60 (interquartiles 0.5 - 0.77, range 0.22 - 1.04). 
We found signiﬁcant correlations between infusion rate before delivery (median 10 mg/h, 
range 2 - 18 mg/h) and umbilical cord concentrations (rs = 0.66, p < 0.05), between duration 
of therapy (median 71 hours, range 3 - 895 hours) and umbilical cord concentrations (rs = 
0.69, p < 0.01) and between cumulative dosages (median 1900 mg, range 39 - 10,240 mg) and 
umbilical cord concentrations (rs = 0.79, p < 0.01) for ketanserin. 
We determined breast milk/plasma ratios in seven patients. In two patients administration 
of ketanserin was already stopped, but maternal ketanserin and ketanserinol were still 
detectable. In ﬁve patients the breast milk/plasma ratios were determined while using 
an intravenous dosage of ketanserin, ranging from 4 to 6 mg/h. We found ketanserin 
concentrations in breast milk ranging from < 10 (below LOQ) to 74 ng/ml and ketanserinol 
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concentrations ranging from 21 to 458 ng/ml. The median breast milk/plasma ratios were 0.4 
(range, 0.2 – 1.27) for ketanserin and 0.76 (range, 0.42-1.44) for ketanserinol, respectively.
We were able to obtain two separate plasma samples from eight neonates (gestational 
age 26 6/7 - 32 4/7 weeks, birth-weight 670-1755 g) to determine the elimination half-life 
of ketanserin and ketanserinol. Maternal ketanserin use varied for these neonates between 
2 - 12 mg/h during delivery and cumulative antenatal maternal ketanserin dosage ranged 
between 49 mg – 3295 mg. The individual plasma concentrations in each neonate are 
graphically depicted in Figure 6.1. The calculated half-life of ketanserin in these neonates 
varied between 12.7 and 43.7 hours (median 19.3 hours) and of ketanserinol between 13.8 
and 34.4 hours (median 18.6 hours). 
DISCUSSION
Adequate information regarding exposure and possible eﬀects of ketanserin on the human 
foetus and neonate in humans is lacking. Our study shows that maternal use of ketanserin 
results in high blood concentrations of ketanserin and its metabolite, ketanserinol, in the 
umbilical cord and in the neonate, indicating that ketanserin passes the placenta easily. 
The transplacental passage of ketanserin is in accordance with our expectations, 
considering its physicochemical properties (moderate lipophilic, molecular weight of 365 Da, 
pKa = 7.50) 
4. Being a weak base, ketanserin is highly un-ionised at the physiologic blood pH 
of the mother, which facilitates diﬀusion through the placenta. After passing the placenta, 
the slightly more acidic pH of the foetus might result in a shift of un-ionised ketanserin to a 
higher fraction of ionised ketanserin, which makes redistribution through the placenta back 
to the mother more diﬃcult (ion-trapping).
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Figure 6.1 Neonatal plasma levels of ketanserin within 36 hours after birth, after maternal 
ketanserin use (n = 8).
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In the mothers, ketanserin is metabolised in the liver to ketanserinol 4. The aﬃnity of the latter 
compound for the 5-HT2A receptor is about a thousand- fold less compared to the parent drug 
ketanserin. However, a reduction-oxidation equilibrium seems to exist between ketanserinol 
and ketanserin, resulting in an indirect pharmacological eﬀect of ketanserinol. Ketanserinol is 
more hydrophilic than ketanserin, explaining the lesser degree of placental transmission for 
ketanserinol, compared with ketanserin that we found in this study. We made the assumption 
that the ketanserinol-levels found in the umbilical cord were of maternal origin rather than 
metabolised by the foetus because, although not speciﬁed in the protocol, usually venous 
umbilical cord blood was taken, reﬂecting the blood ﬂow from mother to the foetus. Also, 
the activity of most liver-enzymes in the foetus is low, thus the foetal contribution to the 
formation of ketanserinol is likely to be marginal.
We found a correlation between ketanserin levels in the umbilical cord and cumulative 
maternal dosage, duration of therapy and dosage before delivery, respectively. This correlation 
was in accordance with our expectations, as diﬀusion of the drug which is both concentration 
and time dependent, will play an important part in the placental transfer. The F/M ratio, used 
as a measure of placental transmission, varied extensively in our study. This variation can 
probably be explained not only by diﬀerences in maternal exposure to ketanserin, but also 
by other individual factors, which will inﬂuence placental transfer, such as maternal plasma 
protein concentration and placental blood ﬂow.
The concentrations of ketanserin determined in the umbilical cord plasma samples and 
in the neonate are comparable to and sometimes even higher than, the therapeutic plasma 
concentrations in adult patients treated with ketanserin for chronic hypertension (15-140 ng/
ml) 7. This implies that pharmacological eﬀects in the foetus and neonate are to be expected. 
Bolte et al 8 reported placental transmission of ketanserin, but did not detect any apparent 
adverse eﬀects in the neonate that could be attributed to the drug. Rossouw 9 conﬁrmed the 
apparent safety of ketanserin for mother and foetus, but dosages were lower than used in our 
study. In our study, no apparent side eﬀects were found in foetus or neonate, but because the 
study was non-comparative, no valid conclusions can be drawn. For other antihypertensive 
drugs, used in pregnancy, e.g. labetalol, methyldopa, nifedipine and hydralazin, extensive 
placental transfer has also been described 10. 
The breast milk/plasma ratios found in our study, indicate that the neonate can be exposed 
to substantial amounts of ketanserin and ketanserinol during lactation. These ﬁndings 
support our current policy of discouraging nursing of the neonate while maternal ketanserin 
concentrations are still expected to be in the pharmacologically active range.
In our study, the elimination half-life of ketanserin was prolonged in the neonate, as 
compared with the elimination half-life of 14.3 hours (± 4.4), found in adult volunteers 4. 
Neonates apparently clear ketanserin at a slower rate as compared to adults, probably 
caused by immature metabolising systems in the liver of the neonate, especially in small for 
gestational age or premature neonates, as seen often in pre-eclamptic pregnancies. For the 
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assessment of the elimination rate, we have included in our study only neonates who stayed 
in our hospital for at least two days, for logistical purposes. This might have introduced a 
bias, since these babies probably are the most ill. However, the majority of the neonates, 19 
of 23 babies stayed at the hospital for a longer period. The neonates studied, spanned a wide 
range of gestational age, birth weight and amount of maternal drug use, and so this study 
population is representative of newborns from patients with early-onset pre-eclampsia. Long 
term eﬀects of foetal exposure to ketanserin were not studied but other workers 11 have not 
found eﬀects in infants up to six years after exposure.
CONCLUSION
A high placental transmission and an intermediate transfer into breast milk of ketanserin 
and its metabolite ketanserinol occurred after maternal treatment of pre-eclampsia with 
ketanserin. Pharmacologically relevant concentrations of ketanserin were found in the 
neonate for a prolonged period after delivery. 
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ABSTRACT
Maternal treatment with the 5-HT2A receptor antagonist ketanserin (KT) in pre-eclamptic 
patients is associated with a high placental transmission of KT, resulting in pharmacologically 
active levels of KT in umbilical cord artery (UCA) and neonate. To study whether exposure to 
KT inﬂuences the characteristics of foetal 5-HT receptors, functional studies were performed 
on 5-HT2A and 5-HT1B/1D receptors in UCA from pre-eclamptic patients treated with KT.
UCA were obtained, immediately after delivery, from pre-eclamptic patients (n=7), treated 
antenatally with intravenous ketanserin. Pre-eclamptic patients (n=13), not treated with KT 
(non-KT), were included as a control group. Segments of UCA were prepared and mounted 
in tissue baths and isometric force changes were determined. Cumulative concentration-
response curves to 5-HT and to the 5-HT1B/1D receptor agonist sumatriptan, were constructed 
in the absence or presence of the 5-HT2A receptor antagonist ketanserin or the 5-HT1B/1D 
receptor antagonist GR125743, respectively. 
All UCA segments showed contractile responses to both 5-HT and sumatriptan, and the 
concentration-response curves showed a rightward shift with increasing concentrations of 
KT and GR125743, respectively, indicating the presence of functional 5-HT2A and 5-HT1B/1D 
receptors in the foetal tissue. No signiﬁcant diﬀerences were found in maximum response Emax 
(expressed in % of response on 100 mM KCl), or potency (pEC50) of 5-HT in both groups (Emax 
142 ± 11.6 %, pEC50 7.64 ± 0.26 in KT-treated group and Emax 162 ± 12.6 %, pEC50 7.69 ± 0.14 in 
non-KT treated group, respectively). No signiﬁcant diﬀerences were found in the potency of 
the antagonist ketanserin in both study groups (pKb 7.58 ± 0.37 in KT group and 7.46 ± 0.17 
in non-KT group, respectively). Similarly, with sumatriptan, no signiﬁcant diﬀerences were 
found between KT-treated patients and non-KT treated patients (Emax 132 ± 20.3 % and 140 
± 14.7%, respectively, pEC50 5.98 ± 0.29 and 6.41 ± 0.28 respectively, pKb of GR125743 7.53 ± 
0.27 and 8.43 ± 0.29, respectively).
In conclusion, foetal exposure to ketanserin in pre-eclamptic patients does not signiﬁcantly 
inﬂuence the functional characteristics of 5-HT2A and 5-HT1B/1D receptors in the umbilical cord 
artery.
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INTRODUCTION
Pre-eclampsia is a disease occurring in 2-5% of the pregnant women and it forms one of the 
leading causes of maternal and neonatal mortality and morbidity during pregnancy 1. The 
pathophysiology of the disease is not yet fully understood, but impaired trophoblast invasion 
and endothelial dysfunction are considered to be important factors in the pathogenesis1,2. 
The main clinical characteristics of pre-eclamptic patients are elevated blood pressure, 
proteinuria and oedema, occurring after the twentieth week of gestation. Treatment with 
antihypertensive drugs is indicated to stabilise the patient and prevent maternal complications 
like organ failure or haemorrhages in retina or brain. Preterm delivery of, often severely 
growth restricted, neonates occurs frequently in early-onset pre-eclamptic patients 3,4. 
In the past years, prolonging the pregnancy of early-onset pre-eclamptic patients 
(“temporising management”), using potent antihypertensive drugs, has been undertaken to 
improve neonatal outcome 5-7. One of the antihypertensive drugs used most often in The 
Netherlands in the treatment of pre-eclampsia, is the 5-HT2A receptor antagonist ketanserin 
(KT). The drug is thought to act by blocking the vasoconstrictive response to 5-HT in the blood 
vessels 8. An increased vasoconstrictive response to 5-HT, leading to increased peripheral 
resistance, has been implicated as one of the mechanisms involved in pre-eclampsia. Hence, 
the use of a 5-HT antagonist such as KT, is considered a rational approach in the treatment of 
pre-eclampsia 9,10. However, for temporising management in severe, early-onset pre-eclamptic 
patients, high intravenous dosages of KT are needed for prolonged periods of time, resulting 
in extensive foetal exposure to KT. Indeed, concentrations of KT equal to maternal levels, were 
found in the umbilical cord (26 - 373 ng/ml) and in the neonate (71 - 302 ng/ml) after maternal 
use of KT 11. Whether these pharmacologically active concentrations of ketanserin, being a 5-
HT2A receptor antagonist, inﬂuence the characteristics and possibly cause desensitisation of 
foetal 5-HT receptors, is unknown. In animal studies, chronic blockade of 5-HT2A receptors by 
KT has been shown to lead to an unexpected down-regulation of 5-HT2A receptors 
12, 13. 
5-HT is known to be one of the earliest neurotransmitters produced during foetal brain 
development 14, 15. It can be speculated that foetal exposure to 5-HT receptor blocking drugs 
such as ketanserin, can cause harmful eﬀects on the foetus, especially considering the 
abundant presence of 5-HT receptors in the foetal brain. Although human studies have not 
yet shown clinical adverse eﬀects in neonates, clearly attributable to maternal KT treatment 8, 
11, 16 studying foetal 5-HT receptors in functional studies will yield more detailed information 
regarding foetal development of these receptors and may lead to a better assessment of the 
risk of long-term eﬀects in the neonate after maternal KT treatment. In our study, we selected 
the umbilical cord artery as representative of foetal vessels, knowing that 5-HT2A and 5-HT1B/1D 
are the major receptors mediating 5-HT induced vasoconstriction in human umbilical cord 
artery 17. 
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Based on the results of animal studies 12, 13, we hypothesise that prolonged exposure of tissue 
and blood vessels to the 5-HT2A receptor antagonist ketanserin inﬂuences the functionality of 
foetal 5-HT receptors, by downregulation of the 5-HT2A receptor. 
In the present study, functional responses of 5-HT2A and 5-HT1B/1D receptors in UCA from 
pre-eclamptic patients treated with ketanserin were compared with responses from pre-
eclamptic patients not treated with KT.
METHODS
Twenty pre-eclamptic patients, admitted to the antenatal ward of the Erasmus MC were 
included in the study in the period 2002 - 2004. The Ethics Committee of the Erasmus MC 
approved the protocol and all patients gave informed consent prior to inclusion.
Pre-eclampsia was deﬁned as the occurrence, after 20 weeks of gestation, of a diastolic 
blood pressure ≥ 110 mmHg and a protein/creatinin ratio ≥ 30 mg/mmol creatinin, or the 
occurrence of a repetitive diastolic blood pressure ≥ 90 mmHg in combination with the 
HELLP (haemolysis, elevated liver-enzymes, low platelet-count) syndrome. 
Patients were divided into two study groups; one study group was treated with KT before 
delivery and the other study group treated with other antihypertensive drugs (dihydralazin, 
nifedipine or nicardipine) without exposure to KT. All patients in the KT group and the 
majority of patients (85%) in the non-KT group used methyldopa orally.
KT treatment consisted of an intravenous bolus injection of 10 mg followed by a continuous 
infusion of KT at 4 mg/h. According to the blood pressure, the infusion rate of KT was increased 
with 2 mg/h every 20 min to a maximum of 20 mg/h. Each increment was preceded by an 
intravenous loading bolus injection of 10 mg KT. Drug treatment was targeted at an intra-
arterial diastolic blood pressure of ≤ 90 mmHg. Antihypertensive treatment was continued as 
long as foetal and/or maternal condition did not warrant delivery, as judged by the attending 
obstetrician. 
The umbilical cords were collected immediately after caesarean or vaginal deliveries. 
Umbilical cord was collected in Krebs solution at 4 ºC (composition in mM: NaCl 118, KCl 
4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 11.1, pH 7.4), transported to 
the laboratory and UCA was isolated from the umbilical cord. Functional experiments were 
performed on the same or subsequent day. Segments of UCA of 3-4 mm length and 1.5-2 mm 
internal diameter were suspended with help of stainless-steel hooks in 15 ml organ baths ﬁlled 
with carbogenated (95% O2 / 5% CO2 ) Krebs solution at 37 °C. Each segment was set under a 
tension of 25 mN, as determined to be the optimal tension in pilot experiments. The segments 
were washed after every 15 min and were allowed to equilibrate for 45 min, to ensure that no 
maternal ketanserin was present in the vessels before start of the experiments.
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Two successive challenges to KCl (30 mM, Merck, Darmstad, Germany) were performed to 
check the reproducibility of the response. 100 mM KCl was subsequently added to determine 
the reference contractile response of the segment. Serotonin (5-HT, Sigma Chemicals 
Co., Steinheim, Germany) and sumatriptan (Pﬁzer Ltd, Sandwich Kent, U.K.) were added 
to diﬀerent segments in a cumulative manner in the absence or presence of antagonists. 
Concentration response curves to 5-HT or to sumatriptan were constructed in a parallel set-
up in presence of vehicle or after 30 min of incubation with the 5-HT2A receptor antagonist 
ketanserin (10 nM, 100 nM or 1μM) (Pﬁzer Ltd, Sandwich Kent, U.K.) or the 5-HT1B/D receptor 
antagonist GR125743 (10 nM, 100 nM or 1 μM) (Pﬁzer Ltd, Sandwich Kent, U.K.) 18, respectively. 
All agonists and antagonists were dissolved in distilled water and stored in aliquots at -80 °C. 
Only a single concentration-response curve was constructed in each artery segment. 
Data and statistical analysis
Clinical characteristics between the two groups were compared using Wilcoxon’s rank sum 
test. All contractile responses to the agonists were expressed as percentage contraction of the 
tone induced by 100 mM KCl. All values were expressed as mean ± S.E.M. The concentration 
response curves for the agonists were analysed using non-linear regression analysis (Graph 
pad Prism 3.01, Graph pad Software Inc., San Diego, CA, U.S.A). The potency of agonist 
was expressed as pEC50 (-log(EC50)) and the blocking potency of the antagonists (pKb) was 
estimated by calculating concentration-ratios between EC50-values of agonist in the presence 
and in the absence of antagonists and plotting a Schild-plot 19, assuming a slope of unity. 
Statistical analysis was performed using SPSS (version 11.5, SPSS Inc, Chicago, USA). 
Statistical signiﬁcance was determined by the Students t-test, with diﬀerences considered 
signiﬁcant at p < 0.05. A post hoc power analysis was performed to verify whether suﬃcient 
patients were investigated. Correlation coeﬃcients between pEC50, Emax or pKb and duration of 
KT treatment, cumulative dosage or maximum dosage was calculated according to Pearson’s 
coeﬃcient of correlation (r). 
RESULTS
The demographic and clinical characteristics of the seven KT- treated and thirteen non-KT 
treated patients included in this study, are summarized in Table 7.1. The groups did not diﬀer 
signiﬁcantly with respect to age, gestational age at admission or delivery, blood pressure at 
admission, neonatal weight or way of delivery. In all KT- treated patients, initially adequate 
blood pressure control was achieved with KT, but in two patients alternative intravenous 
antihypertensive drugs (nicardipine n=1, dihydralazin n=1) were added to maintain adequate 
blood pressure control. In one patient in the KT- treated group, KT treatment was stopped 
two hours before delivery and one patient stopped KT treatment 45 hours before delivery. 
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These patients were included in the analysis in the KT group because possible eﬀects of 
maternal KT treatment on umbilical cord receptors were assumed to persist at least several 
days, considering the half-life of 5-HT2 receptors of 3 to 5.5 days 
20 and the elimination half-life 
of KT of 13 - 18 h 21.
Table 7.1. Clinical characteristics of pre-eclamptic patients, treated with ketanserin before delivery 
(n=7) and treated with other drugs (nifedipine, dihydralazin or nicardipine) before delivery 
(n=13). Data are expressed as median (range) or number (%). 
Pre-eclamptic patients treated 
with ketanserin (n=7)
Pre-eclamptic patients not 
treated with ketanserin (n=13)
Age (years) 34 (25-42) 31 (18-44)
BP diastolic at admission (mmHg) 105 (851-120) 100 (90-120)
BP systolic at admission (mmHg) 180 (140-220) 160 (110-200)
Protein/creatinin ratio (mg/mmol) 355 (80-1856) 470 (127-1257)
Gestational age at admission 
(weeks)
28 (25 4/7 – 36 3/7) 29 4/7 (24 4/7 –34 6/7)
Gestational age at delivery 
(weeks)
31 (26 4/7 – 36 3/7) 30 6/7 (26 3/7 – 36 6/7)
Way of delivery
- Caesarian (n)
- Vaginal (n)
7 (100%)
0
12 (92%)
1 (8%)
Twin gestation (n) 0 1 (8%)
Ketanserin use
- Duration of treatment (h)
- Maximum dosage (mg/h)
- Cumulative dosage (mg)
54 (6-399)
9 (6-18)
379 (47-3055)
-
-
-
Neonatal weight (g)
- below 10th percentile (n)
- below 2.3th percentile (n)
1035 (750-2250)
2 (28%)
1 (14%)
1205 (650-2165)
6 (46%)
1 (8%)
1 One patient with severe HELLP-syndrome
The response to 100 mM KCl did not diﬀer signiﬁcantly between the study groups in the KT-
treated group (35 mN ± 16) versus the non-KT-treated group (24 mN ± 10). 
5-HT and the 5-HT1B/1D agonist, sumatriptan, induced potent contractions in the UCA in 
both groups, which did not diﬀer with respect to Emax and pEC50 (Figure 7.1, Table 7.2). The 
concentration- response curves to 5-HT showed a rightward shift after exposure to increasing 
concentrations of the 5-HT2A antagonist ketanserin (Table 7.2, Figure 7.2a and 7.2b). Similarly, 
30 min incubation with the 5-HT1B/1D antagonist, GR125743, resulted in a rightward shift of 
the concentration-response curves to sumatriptan (Table 7.2). 
No statistical diﬀerences were found between the pKb values of 5-HT receptors in UCA of 
pre-eclamptic patients treated with KT or those not treated with KT. Although our sample 
size was limited, a post hoc power analysis (α=0.05, β=0.8) showed that the group size was 
suﬃciently large to detect a diﬀerence in pEC50 of 0.7, corresponding to a ﬁve-fold diﬀerence 
in potency, which we consider to be clinical relevant. 
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No correlations were found for 5-HT for Emax or pEC50, with duration of KT treatment (for Emax, 
r = -0.573, p = 0.179; for pEC50, r = -0.252, p = 0.585), cumulative dosage (for Emax, r = -0.552, p = 
0.199; for pEC50, r = -0.342, p = 0.454) and maximum dosage respectively (for Emax, r = -0.095, p 
= 0.842; for pEC50, r = -0.281, p = 0.542). Similarly, no correlations were found for sumatriptan 
for Emax or pEC50, with duration of KT treatment (for Emax, r = 0.185, p = 0.691; for pEC50, r = 0.077, 
p = 0.869), cumulative dosage (for Emax, r = 0.228, p = 0.623; for pEC50, r = 0.162, p = 0.728) and 
maximum dosage respectively (for Emax, r = 0.656, p = 0.109; for pEC50, r = 0.052, p = 0.911).
Table 7.2. 5-HT receptor characteristics, expressed as mean (± S.E.M.) of Emax, pEC50 and pKb, 
from umbilical cord arteries obtained from pre-eclamptic patients treated with ketanserin and 
from pre-eclamptic patients not treated with ketanserin. 5-HT and sumatriptan were used as agonists 
in absence or presence of ketanserin (100 nM) and GR125743 (100 nM) as their respective antagonists. 
Preeclamptic patients 
treated with ketanserin 
Pre-eclamptic patients 
not treated with ketanserin 
5-HT Sumatriptan 5-HT Sumatriptan
Emax
1 142 ± 11.6 (n=7) 132 ± 20.3 (n=7) 162 ±12.6 (n=11) 140 ± 14.7 (n=11)
pEC50 7.64 ± 0.26 (n=7) 5.98 ± 0.29 (n=7) 7.69 ± 0.14 (n=11) 6.41 ± 0.28 (n=11)
pKb 7.58 ± 0.37 (n=5) 7.53 ± 0.27 (n=4) 7.46 ± 0.17 (n=10) 8.43 ± 0.29 (n=8)
1expressed as percentage of the response induced by 100 mM KCl.
fig. 7.1 Figure 7.1 Concentration response curves to 5-HT in umbilical cord artery segments of ketanserin 
treated patients (●) (n = 7) and of patients, not treated with ketanserin (ο) (n = 13) and 
concentration response curves to sumatriptan in umbilical cord artery segments of ketanserin 
treated patients (■) (n = 7) and of patients, not treated with ketanserin (�) (n = 13).
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DISCUSSION
The presence of 5-HT2A and 5-HT1B/1D receptors in utero-placental vessels of normotensive 
patients has been described by several authors 22-24. Increased concentrations of 5-HT have 
been reported at birth in maternal and placental circulation 25, indicating a role for 5-HT 
in maintaining vascular tone at birth. In pre-eclampsia, Middelkoop et al 26 have shown an 
increase in maternal circulation of 5-HT in pre-eclamptic patients, suggesting a role for 5-HT 
in the aetiology of pre-eclampsia.
In agreement with these studies, we found that 5-HT and sumatriptan induced contractions 
in all UCA tested, indicating the presence of 5-HT receptors. Ketanserin and GR125743 moved 
the 5-HT and sumatriptan curves rightwards in concentration-dependent manner, conﬁrming 
the presence of functional 5-HT2A and 5-HT1B/1D receptors in umbilical cord artery.
The pKb values (7.58 and 7.46) of ketanserin against 5-HT are one log unit lower than the 
pA2 values of 8.7 - 8.9 described by other authors for umbilical cord artery 
17, 27. This might be 
explained by the fact that the blocking activity of ketanserin is being underestimated in our 
experiments because 5-HT will have functional aﬃnity for 5-HT1 receptor subtypes as well. 
7.2a       7.2b 
Figure 7.2 Concentration response curves to 5-HT in the absence (●) or presence of increasing 
concentrations of the 5-HT2A receptor antagonist, ketanserin (10 nM ( ), 100 nM (∇) and 1 μM (◊), 
in umbilical cord artery segments of ketanserin treated patients (n=7) and of patients, not treated 
with ketanserin (n=13).
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Even though 5-HT is not a selective 5-HT2A receptor agonist, we chose 5-HT as an agonist in 
this study as it encompasses the study of all 5-HT receptor subtypes and allows comparison 
of our results with other studies on 5-HT receptor functionality 17, 28, 29. Furthermore, our 
results are in line with previously reported values of pA2 of 7.7 - 7.85 for 5-HT2A receptor in 
animal tissue 30, 31. The pKb value of GR125743 (7.53-8.43) for sumatriptan is in accordance 
with previously observed pA2 values of 8.18 in human coronary artery and 8.34 in human 
saphenous vein 32. 
The 5-HT2A receptor antagonist KT has been used increasingly in recent years as an 
antihypertensive drug in pre-eclamptic patients. However, the substantial transplacental 
transmission and subsequently high foetal exposure to KT 11 may lead to adverse eﬀects 
on foetal 5-HT receptors. The early appearance and continued expression of foetal 5-HT 
receptors during gestation has been demonstrated in animal studies 15. Lauder et al 15 showed 
in mouse embryos that both structural as well as functional damage occurred after foetal 
exposure to high dosages of the 5-HT2A/2C receptor antagonist, mianserin and the 5-HT2A/2B/2C 
receptor antagonist, ritanserin. No malformations were found after foetal exposure to KT. 
Whitaker et al 33 demonstrated in animal studies that foetal exposure to the 5-HT-agonist, 5-
methoxytryptamine, or exposure to a decreased level of maternal 5-HT (achieved by adding 
a tryptophan hydroxylase inhibitor antagonist) resulted in downregulation and upregulation 
of 5-HT receptors in new born oﬀspring, respectively. 
In humans, only data on foetal eﬀects after use of selective serotonine re-uptake inhibitors 
(SSRI’s) during pregnancy are available. These drugs have shown to aﬀect foetal 5-HT 
regulation, resulting in adverse eﬀects on neonatal behaviour (tremor, restlessness, rigidity 
postnatally) following gestational exposure 34, 35. 
Based on the aforementioned data on adverse foetal eﬀects after maternal drug use, we 
studied the eﬀect of maternal KT treatment on foetal 5-HT receptor characteristics in pre-
eclamptic patients. We hypothesized, based on animal studies 12, 13, that foetal exposure to KT 
might inﬂuence the functionality of 5-HT2A receptor, but not of the 5-HT1B/D receptor.
Our data show no signiﬁcant diﬀerences in 5-HT- or sumatriptan-induced vasoconstrictive 
responses of the UCA between the pre-eclamptic group treated with KT and the pre-eclamptic 
group without exposure to KT, indicating that exposure to KT does not inﬂuence foetal 5-HT2A 
and 5-HT1B/1D receptor characteristics in UCA.
Dosage and duration of treatment
It can be expected that high dosages of KT and long-term treatment will exert a more 
pronounced eﬀect on receptor characteristics than lower dosages, although all dosages 
used in this study were in the pharmacologically active range and have been known to cause 
high umbilical cord plasma levels of KT 11. These plasma levels are in the same range as the 
concentrations KT used in our ex vivo experiments, indicating that results obtained with our 
experiments are of clinically relevance. 
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In our study no relationship between dosage and pEC50, Emax or pKb could be established. It 
should be born in mind that the number of patients in our study was relatively small, due to the 
fact that many early-onset pre-eclamptic patients need alternative treatment before delivery 
after the maximum dosage of ketanserin is reached. However, power analysis established 
that statistical power in our study was suﬃcient to detect clinically relevant diﬀerences. 
Gestational age
Limited information is available with respect to the inﬂuence of gestational age on the 
response of the umbilical artery to 5-HT. Bertrand et al 28 showed an increase in umbilical 
and placental veins sensitivity to serotonin throughout the third trimester in normotensive 
patients, whereas this change was not seen in pre-eclampsia. In our study the study groups 
did not diﬀer with respect to gestational age, therefore a possible confounding factor of 
gestational age on the results was excluded. However, it can be speculated that clinical 
eﬀects of maternal KT treatment on receptor population will (partly) depend on gestational 
age, if sensitivity to 5-HT in UCA indeed changes with gestational age.
Our results, suggesting a lack of eﬀect of maternal KT treatment on functionality of 5-HT 
receptors in UCA support the currently available clinical data, showing that use of KT in pre-
eclamptic patients is safe for foetus and neonate.
In conclusion, prolonged foetal exposure to ketanserin in pre-eclamptic patients does 
not seem to inﬂuence the functional characteristics of 5-HT2A and 5-HT1B/1D receptors in the 
umbilical cord artery. 
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ABSTRACT
To evaluate the eﬃcacy of intravenous administration of nicardipine as second-line 
temporising treatment in pre-eclamptic patients, a prospective study was performed in 
twenty-seven early-onset, pre-eclamptic patients with a median gestational age of 27 weeks 
(range 212 – 321 weeks), with treatment failure on standard intravenous antihypertensive 
drugs (ketanserin, dihydralazin or labetalol). Nicardipine infusion was started for temporising 
management of pre-eclampsia at a dosage of 3 mg/h and was subsequently titrated 
according to blood pressure. Nicardipine treatment was continued as long as maternal and 
foetal condition allowed. The endpoints of the study were deﬁned as percentage of patients 
reaching the target diastolic intra-arterial bloodpressure (< 100 mmHg or < 90 mmHg in 
HELLP-syndrome patients) within 1 h after the start of treatment, and the number of days 
of prolongation of pregnancy under nicardipine treatment. Maternal and foetal side eﬀects, 
foetal death and neonatal outcome were assessed.
In all patients target diastolic blood pressure was obtained within a median of 23 min 
(range 5 - 60 min). Delivery was postponed for a median of 4.7 days (range 1 - 26 days) 
using nicardipine treatment, in a maximum dosage ranging from 3 to 9 mg/h. Detailed 
haemodynamic parameters with corresponding nicardipine dosages were obtained in nine 
patients. In 30% of the patients, unwanted hypotensive periods (< 70 mmHg) were registered 
during treatment, manageable with dosage adaption. 
This evaluation shows that nicardipine is a potent antihypertensive drug and can be used for 
temporising management in severe, early-onset pre-eclampsia when other antihypertensive 
drugs have failed.
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INTRODUCTION
The mainstay of treatment in pre-eclamptic patients is to lower the elevated blood pressure 
to prevent complications in the mother. While the ultimate cure for pre-eclampsia is delivery, 
studies have shown that temporizing management, using potent antihypertensive drugs, 
can improve neonatal outcome in severe early-onset pre-eclampsia 1-4. 
Current options for antihypertensive treatment are limited. Worldwide, (di)hydralazine 
with its direct vasodilatating eﬀect is used most often. In Europe, however, dihydralazin 
has recently been withdrawn from the market for economical reasons. The 5-HT2A receptor 
antagonist ketanserin has been used increasingly, but according to both our experience and 
literature 5, the antihypertensive response is insuﬃcient in a substantial number of patients 
and additional antihypertensive treatment is required.
The combined alpha and beta-blocking agent labetalol is available both orally and 
intravenously, but intravenous administration of high maternal dosages has been associated 
with severe neonatal cardiovascular adverse eﬀects 6.
For oral use, methyldopa and the calcium-channel blocking agent nifedipine are available 
but these drugs lack potency as monotherapy in severe pre-eclamptic patients. Moreover, 
the lack of an intravenous drug dosage form precludes their application in acute situations.
Nicardipine, a dihydropyridine type calcium-channel antagonist, available both orally and 
parenterally, is a drug of interest for use in pre-eclamptic patients. The drug acts by blocking 
the transmembrane ﬂow of calcium ions through voltage-gated L-type channels. This leads 
to a lower concentration of calcium in the cell and thereby diminishes contraction of vascular 
smooth muscle cells. The drug has been licensed for use in acute severe hypertension and 
postoperative hypertension during the ﬁrst 24 hours following surgery, and it has shown a fast 
and potent lowering of the blood pressure after intravenous administration 7. In comparison 
with nifedipine, nicardipine acts more selectively on blood vessels than on myocardial tissue, 
resulting in less reﬂex tachycardia. The short half life of the drug (t½ = 2 - 5 min, increasing to 
1 - 2 h after prolonged use 8) enables an accurate titration of the blood pressure. 
Studies with nicardipine in pre-eclamptic patients are scarce 9-12. Only Carbonne et al 9 
describes the succesful use of nicardipine for temporizing management in pre-eclamptic 
patients with a gestational age mainly above 32 weeks. 
Our obstetric ward is a referral centre for early-onset pre-eclamptic patients (gestational 
age < 32 weeks) and the current policy is to use antihypertensive treatment in these 
patients to prolong pregnancy and improve neonatal outcome. However, failure of adequate 
antihypertensive blood pressure control occurs frequently under antihypertensive treatment 
and may necessitate delivery in very early pregnancy, with a corresponding high neonatal 
morbidity and mortality. Therefore, the need for new potent antihypertensive drugs in early-
onset pre-eclamptic patients is apparent.
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This observational study describes the use of nicardipine for temporizing management, 
when other therapeutic options have failed. Eﬃcacy in terms of blood pressure control and 
postponement of delivery is assessed in a population of extensively pre-treated, early-onset 
pre-eclamptic patients. Safety issues for the mother, foetus and neonate are discussed.
METHODS
Patients, admitted to our High Care antenatal ward with severe pre-eclampsia in the period 
2002 - 2004, were treated with intravenous nicardipine after failure of treatment with 
intravenous ketanserin or dihydralazin (in combination with methyldopa orally). Severe pre-
eclampsia was deﬁned as the occurrence after 20 weeks of gestation, of a diastolic blood 
pressure ≥ 110 mm Hg and proteinuria ≥ 0.3 g/l in a 24-h urine collection, or the occurrence 
of repetitive diastolic blood pressure > 90 mmHg in combination with Haemolysis, Elevated 
Liver Enzymes, Low Platelet Count (HELLP) syndrome. HELLP-syndrome was deﬁned as the 
simultaneous occurrence of alanine aminotransferase and/or aspartate aminotransferase 
> 31 U/l (2 SD above the mean in our hospital), platelet count < 100 x 109 platelets/L and 
haptoglobin < 0.28 g/L. The diastolic blood pressure was measured at Korotkoﬀ phase V with 
a mercury sphygmomanometer. 
During admission, each woman received an indwelling arterial catheter for blood pressure 
measurement and a triple lumen central venous line for central venous pressure measurement 
and parenteral administration of medication. The central venous pressure was continuously 
maintained at 5-6 mmHg, using pasteurized plasma-solution. From 2004 onwards, magnesium 
sulphate treatment was administered prophylactically to all pre-eclamptic patients with a 
diastolic blood pressure ≥ 110 mmHg.
Antihypertensive treatment was continued as long as the foetal and/or maternal condition 
did not warrant delivery, as judged by the attending obstetrician. Foetal viability was set at 
26 weeks gestation and a estimated foetal weight ≥ 650 g. When foetal viability was reached, 
the foetal condition was actively assessed, using cardiotocography (CTG) and taken into 
consideration in the decision to terminate the pregnancy. All patients received a course of 
antenatal corticosteroids after 26 weeks of gestation for foetal lung maturation. 
Since this study comprises an evaluation of our current protocol regarding antihypertensive 
treatment using only observations and no interventions, no permission from the Institutional 
Review Board was required according to Dutch Law.
Drug treatment
Treatment was targeted at a diastolic intra-arterial blood pressure (DAP) of < 100 mmHg (or 
< 90 mmHg in patients with HELLP-syndrome) within 1 h after the start of treatment. All 
patients continued to use methyldopa orally in a maximum dosage of 4 g daily. The starting 
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dosage of nicardipine was 3 mg/h by continuous infusion through a central venous line. As 
soon as the target DAP was reached, the dosage was reduced. Nicardipine dosages were 
subsequently titrated according to the blood pressure with increments of 0.5 – 1 mg/h to a 
maximum of 10 mg/h.
Treatment was continued until maternal and/or foetal condition warranted delivery.
Data analysis
The eﬃcacy of nicardipine was evaluated by assessing the number of patients that reached the 
target DAP and the time-interval needed to reach the target DAP. Treatment was considered 
a failure when target blood pressure could not be reached with nicardipine within 60 min. 
The prolongation of pregnancy with nicardipine treatment was determined until delivery or 
occurrence of intra-uterine foetal death. Safety of the therapy was assessed as the occurrence 
of hypotensive periods, deﬁned as DAP < 70 mmHg and the occurrence of adverse maternal 
eﬀects. Tachycardia was deﬁned as the occurrence of a heart beat > 120 beats/min, and 
the dosage of nicardipine was adjusted when tachycardia was sustained for more than 20 
min. Postpartum, the incidence of haemorrhage was registered (deﬁned as blood loss after 
delivery of more than 500 ml).
Maternal side eﬀects were registered daily by nurses, using a standardized questionnaire. 
The foetal condition was assessed by CTG in patients with a viable foetus. Possible inﬂuences of 
nicardipine dosage change or hypotension during nicardipine treatment on CTG parameters 
(appearance of decelerations and eﬀect on baseline foetal heart rate) were retrospectively 
analysed visually by a single investigator without knowledge of the nicardipine dosage or 
DAP at the time of CTG interpretation.
Foetal and neonatal outcome was assessed in terms of intra-uterine foetal death, neonatal 
death (death within 6 weeks after birth), the number of severely growth-restricted neonates 
at birth, the pH value in the umbilical artery, the number of neonates with an APGAR score 
< 7 at 5 min, the number of neonates admitted to the intensive care unit, the number of 
neonates requiring artiﬁcial ventilation and the number of days of artiﬁcial ventilation, and 
the number of neonates with hypotension within 24 h after birth, needing to be treated with 
volume expansion and /or cardiovascular drugs.
RESULTS
Twenty-seven pre-eclamptic patients received nicardipine as second-line treatment, after 
failing ﬁrst-line treatment with parenteral ketanserin (n=22), dihydralazine (n=2) or labetalol 
(n=1). Two patients received both ketanserin and dihydralazin, successively, before the start of 
nicardipine. The clinical characteristics of the study population are presented in Table 8.1. All 
patients but one continued or started on methyldopa orally, during nicardipine treatment.
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The indication to start nicardipine was insuﬃcient blood pressure control in 18 patients treated 
with ketanserin (maximum dosage, 20 mg/h) and in one patient treated with dihydralazin 
(maximum dosage, 9 mg/h). Three patients on ketanserin experienced side-eﬀects necessitating 
a switch of therapy (hypotension and QT-interval prolongation respectively), whereas one 
patient on dihydralazin experienced hypotension. One patient was started on ketanserin in 
combination with methyldopa, but, due to the occurrence of hypotension, ketanserin was 
stopped. Monotherapy with methyldopa eventually was not suﬃcient to keep adequate 
blood pressure control, and nicardipine was added. In two patients nicardipine was started 
after both ketanserin (insuﬃcient eﬀect and bradycardia, respectively) and, subsequently, 
dihydralazin (general malaise and unstable blood pressure, respectively) were stopped. One 
patient was switched from labetalol to nicardipine due to lack of eﬃcacy.
In 22 patients CTG were obtained during nicardipine treatment. Two other patients were 
below 26 weeks gestation, and the remaining three patients had incomplete data.
Table 8.1. Clinical characteristics of pre-eclamptic patients (n=27) treated with nicardipine as 
second-line treatment 
Number (%) or Median (range)
Systolic blood pressure (mm Hg)
- At admission1
- At start nicardipine2
175 (130-220)
191 (151-224)
Diastolic blood pressure (mm Hg)
- At admission1
- At start nicardipine2
110 (80-130)
104 (803-123)
Proteinuria at admission (g/l) 1.94 (0.15-34.7)
Maternal age (years) 31 (18-41)
Gestational age (weeks)
- At admission
- At start nicardipine
264 (211 - 31 2)
271 (212 – 324)
Nulliparous (n) 19 (70%)
Pre-existent hypertension (n) 6 (22%)
HELLP syndrome (n) 
- At admission 
- At start nicardipine 
8 (30%)
9 (33%)
Oral antihypertensive co-medication at admission (n)
 - Methyldopa 
 - Nifedipine 
 - Labetalol 
 - None 
25 (92%)
2 (7%)
3 (11%)
1 (4%)
First-line intravenous antihypertensive treatment (n)
- Ketanserin 
- Dihydralazin 
- Ketanserin and dihydralazin
- Labetalol 
22 (81%)
2 (7%)
2 (7%)
1 (4%)
1 manually measured, 2 intra-arterially measured, 3 Two patients with adverse effects on ﬁrst-line treatment
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Eﬃcacy
In all patients with elevated blood pressure at time of start of nicardipine, the target DAP 
was obtained within a median period of 23 min (range 5 - 60 min) using nicardipine. No 
treatment failures occurred. In three patients the starting dosage of nicardipine was below 3 
mg/h because of border-line hypertension before start of nicardipine [2 mg/h (n=1), 1 mg/h 
(n=2)]. All other patients started with intravenous nicardipine in a dosage of 3 mg/h. In three 
patients a temporary increase of the dosage to 4 mg/h was necessary to obtain target blood 
pressure initially. After reaching the target blood pressure, the dosage of nicardipine was 
reduced by 0.5, 1 or 2 mg/h in all patients. 
In nine patients we performed continuously arterial sampling of systolic, diastolic and 
mean arterial blood pressure and the heart rate during the ﬁrst 90 min of nicardipine infusion. 
These measurements are shown in Figure 8.1a-d.
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Figure. 8.1 Haemodynamic characteristics of pre-eclamptic patients before and after start of 
nicardipine infusion (n=9)
Figure. 8.1b Mean (standard deviation) systolic arterial blood pressure (SBP) and corresponding 
nicardipine dosage
Fig. 8.1a Mean (standard deviation) diastolic arterial blood pressure (DBP) and corresponding 
nicardipine dosage 
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Twenty-six patients received nicardipine treatment until delivery. In one patient 
nicardipine was stopped after 3.5 days because of a lack of need for continuing intravenous 
antihypertensive treatment. In this patient, treatment was switched to nifedipine orally.
The maximum dosage of nicardipine during treatment ranged from 3 to 9 mg/h, with a 
median of 4 mg/h. 
Maternal outcome is summarized in Table 8.2. Foetal death occurred in three patients; in 
two women at 24 weeks of gestation and in one women at 275 weeks of gestation. In all three 
patients a non-intervention policy was followed because of the early gestational age or a 
severely growth-restricted foetus with a poor prognosis; in these patients only the maternal 
condition and not the foetal condition, was taken into consideration in the decision to deliver 
the mother.
In our cohort, pregnancy was prolonged for a median of 4.7 days (median 1 - 26 days) 
under nicardipine treatment, after failure of earlier intravenous antihypertensive treatment. 
Most women (74%) were delivered because of deteriorating foetal condition. In four patients 
the maternal condition was the reason for delivery.
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Figure. 8.1d Mean (standard deviation) heart rate and corresponding nicardipine dosage 
Figure 8.1c Mean (standard deviation) arterial blood pressure (BP) and corresponding nicardipine 
dosage 
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Using the dosage schedule as already described, no patients experienced inadequate 
blood pressure control during nicardipine treatment. However, in the ﬁrst months after 
implementing the protocol, oral metoprolol was added during nicardipine treatment in ﬁve 
patients when nicardipine dosages were 7 mg/h or higher. Due to the limited experience 
with nicardipine at that time, the attending physician felt the need to add metoprolol, to 
ensure adequate blood pressure control in the long term. During the course of the study, this 
practice was not deemed necessary anymore.
Table 8.2. Maternal outcome after treatment with nicardipine for pre-eclampsia (n=27) 
Number (%) or Median (range)
Gestation age at delivery or at occurrence of IUFD (weeks) 275 (244 - 34)
Target diastolic blood pressure within 60 min 27 (100%)
Prolongation of pregnancy on nicardipine (days) 4.7 (1-26)
Caesarean section (n) 24 (89%)
Indication for delivery (n)
- Foetal distress
- Maternal condition
- IUFD 
20 (74%)
4 (15%)a
3 (11%)
Complete antepartum resolution of HELLP-syndrome 
during nicardipine treatment (n) 4 (15%)
IUFD, intra-uterine foetal death; a Respectively fever, dyspnoea, severe subcutaneous oedema and pulmonary 
oedema after ﬂuid overload.
Safety
In eight patients (30%) short episodes of hypotension (DAP < 70 mmHg) were registered. 
In two patients the hypotension necessitated a reduction of the dosage of nicardipine, and 
in three patients nicardipine was temporarily withdrawn, leading in all patients to a DAP > 
70 mmHg. In the remaining patients, DAP < 70 mmHg was accepted based on the clinical 
condition of the mother. No patients suﬀered a hypotensive episode severe enough to 
require delivery. Tachycardia (heart rate > 120 beats/min) occurred in ﬁve (18%) patients 
during nicardipine treatment, but since the observed tachycardia was sustained for a period 
shorter than 20 min, no stopping or lowering of the dosage of nicardipine was necessary. 
From 2004 onwards, magnesium was used as prophylaxis against seizures in pre-eclamptic 
patients. Three patients in our study received magnesium during nicardipine treatment, 
without showing any eﬀect on the blood pressure.
The side eﬀects most frequently reported by the patients were fatigue, dry mouth, stuﬀy 
nose, lost of appetite and constipation. One patient experienced severe diarrhoea and in one 
patient serum urea was increased (during steroid treatment). Because these eﬀects could not 
be excluded as caused by nicardipine, intravenous ketanserin was added and the dosage of 
nicardipine was not increased.
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In one patient with intra-uterine foetal death at 24 weeks, induction of labor with 
prostaglandine E2 (Sulproston) took several days to be successful, which may be (partly) 
attributed to a tocolytical eﬀect of nicardipine. Haemorrhage postpartum (deﬁned as > 500 
ml blood loss) occurred in six patients (27%) and blood transfusions were needed in ﬁve 
of these patients. This is high in comparison with historical data from 254 pre-eclamptic 
patients treated at our unit with dihydralazin, in which haemorrhage postpartum occurred 
in 15 patients (6%) 1.
Foetal safety
Two patients showed the appearance of variable decelerations within 1 h after hypotension 
during nicardipine treatment. Intervention for foetal distress was not indicated. Decelerations 
disappeared spontaneously in both patients. Both patients also had variable decelerations 
before starting nicardipine. 
Raising the nicardipine dosage resulted in the appearance of decelerations (within 2 h) in 
four patients. None of these patients were hypotensive. Intervention for foetal distress was 
indicated once in a patient with a systolic blood pressure of 190 mmHg and a diastolic blood 
pressure of 110 mmHg. The other patients had no change in therapy, and decelerations 
resolved spontaneously. All patients also had variable decelerations before starting 
nicardipine.
Dosage reduction resulted in appearance of decelerations in four patients (total of ﬁve 
episodes). None of these patients were hypotensive. One patient again had dosage reduction, 
but change of treatment in other patients was not indicated and decelerations resolved 
spontaneously. All patients also had variable decelerations before starting nicardipine. No 
changes in the baseline foetal heart rate were observed. 
Neonates
Neonatal outcome is presented in Table 8.3. Two neonates died within 6 weeks after birth. One 
neonate died after 6 days of severe idiopathic respiratory distress syndrome and the other 
neonate died 17 days after birth after relaparotomy because of necrotizing enterocolitis.
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Table 8.3.  Foetal (n=27) and neonatal (n=24) outcome after maternal treatment with nicardipine 
for pre-eclampsia 
Number (%) or median (range)
Number of foetuses (n)
Foetal death 
Number of neonates (n)
Gestational age at birth (weeks)
Birth weight (g)
Growth percentile (n)
- Below 10% percentile
- Below 2.3% percentile 
pH value umbilical artery 
Apgar score <7 at 5 min (n) 
Neonatal death (< 6 weeks)
Neonatal care (n)
- Intensive Care 
 - days on Intensive Care 
- Medium Care 
- No admission 
Mechanical ventilation (n)
- Days on mechanical ventilation 
Hypotension within 24 h after birth, needed to be treated with 
volume expansion and /or cardiovascular drugs (n)
27 
3 (11%)
24 (89%)
282 (256 - 34)
925 (560 - 1685)
11 (46%) 
2 (8%)
7.23 (7.06-7.38)
2 (8%)
2 (8%)
21(88%)
15.5 (1-70)
3 (12%)
0
18 (75%)
8 (1-39)
8 (33%)
DISCUSSION
In severe pre-eclamptic patients, aggressive antihypertensive treatment should be used to 
stabilize the condition of the mother. Furthermore, delivery can sometimes be postponed, 
while corticosteroids are administered to the mother to improve foetal lung maturation. 
There is still a lot of debate whether prolonged antihypertensive treatment in early-onset pre-
eclampsia results in improved neonatal outcome 13-16, but in our hospital the current policy is 
to use temporizing antepartum management with parenteral antihypertensive treatment in 
early-onset pre-eclampsia, as long as the foetal and maternal condition allows. 
Parenteral antihypertensive treatment should be administered under close monitoring of 
the mother and foetus. Preferably, continuous arterial blood pressure measurements and 
central venous pressure monitoring should be carried out in each patient in a high-care 
obstetric setting. Inadequate maternal blood pressure control or an overshoot of blood-
pressure-lowering therapy, resulting in foetal distress, can compromise a safe delivery. 
However, therapeutic options with respect to antihypertensive treatment are limited and 
far from optimal with respect to eﬃcacy and side-eﬀects 5. Therefore, alternative drugs that 
are eﬀective and safe for both mother and child are sorely needed.
In studies in pregnant rhesus monkeys and sheep 17-19, the calcium-channel blocking 
agents nifedipine and nicardipine have been associated with foetal acidemic responses and 
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concern has risen for treatment with dihydropyridine derivates in pregnant women. However, 
extensive experiences with nifedipine as a tocolytical drug in pregnant women have not 
revealed any negative eﬀects on foetal or uteroplacental circulation 20. 
Nicardipine has less eﬀect on myocardial function than nifedipine, and its fast and 
easily controllable antihypertensive eﬀect makes the drug useful for acute hypertensive 
emergencies. Haemodynamic eﬀects of short-term infusions of nicardipine in pre-eclamptic 
patients have been described in the literature 10-11, resulting in a fast and eﬀective decrease of 
blood pressure in all patients. 
Carbonne et al. 9 reported the successful use of intravenous nicardipine in a ﬁxed dosage-
schedule for prolongation of the pregnancy for a mean of 5.3 ± 3.6 days in 20 pre-eclamptic 
patients (gestational age 33 ± 3.6 weeks), and no adverse eﬀects on foetus or neonates were 
found. Seki et al. 11 demonstrated that prophylactic treatment with nicardipine in patients 
with severe hypertension during pregnancy was both eﬀective and safe for mother and 
child. 
However, since data regarding long-term eﬃcacy in pre-treated, early onset pre-eclamptic 
patients are lacking, the current observational study was carried out to determine eﬃcacy of 
nicardipine, after failure of ﬁrst-line antihypertensive treatment. 
Eﬃcacy
We demonstrate in our study that nicardipine is an eﬀective drug in obtaining and 
maintaining blood pressure control in severe, early-onset pre-eclamptic patients, even when 
other antihypertensive treatment has failed. Within a median period of 20 min after the start 
of the drug, patients reached target blood pressure and no treatment failures occurred. In 
comparison with the 5-HT2A antagonist ketanserin, which was shown to be ineﬀective in a 
substantial part of pre-eclamptic patients 5, these results indicate a high eﬃcacy proﬁle for 
nicardipine, even in our population of non-responsive pre-treated patients. Adequate blood 
pressure control using nicardipine was maintained for a period of days in most patients 
and pregnancy was prolonged for a clinically signiﬁcant period of time under nicardipine 
treatment. Maternal condition was the reason for delivering the patient only in a minority of 
patients, indicating that the drug is eﬀective and tolerated well by the mother. 
As shown by the continuous blood pressure measurements after the start of the infusion, 
the antihypertensive eﬀect of the drug was easily manageable by titration of the dosage, due 
to the fast onset of antihypertensive eﬀect and short half-life of the drug. 
However, some characteristics of nicardipine, such as its high intrinsic potency, the extensive 
metabolism by the liver and the side-eﬀects like tachycardia and tocolytic eﬀects, might 
be disadvantageous in pre-eclamptic patients. These safety issues have been looked upon 
speciﬁcally in our patients.
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Hypotension
In pre-eclamptic patients, the risk of compromising the foetal condition by aggressive 
lowering of maternal blood pressure has to be weighted against the need to protect the 
mother from complications due to a highly elevated blood pressure.
The widely used antihypertensive drug (di)hydralazin is known to cause foetal distress 
because of the unpredictable fall in maternal blood pressure, especially when circulating 
volume is low and in circumstances where adequate monitoring of maternal blood pressure 
and pulmonary capillary wedge pressure or central venous pressure is not feasible 6. 
In our study, an unwanted hypotensive period (deﬁned as DAP < 70 mmHg) occurred during 
the use of nicardipine in one ﬁfth of the patients. Although these hypotensive periods did not 
result in acute foetal distress or emergency delivery, intervention in treatment (reduction of 
dosage or temporarily stopping of the treatment) was deemed necessary in these patients. 
This shows that the current dosage schedule of nicardipine might not be optimal in all 
patients and that more studies are needed to evaluate the relationship between the dosage 
of nicardipine and antihypertensive eﬀects in individual pre-eclamptic patients.
HELLP-syndrome
Nicardipine is metabolised extensively by the liver and therefore, in non-pregnant patients 
with liver function disorders, administration with caution is advised 8. The occurrence of 
HELLP-syndrome in pre-eclamptic patients might inﬂuence the pharmacokinetic parameters 
of nicardipine, and more data in this subpopulation are needed. Our observation that the 
HELLP-syndrome was resolved under nicardipine treatment in 15% of the patients is in 
agreement with the fact that resolution of HELLP-syndrome during temporizing management 
of pre-eclampsia is known to occur 16.
Heart rate
The increase in heart rate under nicardipine treatment is a common side eﬀect in all calcium- 
channel blocking agents of the dihydropyridine type, as well as with (di)hydralazin, and 
is caused by a reﬂex response to systemic arterial vasodilatation. The tachycardia was not 
considered a clinical problem in our patients by the treating physician, but almost all patients 
in our evaluation used methyldopa as co-medication as part of the protocol, which may have 
been beneﬁcial because of its slowing eﬀect on heart rate. 
Combination with magnesium sulphate
Simultaneous use of magnesium sulphate for prophylaxis of seizures with nicardipine has 
been associated with an excessive hypotensive response, due to a combined blocking eﬀect 
on calcium entry in the cell 21. In our evaluation, magnesium sulphate was administered 
during nicardipine treatment in three patients, but in none of these patients an increase in 
antihypertensive response was seen.
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Tocolytical eﬀects
Nicardipine, as well as nifedipine, has been shown to possess tocolytical eﬀects, because 
of its relaxing eﬀect on smooth muscle contractility 22. Obviously, induction of labor can 
be more diﬃcult if a tocolytical (side) eﬀect of nicardipine is present, as was seen in one 
of our patients after intra-uterine foetal death. After delivery, the risk on haemorrhage may 
be increased, because of uterine atonia. In our evaluation, no major clinical problems were 
experienced, but the increased incidence of haemorrhage postpartum, as compared with our 
historical data 1, suggest that possible inhibitory eﬀects of nicardipine on postpartum uterine 
contractions may indeed result in an increased risk of haemorrhage postpartum.
Foetal outcome
Nicardipine dosage change or hypotension during nicardipine treatment did not result in an 
increase in appearance of deceleration, which needed treatment. No foetal distress caused 
by nicardipine occurred. All patients with decelerations already had transient decelerations 
before onset of nicardipine, suggesting other causes of decelerations such intra-uterine 
growth restriction or placental dysfunction. 
Neonatal outcome
Our neonatal data are comparable with respect to APGAR scores and umbilical core pH to 
our own data 23 from neonates after temporising management with only ketanserin and/or 
dihydralazin, indicating the lack of any eﬀect of nicardipine on neonatal acid-base status at 
delivery. 
Transplacental transmission of nicardipine after maternal use is thought to be limited 9. 
However, pharmacological eﬀects of nicardipine in the neonate after maternal use cannot 
be excluded, and our incidence of hypotension in one-third of the neonates might in part be 
attributed to maternal use of nicardipine.
From our observational study, the data on neonatal morbidity and mortality are diﬃcult to 
interpretate without a control group of neonates of pre-eclamptic mothers with comparable 
gestational age and temporizing management, preferably treated in the same hospital in 
the same time-period. However, within the limitations of this setting, perinatal and neonatal 
outcome did not seem compromised for our group of patients, especially when taken 
into account the pre-selected patient-population with failure of ﬁrst-line antihypertensive 
treatment. 
For comparative eﬃcacy and safety with other antihypertensive drugs in pre-eclamptic 
patients, randomised clinical trials are warranted.
In conclusion, this observational study conﬁrms that nicardipine is a potent antihypertensive 
drug, and in addition shows that nicardipine can be used eﬀectively for temporizing 
management in early-onset pre-eclampsia when other antihypertensive drugs have failed. 
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ABSTRACT
To assess the safety risks on the foetus and neonate caused by maternal use of nicardipine 
in pre-eclamptic patients, we evaluated the transplacental transfer and the transfer to breast 
milk after maternal intravenous administration of nicardipine. In ten pre-eclamptic patients 
nicardipine concentrations of maternal blood (P) and both arterial and venous umbilical 
cord blood samples (Uarterial and Uvenous) were assessed and the ratio of maternal and foetal 
plasma concentrations was calculated as an indication of transplacental transfer. We found 
a median transfer of 0.15 (Uarterial/P, range 0.05-0.22), and 0.17 (Uvenous/P, range 0.023 – 0.22). 
The concentration nicardipine in umbilical cord was correlated with the maternal dosage of 
nicardipine at delivery (arterial: rs=0.857 (p=0.007), venous: rs=0.800 (p=0.005)). The highest 
umbilical cord concentration, found after a maternal dosage of 4.5 mg/h was 18 ng/ml, which 
can be considered as subtherapeutic. Therefore foetal adverse reactions caused by a direct 
pharmacological eﬀect of nicardipine are unlikely to occur.
Nicardipine levels were determined in 34 breast milk samples of seven patients and were 
found to be undetectable in 82% of the samples. In six breast milk samples of four diﬀerent 
patients, nicardipine levels (ranging from 5.1 to 18.5 ng/ml) were detectable during maternal 
nicardipine dosages ranging from 1 to 6.5 mg/h. The maximum possible exposition of a 
neonate to nicardipine was calculated to be less than 300 ng/day, which is an insigniﬁcant 
fraction of the therapeutic dosages used in neonates. 
In conclusion, the exposition of the foetus and neonate to nicardipine through transpla-
cental transfer and disposition in breast milk expression is low. 
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INTRODUCTION
The main goal of treatment of severe pre-eclampsia is to lower the elevated blood pressure 
to prevent complications to the mother and, in early onset pre-eclampsia, to prolong the 
pregnancy to improve the outcome of the foetus. The ideal antihypertensive drug for 
the treatment of severe hypertension in pre-eclampsia should be potent, rapidly acting 
controllable and with a limited placental transfer. Unfortunately, as yet no such drugs are 
available. 
Intravenous administration of the calcium-channel blocking agent nicardipine has 
eﬀectively been used as temporising management in pre-eclamptic patients 1. The drug has 
shown a high potency in lowering maternal blood pressure, while its fast onset of action and 
its short elimination half-life (2-5 min) enables accurate blood pressure control. The use of 
calcium-channel blocking agents with a dihydropyridine structure, such as nifedipine and 
nicardipine, has for a long time been considered hazardous in pregnant women because 
of studies showing foetal acidemic responses in pregnant rhesus monkey and sheep 2,3. 
However, extensive experiences with nifedipine as a tocolytical drug in pregnant women 
have not revealed any negative eﬀects on the uteroplacental circulation 3. Foetal and 
neonatal outcome data after maternal use of nicardipine are more scarce, but outcomes 
seem comparable with those of neonates from pre-eclamptic patients, treated with other 
antihypertensive drugs 1. 
Still, maternal use of nicardipine may expose the foetus to pharmacologically active 
concentrations of the drug by transplacental transfer, whereas postnatally the neonate may 
be exposed to nicardipine during lactation. Because data regarding transplacental transfer 
and transfer into breast milk are lacking, we determined the transplacental transfer of 
nicardipine and disposition of nicardipine in breast milk.
METHODS
Patients with severe pre-eclampsia were treated at the Obstetric High Care unit at our 
antenatal ward with intravenous nicardipine in 2004 - 2005 as second-line treatment, 
after failure of treatment with intravenous ketanserin or dihydralazin (in combination 
with methyldopa orally). Severe pre-eclampsia was deﬁned as the occurrence after 20 
weeks of gestation, of a diastolic blood pressure ≥ 110 mmHg and proteinuria ≥ 0.3 g/l in 
a 24 hours urine collection, or the occurrence of repetitive diastolic blood pressure > 90 
mmHg in combination with the HELLP-syndrome. HELLP-syndrome was deﬁned as ALAT 
and/or ASAT > 31 U/l, platelet count below 100 x 109 platelets/L and haptoglobin below 
0.28 g/l. At admission, diastolic blood pressure was measured at Korotkoﬀ phase V with a 
mercury sphygmomanometer. During admission patients received a radial arterial line for 
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intra-arterial blood pressure. Target diastolic arterial blood pressure (DAP) with nicardipine 
treatment was < 100 mmHg (< 90 mmHg for patients with HELLP-syndrome) measured intra-
arterially. Treatment with nicardipine started with continuous intravenous infusion of 3 mg/h 
and as soon as target DAP was reached, the dosage was reduced. Nicardipine dosages were 
subsequently titrated according to the blood pressure with increments of 0.5 - 1 mg/h to 
a maximum of 10 mg/h. Nicardipine treatment was continued as long as the foetal and/or 
maternal condition did not warrant delivery, as judged by the attending obstetrician. The 
study protocol was reviewed and approved by the Institutional Review Board of the Erasmus 
MC and all patients gave informed consent.
Placental transfer and transfer into breast milk
To determine the placental transfer, a maternal blood sample was drawn just before delivery, 
and umbilical cord blood samples, both arterial and venous, were drawn just after delivery. 
Both arterial and venous concentration levels were studied to obtain information with respect 
to foetal metabolism of nicardipine.
To determine exposure during lactation, breast milk was collected from patients until 24 
hours after stopping of the administration of nicardipine after delivery. After each breast milk 
collection, a maternal blood sample was drawn.
Nicardipine levels in plasma and breast milk samples were determined using a validated 
reversed-phase high performance liquid chromatographic assay with UV detection, 
developed at our hospital pharmacy. The lower limit of quantiﬁcation (LOQ) of nicardipine 
in plasma and in breast milk was 1.4 ng/ml and 5.0 ng/ml respectively. The interday variation 
(reproducibility) for the concentrations 10 ng/ml, 50 ng/ml and 100 ng/ml for plasma were 
4.6%, 2.1%, 3.9% respectively, and for breast milk 6.5%, 4.8% and 4.2% respectively. Plasma 
samples and breast milk samples were stored at -18 ºC until analysis.
Data analysis
The concentration ratios of nicardipine in umbilical cord plasma (both arterial and venous 
(Ua,v)) versus maternal plasma (P) were used as a measure of transplacental transfer. The 
concentration ratios of nicardipine in breast milk (M) versus the maternal plasma (P) were 
used as a measure of transfer to breast milk (M/P). Multiplying the volume of every breast 
milk portion with the concentration of the corresponding sample and subsequently totalling 
the absolute amounts of nicardipine for each day, calculated the daily exposure of a neonate 
to nicardipine during lactation. 
The diﬀerences between arterial umbilical cord concentrations and venous umbilical cord 
concentrations were tested, using the Wilcoxon signed rank test (p-level ≤ 0.05). Correlations 
between transplacental transfer and maternal dosage at delivery and total cumulative dosage 
respectively, were tested using the Spearman’s rank correlation test (p-level ≤ 0.05). 
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RESULTS
Placental transfer
Ten patients were included. The patient characteristics are summarised in Table 9.1. Nicardipine 
dosage at time of delivery ranged from 1 to 7 mg/h. Cumulative dosage until delivery ranged 
from 4.5 – 450 mg. Median duration of treatment with nicardipine until delivery was 55 hours 
(range, 1.5-100 hours) and the maximal dosage during treatment varied from 1 to 9 mg/h. 
Eight patients had the same dosage nicardipine during 6 hours before delivery. One patient 
started with nicardipine 3 mg/h 4 hours before delivery and after two hours the dosage was 
lowered to 1.5 mg/h until delivery. Considering the fact that a steady state will have been 
reached by time of delivery, given the short elimination half-life of nicardipine, this patient 
was included in the analysis. One patient started with nicardipine 3 mg/h 1.5 hours before 
delivery and stopped nicardipine just before delivery. Maternal plasma concentrations 
dropped quickly, while the nicardipine concentration in the fetal compartment was still high, 
resulting in a high U/P ratio of 0.5. The plasma concentrations of this patient did not reﬂect 
a steady-state situation and this patient was excluded in further analysis. For one patient 
arterial and venous umbilical cord blood was accidentally pooled and for one patient only 
venous umbilical cord blood was drawn. 
Table 9.1 Maternal and neonatal characteristics. Values are expressed as n (%) or mean (range)
Maternal characteristics (n=10)
Maternal age (years)
Gestational age at admission (weeks)
Gestational age at start nicardipine (weeks)
Nulliparity (n)
Systolic bloodpressure at admission (mmHg)
Diastolic bloodpressure at admission (mmHg)
HELLP at admission (n)
Caesarian deliveries
Vaginal deliveries
Indication for delivery
- Foetal distress (n)
- Maternal distress (n)
28 (17-36)
28 3/7 (25 5/7 – 32 4/7)
28 4/7 (26 3/7 – 31 4/7)
5 (50%)
190 (160 – 220)*
115 (100 – 130)*
2 (20%)
9 (90%)
1 (10%)
6 (60%)
4 (40%)
Neonatal outcome (n=10)
Perinatal deaths
pH umbilical cord
Apgar < 7 at 5 min (n)
Birthweight (g)
Admission
- intensive care unit 
- medium care
ICU stay (days)
0 (0%)
7,29 (7,08 – 7,42)
0 (0%) 
980 (630 – 1660)
9 (90) 
1 (10)
16 (4-56)
*Measured with cuff
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Nicardipine could be detected in all maternal and umbilical cord blood samples. Maternal 
nicardipine concentration levels ranged from 9.8 to 116 ng/ml. In one umbilical cord sample 
nicardipine concentration was below the limit of quantiﬁcation (LOQ), for further calculation 
we assumed the concentration being 1.4 ng/nl (LOQ). Venous umbilical cord nicardipine 
concentrations ranged from 1.4 to 18.6 ng/ml and arterial umbilical cord nicardipine 
concentrations ranged from 1.4 to 15.7 ng/ml. 
The calculated median transplacental transfer was 0.15 (Uarterial/P, range 0.05-0.22), and 0.17 
(Uvenous/P, range 0.023 – 0.22). No diﬀerences could be detected between arterial and venous 
umbilical cord concentrations (p = 0.15).
A signiﬁcant correlation could be demonstrated between maternal dosage at delivery and 
arterial and venous umbilical blood concentrations (rs=0.857 (p=0.007) and rs=0.800 (p=0.005, 
Figure 9.1). No correlation was found between total cumulative dosage until delivery and 
Uarterial /P (rs=0.429 (p=0.169) and Uvenous/P (rs=0.350 (p=0.178). 
Transfer in breast milk
34 breast milk samples were obtained of seven patients, using nicardipine after delivery. 
Median gestational age at delivery was 286 weeks (261 – 33). After delivery intravenous 
nicardipine was continued for a median of 1.9 days (range 0.8 - 4.6 days). The maximum 
dosage of intravenous nicardipine during lactation was 6.5 mg/h. 
In 82% of the breast milk samples, no nicardipine could be detected and therefore 
the median M/P ratio could not be determined. In 6 breast milk samples of four diﬀerent 
patients nicardipine levels (ranging from 5.1 to 18.5 ng/ml) were detectable during maternal 
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Figure 9.1. Maternal nicardipine dosage at delivery versus umbilical cord nicardipine 
concentration, both arterial and venous. The correlation between maternal nicardipine dosage and 
umbilical cord concentration and arterial and venous umbilical blood concentration was found to be rs=0.857 
(p=0.007) and rs=0.800 (p=0.005) respectively.
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nicardipine dosages, ranging from 1 to 6.5 mg/h. Because of the limited data, no analysis 
could be performed to investigate the inﬂuence of maternal drug dosage and breast milk 
concentrations.
The highest concentration of nicardipine determined in breast milk was 18.5 ng/ml, 
during maternal nicardipine use of 5.5 mg/h intravenously. The maximum possible 
exposition of a neonate to nicardipine during lactation was calculated to be below 300 ng/
day. In comparison, intravenous dosages of nicardipine used for treating preterm neonates 
with hypertension are 0.72 - 2.9 mg/kg/day 4, which correspond to an oral dosage of 2 
mg - 8.3 mg/kg/day, assuming an oral bio-availability of 35% 5. The possible exposure of 
300 ng/day in breast milk corresponds therefore to 0.015% to 0.004% of a therapeutically 
dosage of nicardipine in a one-kg neonate.
DISCUSSION
While using drugs in pregnant women, data with respect to placental transfer are essential to 
assess the risk on adverse eﬀects on foetus and neonate. In this study transplacental transfer 
and disposition in breast milk of nicardipine was assessed after maternal nicardipine use for 
antihypertensive treatment of pre-eclampsia. 
Our study shows that transplacental transfer of nicardipine is low, resulting in subtherapeutic 
concentrations in umbilical cord blood. Carbonne et al 6 have described the use of nicardipine 
in pre-eclamptic patients. From their data on maternal and foetal plasma concentrations in 
two patients, the transplacental transfer can be calculated (0.17 and 0.11, respectively), which 
is comparable with our results.
Studying placental transfer of drugs by comparing umbilical cord blood concentration with 
maternal blood concentration is a well established approach 7. A limitation of this method is 
that only a single set of data is available for each patient, but the results do yield important 
information regarding in vivo transfer and elimination of a drug to and from the foetus.
Passive diﬀusion is the main mechanism of transplacental transfer of drugs. We found 
that higher maternal dosages of nicardipine at delivery result in higher concentrations of 
nicardipine in the umbilical artery. This may agree with a placental transfer of nicardipine 
by diﬀusion, which is characterised by a transfer, proportional to the concentration gradient 
between maternal and foetal plasma. Key factors in this mechanism are the physiochemical 
properties of the drug such as protein binding, pKa, molecular weight and lipophilicity 8. 
Because only the unbound fraction of nicardipine is available for placental transfer, the 
high protein-binding (98%) 9 of nicardipine is probably one of the main causes for the low 
transplacental transfer. Additionally, being a weak base with a pKa of 7.2, the main part 
of nicardipine is protonized at the physiological maternal pH, reducing its availability for 
placental transfer. 
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Another explanation for the low placental transfer of nicardipine might be that metabolism 
in the placenta occurs before the drug reaches the foetus. Nicardipine is thought to be a 
substrate to P-glycoprotein 10 and placental P-glycoprotein is known to provide a mechanism 
of inhibiting placental transfer of xenobiotics that are substrates for his eﬄux pump. This may 
have contributed to the low nicardipine levels in the umbilical cord.
The low transplacental transfer of nicardipine is in contrast with that of other 
antihypertensive drugs used in pre-eclampsia such as hydralazin, nifedipine, methyldopa 
and labetalol which are known to pass the placenta extensively 11,12. This can be considered 
an important advantage for the use of nicardipine during pregnancy.
We found no correlation between total cumulative dosage until delivery and transplacental 
transfer, suggesting that nicardipine does not cumulate in the foetus. Accumulation in the 
foetus may be caused by ion- trapping of nicardipine following a higher proportion of ionized 
drug in the more acidic foetal circulation as compared to the maternal circulation, but our 
results do not support this. 
No diﬀerence between arterial and venous umbilical cord concentrations was found. This 
may be related to the relatively immature foetal hepatic metabolising capacity.
The highest umbilical cord nicardipine level, detected in our patients, was 18 ng/ml. For 
adults nicardipine levels of 70-100 ng/ml are considered therapeutic 13. Holbrook et al 14 
investigated direct nicardipine infusion in foetuses of ewes, which resulted in mean foetal 
plasma concentrations of respectively 78 ng/ml and 114 ng/ml. No signiﬁcant changes of 
foetal heart rate, foetal arterial blood gas values were observed at these concentration levels. 
Although animal data cannot be directly extrapolated, our nicardipine concentrations found 
in human umbilical cord blood indicate a low risk for a direct pharmacological eﬀect on the 
human foetus.
Our data showing absence of nicardipine into the majority of breast feeding samples 
indicate a low transfer in breast milk. Prediction of transfer to breast milk based on 
physicochemical properties is known to be unreliable 15, still, a relatively low transfer 
was expected because of the high protein binding of nicardipine. Nifedipine, structurally 
similar to nicardipine also has a low transfer in breast milk 16. The limited transfer into milk 
in combination with an oral bioavailability of 35% of nicardipine, indicate that exposure of 
the neonate to nicardipine during lactation will be low. 
In conclusion, our results showing limited transplacental transfer and low disposition in 
breast milk support the use of nicardipine as antihypertensive drug in pre-eclampsia.
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INTRODUCTION
Pre-eclampsia is a disease, exclusively occurring in pregnant women and characterised by 
the occurrence after the 20th week of gestation of maternal elevated blood pressure and 
proteinuria. Serious maternal complications can occur, such as HELLP-syndrome (haemolysis, 
elevated liver enzymes, low platelet counts), pulmonary oedema, liver failure or haemorrhage, 
abruptio placentae, eclampsia and even cerebral haemorrhage and maternal death. The 
associated placental dysfunction may result in intrauterine growth restriction and iatrogenic 
preterm delivery of small for gestational age babies and perinatal death 1.
In a tertiary care referral centre for severe early-onset pre-eclamptic patients, like the 
Obstetric and Prenatal Medicine Department of the Erasmus MC, the goal is to stabilise 
the patient using antihypertensive treatment and postpone delivery as long as foetal and 
maternal condition allow, to improve neonatal outcome. To achieve this goal, long-term use 
of often high dosages of antihypertensive drugs is usually necessary, but a delicate balance 
between the optimum treatment for the mother on one hand and the well-being of the 
foetus on the other hand needs to be maintained.
Because of decreasing availability of adequately studied drugs in pre-eclampsia and recent 
controversy surrounding the risks and beneﬁts of the current standard drug (di)hydralazin, 
the need for information on alternative drugs became apparent. To ﬁll this gap, studies on 
several aspects, regarding eﬃcacy and safety of antihypertensive treatment with ketanserin 
and nicardipine in pre-eclampsia, are reported in this thesis.
Ketanserin
Ketanserin is one of the two drugs licensed for treatment of hypertension in pregnancy in 
the Netherlands. In the late nineties, ketanserin became the ﬁrst choice treatment for the 
management of pre-eclampsia in our hospital as well as in many other hospitals in the 
Netherlands. The drug acts by blocking the vasoconstrictive response upon binding of 
serotonin (5-HT) to 5-HT2A receptors in vascular tissue. Pre-eclampsia is characterised by 
endothelial dysfunction and due to the concomitantly loss of 5-HT1 endothelial receptors, free 
serotonin will stimulate mainly 5-HT2A receptors in platelets causing platelet aggregation and 
serotonin release, and 5-HT2A receptors in vascular smooth muscle, causing vasoconstriction. 
Ketanserin acts as an antagonist on the 5-HT2A receptor, counteracting serotonin dependent 
vasoconstriction and platelet aggregation. The latter may especially be important in 
pregnancies complicated with the HELLP-syndrome 2.
Pharmacokinetic aspects
Following our observations that in clinical practice many of our early-onset pre-eclamptic 
patients do not respond or only temporarily respond to ketanserin, we studied the possible 
causes for the limited eﬃcacy of ketanserin.
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Pharmacokinetic problems such as inadequate drug levels at the receptor-site may cause 
eﬃcacy problems. During pregnancy, large physiological changes are known to occur (such 
as increased plasma volume, decreased serum albumin, increased glomerular ﬁltration rate 
and altered hepatic metabolism) which can aﬀect concentrations of drugs in pregnancy 3. In 
pre-eclamptic patients, some of these features are known to diﬀer from normal pregnancies 
(e.g. decreased plasma volume and decreased glomerular ﬁltration) 4. Large intra-individual 
diﬀerences occur in pre-eclamptic patients with respect to bodyweight, amount of oedema, 
blood pressure at presentation, hepatic and renal involvement and occurrence of HELLP-
syndrome, which can be speculated to result in diﬀerences in clearance and volume of 
distribution of drugs. This variety in clinical presentation may necessitate a more individual 
approach in management, as it may be the cause of insuﬃcient eﬃcacy in pre-eclamptic 
patients following a ﬁxed dosage schedule of an antihypertensive drug. 
Our results of therapeutic or even supratherapeutic levels of ketanserin in all our pre-
eclamptic patients and the absence of diﬀerences in pharmacokinetic parameters between 
our pre-eclamptic population and non-pregnant volunteers, indicate that pharmacokinetic 
diﬀerences, however, do not explain the lack of eﬃcacy. The currently used dosage schedule 
apparently yield pharmacologically active blood levels, at which antagonism of the 5-HT2A 
receptor should occur. Furthermore, our data also indicate that increasing the dosage of 
ketanserin in an attempt to improve eﬃcacy will not improve eﬀectiveness but may increase 
the risk of adverse drug eﬀects of ketanserin, the most notorious of which being QT-interval 
prolongation.
Pharmacodynamic aspects
Since our pharmacokinetic analysis did not account for the lack of eﬃcacy, we searched for 
a pharmacodynamic explanation, studying in vitro serotonin receptor functionality in both 
maternal and foetal pre-eclamptic blood vessels in comparison to vessels of normotensive 
pregnant women. We conﬁrmed the presence of both 5-HT2A receptors and 5-HT1B/1D receptors 
in the maternal vessels but we did - on average - not observe diﬀerences in functionality 
between pre-eclamptic women or normotensive women. This does not support the theory of 
a prominent role for 5-HT2A receptors in pre-eclampsia. Our results do suggest an enhanced 
development of foetal 5-HT1B/1D receptors in pre-eclamptic patients at an earlier gestational 
age as compared to normotensive women. It can be speculated that in the future these 
observed diﬀerences can be used to study the role of selective 5-HT1B/1D receptors antagonists 
in improving the haemodynamics in umbilical artery vasculature in pre-eclamptic patients. 
Given the fact that the impaired uteroplacental perfusion in pre-eclamptic patients adversely 
aﬀect foetal development, improvement of the umbilico-placental circulation with the use 
of selective 5-HT1B/1D receptors antagonists, may provide an additional potential for foetal 
growth and development.
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Polymorphism
Another possibility to explain diﬀerences in drug-responses may be polymorphisms in the 5-
HT2A receptor. However, although 5-HT2A receptor polymorphisms have been identiﬁed 
5, these 
polymorphisms are silent and their functional signiﬁcance remain obscure. Polymorphisms 
with respect to the metabolic pathway for ketanserin are not described in literature to 
our knowledge and our own ﬁndings of therapeutic plasma levels of ketanserin in all pre-
eclamptic patients do not support the theory of a relevant contribution of a genetically 
altered metabolism of ketanserin in clinical practice.
Therefore, we did not further explore the possible involvement of polymorphisms in 
explaining diﬀerences in response after ketanserin administration.
Therapeutic studies in pregnant women
The lack of eﬃcacy of ketanserin in the treatment of pre-eclampsia, stimulated the search for 
alternative drugs. However, pharmacotherapeutic research in pregnant women is diﬃcult, 
because not only eﬀects on the mother have to be taken into account but also eﬀects on the 
foetus as well as the neonate. In the latter, both peri- and postnatal eﬀects as well as long 
term eﬀects on growth and development should be studied when analysing the safety of 
maternal drug use. Pharmacotherapeutic research in pre-eclamptic patients is even more 
diﬃcult as the need for urgent treatment may yield several practical and ethical problems 
in adhering to a strict study protocol. The large diﬀerences in severity of the disease and 
variations in gestational age at presentation can cause methodological problems and will 
inﬂuence clinical decision-making. Finally, the limited placental reserve in most severe pre-
eclamptic patients, the presence of a usually growth retarded foetus and the delivery of an 
often premature neonate who may be more susceptible to adverse drug eﬀects, are factors 
that contribute to the wariness of obstetricians in testing new strategies. 
For these reasons, we started our search into alternative antihypertensive drugs in patients 
with failure on ﬁrst-line treatment, whose only remaining treatment option would have been 
delivery.
Nicardipine
Although information regarding the use of nicardipine in pre-eclampsia is limited, we 
selected this calcium-channel blocking agent because its analogue nifedipine has been used 
widely in pregnant women both as tocolytical drug and as oral antihypertensive drug, with 
satisfying outcome 6,7. For use in pre-eclampsia, nicardipine, as compared to nifedipine, has 
the advantages of a more controllable eﬀect, the availability of a parenteral formulation and 
less myocardial side-eﬀects. A disadvantage can be considered the need for intravenous 
administration by a central venous line because of the risk on phlebitis.
Our results showing a high eﬃcacy of nicardipine in heavily pre-treated patients, indicate 
that nicardipine seems to be a promising drug for treatment of pre-eclampsia. However, 
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some aspects still needs to be addressed. The current dosage schedule needs to be further 
evaluated by PK/PD studies and optimised to prevent the unwanted periods of maternal 
hypotension, which may lead to foetal distress. The role of plasma volume expansion in 
combination with use of nicardipine needs to be studied.
After establishing the optimal dosage schedule, its eﬃcacy and safety needs to be conﬁrmed 
as ﬁrst-line treatment in a randomised controlled study. To obtain an adequately powered 
study and to allow for inclusion of women at diﬀerent gestational ages, a collaboration of 
diﬀerent hospitals at both secondary and tertiary care, will be necessary. Outcome of such a 
study should include foetal and neonatal safety, both short as long term. The selection of the 
comparison drug will however be diﬃcult. The golden standard drug (di)hydralazin will not 
be available anymore on a regular basis in the Netherlands as well as in most of Europe. Our 
own results, described in this thesis, indicate that ketanserin is not eﬀective in a substantial 
part of our patients. Probably the best comparison drug for studies evaluating nicardipine 
will be parenteral labetalol, but high dosages should be avoided because of case-reports of 
neonatal bradycardia, hypotension and hypoglycaemia.
Combination of antihypertensive drugs
Since pre-eclampsia is a progressive disease, increased antihypertensive treatment may be 
necessary to maintain adequate blood pressure control during treatment. Combinations of 
antihypertensive drugs may be more eﬀective and safe than increasing the dosage of one 
drug only. When combining antihypertensive drugs, the diﬀerent mechanisms of action and 
diﬀerent side eﬀects of the drugs can be advantageous, e.g. the opposite eﬀects on heart 
rate of methyldopa in combination with nicardipine. However, in selecting consecutive 
treatment strategies, attention should be paid to avoid synergistically occurring side eﬀects 
and to prevent unwanted hypotensive periods following cumulative blood pressure lowering 
eﬀects.
Foetal and neonatal safety
Vasoactive eﬀects on the umbilico-placental circulation after maternal antihypertensive drug 
use, can inﬂuence foetal safety, in relation to the maternal haemodynamic changes. Studies 
using ex vivo placental perfusion may be helpful in determining eﬀects of these drugs on the 
foetoplacental vascular bed.
On the other hand, speciﬁc pharmacological eﬀects of the drug can also occur because 
of placental drug transfer. Management of pre-eclampsia with parenteral antihypertensive 
drugs is usually limited to 2 - 3 weeks prior to delivery, albeit in high dosages. Following 
case-reports of neonatal bradycardia, hypotension and hypoglycaemia after maternal 
use of labetalol, it became recognised that transplacental transmission can occur after 
antihypertensive treatment of pre-eclampsia, resulting in adverse neonatal eﬀects. In this 
thesis, we studied transplacental transmission of ketanserin and nicardipine, showing a 
134
C
ha
pt
er
 1
0
high transplacental transmission of ketanserin with subsequent high neonatal blood levels, 
whereas a relative low transmission of nicardipine was found. 
Furthermore, our results of an intermediate milk/plasma ratio for ketanserin as opposed 
to a low milk/plasma ratio for nicardipine in breastmilk suggest that for prolonged (oral) 
antihypertensive treatment in lactating women after delivery, nicardipine is preferred to 
ketanserin.
The level of placental transmission, determined by the umbilical cord-maternal blood ratio 
at delivery, is useful to indicate the level of foetal exposure. However, the ultimate goal is to 
establish whether adverse eﬀects in the neonate occur because of maternal drug use. Since 
serotonin receptors are known to develop extensively early in pregnancy in the foetal brain, 
a possible inﬂuence on the functionality of foetal serotonin receptors by maternal ketanserin 
treatment is theoretically possible and may even have long term consequences for the 
child. Fortunately, our ex vivo data studying foetal 5-HT receptor functionality after maternal 
ketanserin use could not conﬁrm such an inﬂuence.
For nicardipine, the lack of adverse eﬀects on neonatal well-being after maternal drug 
use during pregnancy, still needs to be conﬁrmed in larger comparative studies, preferably 
including a long term follow-up of the neonates. The current policy in our hospital of a regular 
follow-up of the neonates into their childhood, after discharge from our neonatal intensive 
care unit, will contribute to the analysis of the safety of nicardipine.
Future perspectives
In the future, with the unravelling of the pathogenesis of pre-eclampsia, pharmacological 
interventions to prevent pre-eclampsia or to treat the disorder more speciﬁcally, instead 
of ameliorating only the symptoms, may become feasible. During several decades, the 
pathophysiology of pre-eclampsia has been extensively studied. The recent discovery of 
the involvement of an imbalance among the pro- and antiangiogenic factors in the failure 
of placental vasculogenesis could be of signiﬁcance 8. The antiangiogenic protein sFlt1 
(soluble fms-like tyrosine kinase) was found to be up-regulated in the placenta of women 
in conjunction with decreased VEGF (vascular endothelial growth factor) and decreased 
PIGF (placental growth factor). These alterations in angiogenic balance are hypothesized 
to contribute to placental ischemia and maternal endothelial dysfunction in pre-eclampsia. 
If the levels of these proteins are found to be speciﬁc predictors of pre-eclampsia early in 
pregnancy, interventions can be undertaken before extensive vascular dysfunction and 
severe maternal complications occur or before severe intra-uterine growth retardation due 
to placental dysfunction has occurred. Indeed, if sFlt-1 is conﬁrmed to be a causal factor in 
the pathophysiology of pre-clampsia, pharmacological agents counteracting the eﬀect of 
sFlt-1, can be of clinical importance in treatment of pre-eclampsia. 
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At this time, supportive treatment using antihypertensive drugs is the only available treatment 
option for pre-eclampsia (except for delivery). Use of antihypertensive drugs should be 
targeted at the safe treatment of the mother while at the same time improving perinatal 
outcome. To avoid the current situation that well studied drugs are not available anymore 
and drugs that have not been adequately studied have to be used in this population of high-
risk patients, pharmacological research into antihypertensive treatment of pre-eclampsia is 
needed. 
This thesis has focused on the eﬃcacy and safety of two new antihypertensive drugs, the 
serotonin antagonist ketanserin and the calcium-channel blocking agent nicardipine. Our 
data show that administration of ketanserin results in insuﬃcient antihypertensive response 
in many severe pre-eclamptic patients and that increasing the dosage will not solve this 
problem. Nicardipine appears to be a potent alternative drug with the advantage of a low 
placental transfer and it may become a standard treatment modality in pre-eclampsia.
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Pre-eclampsia occurs in 2 – 7% of the pregnancies and the disorder still forms the leading 
cause of maternal and neonatal mortality and morbidity in pregnancy in the Netherlands. 
Pre-eclampsia is characterised by the occurrence of elevated blood pressure and proteinuria 
after the 20th week of pregnancy, which may lead to serious maternal complications, such 
as HELLP-syndrome (haemolysis, elevated liver enzymes, low platelet counts), abruptio 
placentae and eclampsia. Increased perinatal morbidity and mortality may occur, following 
intra-uterine growth restriction, reduced amniotic ﬂuid and abnormal oxygenation. The 
pathogenesis remains unknown but most hypothesis focus on vascular dysfunction and 
maternal-foetal (paternal) immune maladaptation. 
The high maternal blood pressure in severe pre-eclampsia poses a serious risk of 
acute cerebrovascular complications in these women, necessitating the use of potent 
antihypertensive treatment in pre-eclampsia. However, the availability of parenteral 
antihypertensive drugs for use in pre-eclampsia has decreased in the past years. Also, 
a controversy has risen surrounding the risks and beneﬁts of the current standard drug 
(di)hydralazin. 
In this thesis, the eﬃcacy and safety in pre-eclampsia of two new antihypertensive drugs, 
the 5-HT2A antagonist ketanserin and the calcium-channel blocking agent nicardipine, are 
studied.
In CHAPTER 1 the diﬀerent antihypertensive drugs, used in the management of pre-
eclampsia, are reviewed with a focus on eﬃcacy and maternal and neonatal safety. The 
characteristics of each drug are summarized, including placental transfer. Comparisons 
between antihypertensive drugs are described, based on recent publications. 
The 5-HT2A receptor antagonist the drug ketanserin is one of the two drugs licensed in the 
Netherlands for use in pre-eclampsia and has been used as ﬁrst-line parenteral treatment in 
many Dutch hospitals. The drug acts by blocking the vasoconstrictive response upon binding 
of serotonin (5-HT) to 5-HT2A receptors in vascular tissue. Its use is based upon the concept 
that pre-eclampsia is characterised by endothelial dysfunction. Due to the concomitantly 
loss of 5-HT1 endothelial receptors, free serotonin will stimulate mainly 5-HT2A receptors in 
platelets causing platelet aggregation and serotonin release, and 5-HT2A receptors in vascular 
smooth muscle, causing vasoconstriction, which contributes to the elevated blood pressure. 
Because of ambiguous reports on the eﬃcacy of ketanserin in pre-eclampsia, we analysed 
in CHAPTER 2 retrospectively the eﬃcacy of intravenous ketanserin in controlling blood 
pressure of a population of severe early-onset pre-eclamptic patients. Pre-eclamptic patients 
(n = 47) with a gestational age between 21 and 32 weeks were treated with intravenous 
ketanserin at a maximum dosage of 14 mg/h, to obtain an intra-arterial diastolic blood 
pressure of 90 mmHg or below. We found that, even using the maximum intravenous dosage 
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of ketanserin, target blood pressure was not achieved in 15 (32%) patients. A high systolic 
blood pressure at the start of treatment was associated with failure of ketanserin treatment. 
The median period of ketanserin treatment in the responding group was three days (range 
1 - 10 days). In 26 (55%) of initially successfully treated patients, additional antihypertensive 
drugs were necessary to maintain blood pressure control. 
It was concluded that administration of intravenous ketanserin does not result in an 
adequate antihypertensive response in a substantial proportion of severe pre-eclamptic 
patients, despite high dosages. These results lead us to investigate in further detail the 
insuﬃcient response on ketanserin.
To perform a pharmacokinetic analysis, a sensitive and selective high-performance liquid 
chromatographic assay with solid-phase extraction and ﬂuorimetric detection was developed 
and validated for the quantiﬁcation of ketanserin and its metabolite ketanserinol in human 
plasma, as described in CHAPTER 3. Calibration curves were linear in the range of 0 – 400 
ng/ml for both ketanserin and ketanserinol and the lower limit of quantiﬁcation for both 
ketanserin and ketanserinol was 2.0 ng/ml. The small sample size required in this assay made 
the method useful for determination of drug concentrations in neonates. 
As described in CHAPTER 4, plasma concentrations of ketanserin were determined in 51 pre-
eclamptic patients. Population pharmacokinetic parameters were assessed, using the iterative 
two-stage Bayesian population procedure. The inﬂuence of individual pharmacokinetic 
parameters on antihypertensive response, expressed as the attainment of a diastolic blood 
pressure ≤ 90 mmHg using ketanserin treatment, was analyzed. 
Almost all plasma concentrations of ketanserin were found to be in or even above the 
therapeutic range, indicating that the current dosage schedule results in pharmacologically 
active plasma concentrations. The individual pharmacokinetics of ketanserin in pre-eclamptic 
patients showed an accurate ﬁt, applying a three-compartment model. A metabolic clearance 
(Clm) of 37.9 ± 10.86 L/h and a volume of distribution (V1) of 0.544 ± 0.188 L/kg were found in 
the pre-eclamptic patients, which is comparable with historical data from healthy volunteers. 
Despite a considerable interindividual variation, no correlation was found between diﬀerences 
in Clm or V1 and antihypertensive response, indicating that variation in the pharmacokinetic 
parameters does not explain the lack of response in pre-eclamptic patients.
Subsequently, the role of pharmacodynamics was studied in the search for an explanation for 
the limited eﬃcacy of ketanserin. 
In CHAPTER 5, we describe the comparison of the functional reactivity of 5-HT receptors 
in foetal and maternal blood vessels in pre-eclamptic pregnancies and normotensive 
pregnancies. Foetal umbilical cord arteries were used as representative of foetal blood 
vessels, and subcutaneous fat arteries were used as representative of maternal resistance 
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arteries. Segments of arteries were mounted in tissue baths and isometric force changes 
were determined after exposure to 5-HT and the 5-HT1B/1D receptor agonist, sumatriptan. 
Concentration-response curves to 5-HT and sumatriptan were constructed in the absence 
and presence of ketanserin or GR125743 (5-HT1B/1D receptor antagonist). We found that 
both 5-HT and sumatriptan contracted all segments studied, conﬁrming that 5-HT1B/1D and 
5-HT2A receptors mediate vasoconstriction in these arteries. The responses to 5-HT and 
the potency of ketanserin in umbilical cord arteries were not diﬀerent between the study 
groups, indicating similar characteristics of the foetal 5-HT2A receptor in pre-eclampsia and 
normotensive pregnancies. In contrast, the potencies of both sumatriptan and GR125743 
in umbilical cord arteries were positively correlated to gestational age in the normotensive 
group, while this relationship was absent in the pre-eclamptic group. We concluded that the 
sensitivity of foetal 5-HT1B/1D receptors increases in the last trimester in normal pregnancies, 
which seems to be expedited in pre-eclamptic patients. 
In maternal resistance arteries, responses to 5-HT and sumatriptan were not diﬀerent 
between the pre-eclamptics patients and normotensive controls. These ﬁndings do not 
support the theory of a prominent role for 5-HT2A receptors in pre-eclampsia and may explain 
the disappointing eﬃcacy of a 5-HT2A receptor blocking agent, such as ketanserin.
Foetal and neonatal safety are important issues to address when evaluating maternal drug 
use during pregnancy. For ketanserin, no apparent clinical adverse eﬀects were seen in 
neonates after maternal drug use, but detailed information regarding transplacental transfer 
and transmission in breast milk was not available.
In CHAPTER 6, a prospective, observational study is described, assessing transplacental 
transfer of ketanserin, transfer into breast milk and disposition in the neonate after 
maternal ketanserin use. In 22 pregnant women with severe pre-eclampsia, the ratio of drug 
concentrations in the umbilical cord to drug concentrations in maternal blood just before 
delivery was used as a indicator of placental transfer. Disposition of ketanserin was determined 
using neonatal plasma concentrations of ketanserin in eight neonates after birth. 
A high placental transfer was found in the pre-eclamptic women (median transfer 0.95, 
range 0.612-1.24) for ketanserin and for its metabolite, ketanserinol (median transfer 0.60, 
range 0.5-0.77). Pharmacologically active concentrations of ketanserin were found in the 
neonate after delivery. The elimination half-life of ketanserin in the neonate varied between 
12.7 and 43.7 h (median 19.3 h) and of ketanserinol between 13.8 and 34.4 h (median 18.7 
h). Despite the high placental transfer and the substantial disposition in the neonate, no 
apparent short-term adverse eﬀects in the neonates were detected. 
A median breast milk/ plasma ratio for ketanserin of 0.4 (range, 0.2 – 1.27) and 0.76 
(range, 0.42 – 1.44) for ketanserinol, was found after analysing breast milk samples and 
corresponding maternal plasma concentrations of seven lactating women during use of 
Summary and conclusions 141
intravenous ketanserin. This indicates that the neonate may be exposed to pharmacological 
concentrations of ketanserin and ketanserinol during lactation.
Given the abundant presence of 5-HT receptors in the foetus, including the foetal brain, 
more safety data on the inﬂuence of the exposure to ketanserin on foetal 5-HT receptors 
after maternal use, were needed. Functional studies were performed on 5-HT2A and 5-HT1B/1D 
receptors in umbilical cord artery from pre-eclamptic patients treated with ketanserin 
(CHAPTER 7). Umbilical cord arteries were obtained immediately after delivery from pre-
eclamptic patients (n=7, gestational age 28 weeks, range 254 – 363 weeks), treated antenatally 
with intravenous ketanserin. Pre-eclamptic patients (n=13, GA 294 weeks, range 244 – 366 
weeks), not treated with ketanserin, were included as a control group. Segments of umbilical 
cord arteries were mounted in tissue baths and isometric force changes were measured. 
Cumulative concentration-response curves to 5-HT and to the 5-HT1B/1D receptor agonist, 
sumatriptan, were constructed in the absence or presence of the 5-HT2A receptor antagonist 
ketanserin or the 5-HT1B/1D receptor antagonist GR125743, respectively. 
All segments showed contractile response to both 5-HT and sumatriptan, and the 
concentration-response curves showed a rightward shift with increasing concentrations of 
ketanserin and GR125743, respectively, indicating the presence of functional 5-HT2A and 
5-HT1B/1D receptors in the foetal tissue. No signiﬁcant diﬀerences were found in maximum 
response or potency of 5-HT in both groups and no signiﬁcant diﬀerences were found in 
the potency of the antagonist ketanserin in both study groups (pKb 7.58 ± 0.37 in ketanserin 
treated group and 7.46 ± 0.17 in the control group, respectively). Similarly, with sumatriptan, 
no signiﬁcant diﬀerences were found between ketanserin-treated patients and control 
patients. 
We concluded that foetal exposure to ketanserin in pre-eclamptic patients does not inﬂuence 
the functional characteristics of 5-HT2A and 5-HT1B/1D receptors in the umbilical cord artery.
The insuﬃcient response on ketanserin in the pre-eclamptic patients stimulated the search 
for alternative drugs. 
The calcium-channel blocking agent nicardipine was selected for further study because 
of its controllable antihypertensive eﬀect due to the short half-life, the availability of a 
parenteral formulation and the advantage of less myocardial side-eﬀects compared to its 
analogue nifedipine, which is used as tocolytical drug and as oral antihypertensive drug in 
pre-eclampsia.
Because data on eﬃcacy and safety of nicardipine in pre-eclampsia were scarce, we started 
to evaluate prospectively the eﬃcacy of intravenous administration of nicardipine as a 
second-line temporizing treatment in severe, early-onset, pre-eclamptic patients (CHAPTER 
8). Nicardipine was administered to 27 early-onset, pre-eclamptic patients with a median 
gestational age of 27 weeks (range 21 – 32 weeks) with treatment failure on standard 
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intravenous antihypertensive drugs (ketanserin, dihydralazin or labetalol). Nicardipine 
infusion was initiated at a dosage of 3 mg/h and was titrated according to blood pressure. 
Treatment was continued for as long as the maternal and foetal conditions allowed. In all 
patients the target diastolic intra-arterial blood pressure (<100 mmHg or <90 mmHg in 
HELLP-syndrome patients), registered by continuous arterial blood pressure measurements, 
was obtained within a median of 23 min (range, 5 – 60 min). Delivery was postponed for a 
median of 4.7 days (range, 1 – 26 days) using nicardipine treatment, at a maximum dosage 
ranging from 3 to 9 mg/h. In 30% of the patients, unwanted hypotensive periods (< 70 mmHg) 
were registered during treatment, manageable with dosage adaptation. Foetal well-being 
did not seem adversely aﬀected. 
This evaluation showed that nicardipine is a potent antihypertensive drug, even in severe, 
early-onset pre-eclampsia when other antihypertensive drugs have failed. The dosage-
schedule needs to be optimized to prevent maternal hypotension.
The safety of nicardipine in pre-eclampsia was further analyzed by studying the transplacental 
transfer and disposition in human milk (CHAPTER 9).
In ten pre-eclamptic patients, nicardipine concentrations of maternal blood and both 
arterial and venous umbilical cord blood samples were assessed and the ratio of maternal 
(P) and foetal plasma concentrations (Uarterial and Uvenous) was calculated as an indication of 
transplacental transfer. We found a median transfer of 0.15 (Uarterial/P, range 0.05-0.22), and 
0.17 (Uvenous/P, range 0.023 – 0.22). The concentration nicardipine in umbilical cord correlated 
with the maternal nicardipine dosage at delivery. Umbilical cord concentrations ranged 
between 1.3 and 18 ng/ml, which can be considered as subtherapeutic. 
Nicardipine levels were determined in 34 breast milk samples of seven patients and in 80% 
of the samples, nicardipine was below the lower limit of detection of 5 ng/ml. The maximum 
possible exposition of a neonate to nicardipine was extrapolated to be 300 ng/day, which is 
insigniﬁcant compared to therapeutic dosages used in neonates. 
We concluded that the exposition of a foetus and neonate to nicardipine by transplacental 
transmission and disposition in breast milk is low. 
In CHAPTER 10 our results are discussed and future perspectives are indicated. We 
conclude that administration of ketanserin results in insuﬃcient antihypertensive response 
in a considerable number of severe pre-eclamptic patients and that increasing the dosage 
probably does not solve this problem. 
Nicardipine appears to be a potent alternative drug with the advantage of a low placental 
transfer, as opposed to the extensive placental transfer found for ketanserin. Further 
experience in the use of nicardipine as ﬁrst-line treatment in pre-eclampsia is needed, 
including more data on the optimal dosage schedule and more data on neonatal safety, to 
conﬁrm the promising role of nicardipine in pre-eclampsia.
APPENDICES
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SAMENVATTING
Bij 2 - 8% van de zwangere vrouwen treedt zwangerschapsvergiftiging (pre-eclampsie) op 
tijdens de zwangerschap of het kraambed. De aandoening kenmerkt zich door een plotseling 
sterk stijgende bloeddruk, eiwit in de urine en vochtophoping in enkels, handen en gezicht 
en klachten van hoofdpijn, misselijkheid en slecht kunnen zien. Zwangerschapsvergiftiging 
kan zowel de moeder als het kind in gevaar brengen. Bij de moeder kunnen als gevolg van 
de sterk verhoogde bloeddruk, ernstige complicaties ontstaan, zoals het HELLP-syndroom 
(gekenmerkt door afbraak van rode bloedcellen, verhoogde leverenzymen en een verminderd 
aantal bloedplaatjes), epileptische aanvallen (eclampsie), lever- en nierbeschadiging, 
loslating van de placenta, of een hersenbloeding. Bij het kind kan door een verminderde 
aanvoer van voedingsstoﬀen groeiachterstand optreden en door langdurig zuurstoftekort 
kunnen hersenbeschadigingen, geboorteafwijkingen en zelfs overlijden van het ongeboren 
kind het gevolg zijn. Veelal moeten de kinderen vroegtijdig met een keizersnede ter wereld 
worden gebracht.
Een stoornis in de aanleg van de placenta wordt gezien als de belangrijkste factor in 
het ontstaan van pre-eclampsie. Een goede doorbloeding van de placenta wordt bij een 
ongestoorde zwangerschap gewaarborgd doordat na innesteling van de vrucht in de 
baarmoeder, cellen van het embryo ingroeien in de bekleding van de bloedvaten van de 
moeder. Hierdoor gaan deze bloedvaten van de moeder sterk verslappen en daarmee wijd 
open staan om zodoende voldoende bloed met voedingsstoﬀen en zuurstof door te kunnen 
laten tijdens de zwangerschap. Men veronderstelt dat bij pre-eclampsie deze ingroei van 
cellen van het embryo in de bloedvaten van de moeder niet goed plaatsvindt. De oorzaak van 
pre-eclampsie is niet volledig opgehelderd, maar genetische, immunologische en mogelijk 
ook omgevingsfactoren lijken een rol te spelen.
Tot op heden is de enige manier om pre-eclampsie te verhelpen, het beëindigen van de 
zwangerschap. Echter, wanneer pre-eclampsie vroeg in de zwangerschap optreedt, kan de 
vroeggeboorte van het kind ernstige complicaties voor het kind met zich mee brengen en 
zelfs diens leven bedreigen. Daarom wordt in die gevallen geprobeerd de zwangerschap 
te verlengen door het toedienen van bloeddrukverlagende middelen aan de moeder. Het 
probleem hierbij is dat er slechts zeer weinig bloeddrukverlagende middelen hiervoor 
gebruikt kunnen worden. De beschikbaarheid van het meest toegepaste bloeddrukverlagend 
middel dihydralazine is in Nederland inmiddels sterk afgenomen, zodat onderzoek naar 
alternatieve bloeddrukverlagende middelen noodzakelijk is.
Het onderzoek, beschreven in dit proefschrift, gaat over de eﬀectiviteit en veiligheid 
van twee nieuwe bloeddrukverlagende middelen bij de behandeling van zwangerschaps-
vergiftiging, namelijk de serotonine receptor antagonist ketanserine en de calcium-instroom 
blokker nicardipine. De eigenschappen van beide geneesmiddelen worden hieronder verder 
beschreven.
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In Hoofdstuk 1 worden de verschillende geneesmiddelen die worden toegepast bij 
de behandeling van pre-eclampsie besproken. Hoewel veel onderzoek is gedaan naar 
geneesmiddelen die het ontstaan van pre-eclampsie zouden kunnen voorkómen, is er 
helaas tot nu toe geen doeltreﬀend middel hiervoor gevonden. Wanneer een patiënt wordt 
opgenomen met symptomen van pre-eclampsie, is het toedienen van bloeddrukverlagende 
medicatie de enige behandelingsmogelijkheid, indien uitstel van de bevalling is gewenst 
vanwege het onvoldragen kind. Zowel oraal als intraveneus toegediende bloeddrukver-
lagende geneesmiddelen worden toegepast. In dit hoofdstuk wordt, op basis van recente 
publicaties, ingegaan op de eﬀectiviteit en eventuele bijwerkingen voor de moeder van de 
verschillende geneesmiddelen. Ook wordt de mogelijke invloed van de geneesmiddelen op 
de veiligheid van het (ongeboren) kind besproken. 
(Di)hydralazine is het meest gebruikte bloeddrukverlagend geneesmiddel bij de 
behandeling van ernstige pre-eclampsie. Na intraveneuze toediening werkt het direct op 
de bloedvaten, waardoor verwijding van de vaten optreedt en de bloeddruk van de moeder 
daalt. Het geneesmiddel is eﬀectief maar geeft wel vaak bijwerkingen bij de moeder, zoals 
hoofdpijn en misselijkheid. Recent is uit een grote analyse gebleken dat bij gebruik van 
(di)hydralazine mogelijk meer nadelige eﬀecten bij het ongeboren kind zouden optreden 
dan bij andere middelen. Een belangrijke factor hierbij is de dosis en de wijze van toediening 
van (di)hydralazine, waarbij een té lage bloeddruk bij de moeder voorkomen moet worden, 
omdat de doorbloeding van de placenta mogelijk in gevaar kan komen. 
Ketanserine is een bloeddrukverlagend middel dat zijn werking ontleent aan een blokkade van 
de zogeheten 5-HT2A receptoren. De toepassing bij pre-eclampsie berust op het feit dat wordt 
aangenomen dat de wand van bloedvaatjes is beschadigd bij een pre-eclamptische patiënt. 
Hierdoor kan in het bloed aanwezig serotonine (5-HT) binden aan 5-HT2A receptoren, die zich 
onder de beschadigde wand van het bloedvat bevinden. Dit heeft een bloedvatvernauwing 
tot gevolg waardoor de bloeddruk van de moeder stijgt. Ketanserine voorkomt dat serotonine 
zich bindt aan de 5-HT2A receptor waardoor minder bloedvatvernauwing zal optreden.
In Hoofdstuk 2 wordt de eﬀectiviteit en veiligheid van het gebruik van ketanserine bij 47 
patiënten met ernstige pre-eclampsie beschreven, met een zwangerschapsduur tussen 21 
en 32 weken bij start van de behandeling. De dosering van ketanserine werd aangepast op 
geleide van de bloeddruk tot een maximale dosis van 14 mg/uur intraveneus. Helaas bleek 
het middel bij 32% van de patiënten niet in staat om de bloeddruk voldoende te laten dalen, 
ondanks maximale doseringen. Een hoge systolische bloeddruk bij start van de behandeling 
bleek geassocieerd te zijn met onvoldoende reactie op ketanserine. De zwangerschap kon in 
de groep patiënten die aanvankelijk goed reageerden met 3 dagen worden verlengd (range 
1-10 dagen). Bij 55% van deze patiënten was gedurende de behandeling toevoeging van 
andere bloeddrukverlagende middelen noodzakelijk om de bloeddruk onder controle te 
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houden. Hieruit werd geconcludeerd dat de eﬀectiviteit van ketanserine bij een aanzienlijk 
deel van de vroege, ernstige pre-eclamptische patiënten onvoldoende is.
Een van de oorzaken van de onvoldoende eﬀectiviteit kan zijn dat de concentratie van 
ketanserine in het bloed van een pre-eclamptische patiënt te laag is voor een adequate 
respons. Om dit te kunnen onderzoeken, werd een chromatograﬁsche methode opgezet 
en gevalideerd voor de bepaling van ketanserine en zijn metaboliet ketanserinol in plasma 
(Hoofdstuk 3). 
Bij 51 pre-eclamptische patiënten werd de concentratie van ketanserine in plasma bepaald 
en werden farmacokinetische parameters berekend. Uit dit onderzoek, beschreven in 
Hoofdstuk 4, bleek dat in vrijwel alle patiënten de concentratie van ketanserine in het bloed 
voldoende hoog was om een bloeddrukverlagend eﬀect te mogen verwachten. De gevonden 
klaring (Clm 37.9 ± 10.86 L/uur) en het verdelingsvolume (V1 0.544 ± 0.188 L/kg) waren 
vergelijkbaar met historische waardes van gezonde vrijwilligers. Er werd geen correlatie 
gevonden tussen verschillen in klaring en verdelingsvolume en een adequate respons op 
ketanserine. Dit maakt het onwaarschijnlijk dat variaties in de farmacokinetiek de oorzaak 
zijn van de beperkte eﬀectiviteit van ketanserine.
Vervolgens is onderzocht of een verschil in de functionaliteit van serotonine receptoren in 
de bloedvaten van pre-eclamptische patiënten een verklaring zou kunnen vormen voor 
de verminderde eﬀectiviteit van ketanserine (Hoofdstuk 5). Zowel bij pre-eclamptische 
zwangeren als bij zwangeren zonder pre-eclampsie (controle groep) werden bloedvaatjes 
uit het onderhuids vetweefsel van de moeder en van de navelstreng (representatief voor 
foetaal weefsel) ex vivo onderzocht. De vaatjes werden blootgesteld aan serotonine en aan 
sumatriptan (een verbinding die selectief aangrijpt op 5-HT1B/D receptoren). De contractie 
werd gemeten, zowel in afwezigheid als in aanwezigheid van opklimmende concentraties 
van speciﬁeke 5-HT1B/D en 5-HT2A receptor blokkerende stoﬀen. Uit dit onderzoek bleek dat 
zowel 5-HT1B/D als ook 5-HT2A receptoren betrokken zijn bij vernauwing van deze bloedvaten. 
Er bleek geen verschil aantoonbaar tussen de pre-eclamptische patiënten en de controle 
groep wat betreft functionaliteit van 5-HT2A receptoren in de navelstreng en de bloedvaten 
van de moeder. Hiermee lijken 5-HT2A receptoren een ondergeschikte rol te spelen in de 
onderliggende oorzaken van pre-eclampsie, hetgeen een verklaring kan zijn voor de beperkte 
eﬀectiviteit van ketanserine.
Voor 5-HT1B/D receptoren werd in foetaal weefsel van de controle groep aangetoond dat de 
zwangerschapsduur van invloed is op de ontwikkeling van deze receptoren. Deze invloed 
kon niet worden aangetoond bij pre-eclamptische zwangeren. Bij deze patiënten waren de 
5-HT1B/D receptoren al vroeg in de zwangerschap volledig functioneel.
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Om de veiligheid van het gebruik van ketanserine in de zwangerschap beter te kunnen 
beoordelen, werd gekeken naar de overgang van ketanserine door de placenta naar het 
bloed van de foetus en naar de mate waarin ketanserine voorkomt in het bloed van de 
pasgeborene (Hoofdstuk 6). Bij 22 pre-eclamptische zwangeren die ketanserine gebruikten, 
werd de verhouding tussen de concentratie in navelstrengbloed en de concentratie in het 
bloed van de moeder vlak voor de bevalling, gebruikt als maat voor de placentaire overgang 
van ketanserine. Het bleek dat ketanserine de placenta nagenoeg volledig passeerde 
(gemiddelde verhouding concentratie navelstrengbloed/concentratie moeder: 0.95 [range 
0.6-1.24]). Farmacologisch actieve concentraties van ketanserine werden aangetoond in het 
bloed van pasgeborenen. Ook werden na de bevalling ketanserine concentraties bepaald 
in moedermelk van zeven patiënten. Ketanserine bleek in redelijke mate over te gaan in 
moedermelk (gemiddelde verhouding moedermelk/plasmaconcentratie van 0.4 [range 
0.2-1.27]). Hoewel er klinisch geen aanwijsbare bijwerkingen bij de foetus of pasgeborene 
werden gevonden, geven de resultaten van dit onderzoek aan dat eﬀecten bij het kind 
kunnen optreden ten gevolge van gebruik van ketanserine bij de moeder.
Serotonine receptoren worden al vroeg in de zwangerschap bij de foetus aangelegd, 
met name in de hersenen van het kind. In Hoofdstuk 7 is het onderzoek beschreven 
waarin is nagegaan of de blootstelling van de foetus aan ketanserine via de moeder 
nadelige eﬀecten heeft op de ontwikkeling van foetale serotonine receptoren. Hiertoe 
werd de functionaliteit van 5-HT1B/D en 5-HT2A receptoren uit navelstrengvaten vergeleken 
(op de wijze zoals beschreven in Hoofdstuk 5) tussen zeven vroege, pre-eclamptische 
zwangeren die ketanserine hadden gebruikt en dertien pre-eclamptische zwangeren 
die geen ketanserine hadden gebruikt, met eenzelfde zwangerschapstermijn. Er werden 
geen verschillen gevonden tussen de twee groepen wat betreft functionaliteit van beide 
receptortypes, waardoor ketanserine in dat opzicht als relatief veilig voor de foetus kan 
worden beschouwd.
Vanwege de beperkte eﬀectiviteit van ketanserine bij de ernstige pre-eclampsie patiënten, 
werd onderzoek verricht naar een geschikt alternatief bloeddrukverlagend middel. De 
calcium-instroom blokker nicardipine werd geselecteerd omdat naar verwachting, de snelle 
werking en de korte werkingsduur na intraveneuze toediening een goed controleerbare 
bloeddrukregulatie mogelijk maakt. Het bloeddrukverlagende eﬀect berust op het blokkeren 
van de instroom van calcium-ionen in speciﬁeke kanaaltjes in het bloedvat, waardoor 
verwijding van de bloedvaten optreedt. Hoewel nicardipine niet is geregistreerd voor gebruik 
tijdens de zwangerschap, worden de risico’s gering geacht, omdat het hieraan verwante 
middel, nifedipine, al eerder veilig is gebleken voor het ongeboren kind bij toepassing als 
weeënremmer en als oraal bloeddrukverlagend middel tijdens de zwangerschap.
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In Hoofdstuk 8 staan de resultaten beschreven van de toepassing van intraveneus 
nicardipine als tweedelijns behandeling bij 27 pre-eclampsie patiënten, waarbij ketanserine 
of dihydralazine onvoldoende eﬀectief was of tot onaanvaardbare bijwerkingen leidde. 
Nicardipine werd gestart in een dosis van 3 mg/uur en opgehoogd op geleide van de 
bloeddruk tot maximaal 9 mg/uur. Binnen 20 minuten werd de streefwaarde voor de 
diastolische bloeddruk (< 100 mmHg) bereikt in alle patiënten. De zwangerschap kon met 
gemiddeld 4.6 dagen (range 1 – 26 dagen) worden verlengd. Bij een derde van de patiënten 
daalde de bloeddruk echter incidenteel tot te lage waardes (< 70 mmHg), waarop de dosis 
moest worden verlaagd. Er werd geen relatie tussen de hypotensieve periodes en het 
optreden van foetale nood vastgesteld.
Geconcludeerd werd dat nicardipine een potent bloeddrukverlagend middel is, dat goed 
bruikbaar is als tweedelijns behandeling van pre-eclampsie. Gezien het frequent optreden 
van periodes met een té lage bloeddruk, dient het doseerschema nog verder te worden 
geoptimaliseerd.
Ook voor nicardipine werd de overgang door de placenta en naar moedermelk bepaald 
(Hoofdstuk 9). In tien pre-eclamptische patiënten werd uitgaande van de bloedconcentraties 
in de navelstreng ten opzichte van de concentraties in het bloed van de moeder, een 
placentaire overgang gevonden van gemiddeld 20% (0.023-0.22). De gevonden 
bloedconcentraties in de navelstreng varieerden tussen 1.3 en 18 ng/ml, hetgeen zo laag 
is dat belangrijke eﬀecten bij het (ongeboren) kind niet waarschijnlijk zijn. In 34 porties 
moedermelk van zeven patiënten werd nicardipine bepaald, waarbij in 80% van de porties, 
nicardipine niet aantoonbaar was. De maximaal mogelijke blootstelling van een pasgeborene 
via de moedermelk werd berekend als 300 ng/dag, hetgeen een zeer geringe hoeveelheid is. 
Deze resultaten geven aan dat nicardipine een gunstig proﬁel heeft ten aanzien van kans op 
eﬀecten op het kind bij gebruik in de zwangerschap of tijdens het geven van borstvoeding. 
In Hoofdstuk 10 wordt geconcludeerd uit de onderzoeken, zoals beschreven in dit 
proefschrift, dat ketanserine onvoldoende werkzaam is in een aanzienlijk deel van de 
vroege, pre-eclamptische patiënten. Gezien het feit dat bij vrijwel alle pre-eclamptische 
patienten hoge concentraties ketanserine in het bloed worden aangetoond en gezien het 
feit dat serotonine receptoren geen belangrijke rol lijken te spelen bij pre-eclampsie, kan 
geconcludeerd worden dat dosisverhoging van ketanserine weinig toegevoegde waarde zal 
hebben.
Uit de onderzoeken waarin intraveneus nicardipine is toegepast, blijkt een goede 
eﬀectiviteit bij vroege pre-eclamptische patiënten en een geringe overgang door de placenta. 
Verder onderzoek moet zich richten op het ontwikkelen van een optimaal doseerschema en 
op bevestiging van de gunstige werkzaamheid en veiligheid van nicardipine als eerste-lijns 
behandeling, ten opzichte van andere bloeddrukverlagende middelen. 
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Geconcludeerd wordt dat intraveneus nicardipine een veelbelovend bloeddrukverlagend 
geneesmiddel is bij de behandeling van pre-eclampsie.
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